Exhibit 2.1
AGREEMENT AND PLAN OF MERGER
by and among
Takeda America Holdings, Inc.,
Jade Subsidiary Corporation
and
Dated as of May 18, 2009
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
Page |
|
|
|
|
|
|
ARTICLE I THE CASH TENDER OFFER |
|
|
2 |
|
1.1 The Offer |
|
|
2 |
|
1.2 Company Actions |
|
|
4 |
|
1.3 Directors |
|
|
6 |
|
ARTICLE II THE MERGER |
|
|
7 |
|
2.1 The Merger |
|
|
7 |
|
2.2 Closing |
|
|
8 |
|
2.3 Effective Time |
|
|
8 |
|
2.4 Effects of the Merger |
|
|
8 |
|
2.5 Certificate of Incorporation and By-Laws |
|
|
8 |
|
2.6 Directors and Officers |
|
|
9 |
|
2.7 Top-Up Option |
|
|
9 |
|
ARTICLE III CONVERSION OF SECURITIES IN THE MERGER |
|
|
10 |
|
3.1 Effect of Merger of Capital Stock |
|
|
10 |
|
3.2 Surrender of Certificates |
|
|
13 |
|
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY |
|
|
15 |
|
4.1 Organization, Standing and Power |
|
|
15 |
|
4.2 Capitalization |
|
|
18 |
|
4.3 Subsidiaries |
|
|
21 |
|
4.4 Authority; No Conflict; Required Filings and Consents |
|
|
22 |
|
4.5 SEC Filings; Financial Statements; Information Provided |
|
|
24 |
|
4.6 No Undisclosed Liabilities; Indebtedness |
|
|
26 |
|
4.7 Absence of Certain Changes or Events |
|
|
27 |
|
4.8 Taxes |
|
|
27 |
|
4.9 Owned and Leased Real Properties |
|
|
30 |
|
4.10 Intellectual Property |
|
|
31 |
|
4.11 Agreements; Government Contracts |
|
|
33 |
|
4.12 Litigation |
|
|
35 |
|
4.13 Environmental Matters |
|
|
35 |
|
4.14 Employee Benefit Plans |
|
|
38 |
|
4.15 Compliance With Laws |
|
|
41 |
|
4.16 Permits |
|
|
45 |
|
4.17 Labor Matters |
|
|
45 |
|
4.18 Insurance |
|
|
47 |
|
4.19 No Existing Discussions |
|
|
47 |
|
4.20 Opinion of Financial Advisor |
|
|
47 |
|
4.21 Section 203 of the DGCL Not Applicable |
|
|
47 |
|
4.22 Brokers; Schedule of Fees and Expenses |
|
|
47 |
|
4.23 Rule 14d-10 |
|
|
48 |
|
4.24 Controls and Procedures, Certifications and Other Matters Relating to the Sarbanes
Act |
|
|
48 |
|
ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE PARENT AND THE PURCHASER |
|
|
50 |
|
5.1 Organization, Standing and Power |
|
|
50 |
|
i
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
Page |
|
|
|
|
|
|
5.2 Authority; No Conflict; Required Filings and Consents |
|
|
50 |
|
5.3 Information Provided |
|
|
51 |
|
5.4 Interim Operations of the Purchaser |
|
|
51 |
|
5.5 Funds |
|
|
51 |
|
5.6 Not an Interested Stockholder |
|
|
51 |
|
5.7 Absence of Litigation |
|
|
52 |
|
ARTICLE VI CONDUCT OF BUSINESS |
|
|
52 |
|
6.1 Conduct Prior to Effective Time |
|
|
52 |
|
6.2 Certain Communications |
|
|
56 |
|
6.3 Confidentiality |
|
|
56 |
|
ARTICLE VII ADDITIONAL AGREEMENTS |
|
|
56 |
|
7.1 No Solicitation |
|
|
56 |
|
7.2 Efforts; Consents, Notices and Approvals |
|
|
60 |
|
7.3 Notification of Certain Matters |
|
|
62 |
|
7.4 Company Stockholder Approval of the Merger |
|
|
63 |
|
7.5 Access to Information |
|
|
64 |
|
7.6 Public Disclosure |
|
|
65 |
|
7.7 Indemnification |
|
|
65 |
|
7.8 Employee Stock Purchase Plan and 401(k) Plan |
|
|
66 |
|
7.9 Employee Benefits |
|
|
66 |
|
7.10 Stockholder Litigation |
|
|
67 |
|
7.11 Parent Guaranty |
|
|
67 |
|
7.12 Transfer Restrictions |
|
|
67 |
|
ARTICLE VIII CONDITIONS |
|
|
67 |
|
8.1 Conditions to Obligation of Each Party to Effect the Merger |
|
|
67 |
|
ARTICLE IX TERMINATION, AMENDMENT AND WAIVER |
|
|
68 |
|
9.1 Termination |
|
|
68 |
|
9.2 Effect of Termination |
|
|
71 |
|
9.3 Fees and Expenses |
|
|
71 |
|
9.4 Amendment |
|
|
72 |
|
9.5 Extension; Waiver |
|
|
72 |
|
9.6 Procedure for Termination, Amendment, Extension or Waiver |
|
|
72 |
|
ARTICLE X MISCELLANEOUS |
|
|
73 |
|
10.1 Nonsurvival of Representations and Warranties |
|
|
73 |
|
10.2 Notices |
|
|
73 |
|
10.3 Entire Agreement |
|
|
74 |
|
10.4 No Third Party Beneficiaries |
|
|
74 |
|
10.5 Assignment |
|
|
74 |
|
10.6 Severability |
|
|
74 |
|
10.7 Counterparts and Signature |
|
|
75 |
|
10.8 Interpretation |
|
|
75 |
|
10.9 Governing Law |
|
|
76 |
|
10.10 Remedies |
|
|
76 |
|
10.11 Submission to Jurisdiction |
|
|
76 |
|
10.12 WAIVER OF JURY TRIAL |
|
|
77 |
|
ii
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
Page |
|
|
|
|
|
SCHEDULE A
|
|
Stockholders signing Stockholders’ Agreement |
|
|
ANNEX I
|
|
Conditions of The Offer |
|
|
EXHIBIT A
|
|
Form of Certificate of Incorporation of the Surviving Corporation |
|
|
iii
TABLE OF DEFINED TERMS
|
|
|
Acceptance Time |
|
1.3(a) |
Accredited Investor |
|
2.7(d) |
Acquisition Agreement |
|
7.1(b) |
Acquisition Proposal |
|
7.1(f) |
Adverse Recommendation Notice |
|
7.1(b) |
Affiliate |
|
4.2(f) |
Agreement |
|
Introduction; Annex I |
Antitrust Laws |
|
7.2(b) |
Approved Company Compensation Arrangement |
|
4.23 |
Assumed French Options |
|
3.1(d) |
Book-Entry Shares |
|
3.1(a)(iii) |
Certificate of Merger |
|
2.3 |
Certificate |
|
3.1(a) |
Change |
|
4.1 |
Closing |
|
2.2 |
Closing Date |
|
2.2 |
Code |
|
1.1(e) |
Company |
|
Introduction |
Company Adverse Recommendation Change |
|
9.1(c) |
Company Balance Sheet |
|
4.5(b) |
Company Board |
|
1.2(b) |
Company Common Stock |
|
Introduction |
Company Compensation Arrangement |
|
4.23 |
Company Disclosure Schedule |
|
Article IV |
Company Employee Plans |
|
4.14(a) |
Company Intellectual Property |
|
4.10(d) |
Company Leases |
|
4.9(b) |
Company Material Adverse Effect |
|
4.1 |
Company Material Contracts |
|
4.11(a) |
Company Meeting |
|
4.4(d) |
Company Permits |
|
4.16 |
Company Preferred Stock |
|
4.2(a) |
Company SEC Documents |
|
4.5(a) |
Company Stockholder Approval |
|
4.4(a) |
Company Stock Options |
|
4.2(d) |
Company Stock Plans |
|
4.2(d) |
Company Voting Proposal |
|
4.4(a) |
Company Warrants |
|
4.2(e) |
Compensation Committee |
|
4.23 |
Confidentiality Agreement |
|
6.3 |
iii
|
|
|
Contamination |
|
4.13(c) |
Continuing Employees |
|
7.9(a) |
DGCL |
|
Introduction |
Dissenting Shares |
|
3.1(c) |
Effective Time |
|
2.3 |
EMEA |
|
4.15(d) |
Employee Benefit Plan |
|
4.14(a) |
Environmental Law |
|
4.13(b) |
ERISA |
|
4.14(a) |
ERISA Affiliate |
|
4.14(a) |
EU Approval |
|
4.15(d) |
EU Territory |
|
4.15(d) |
Exchange Act |
|
1.1(a) |
ESPP |
|
7.8 |
FDA |
|
4.15(e) |
February Warrants |
|
3.1(g) |
Financial Advisor |
|
4.20 |
Form 10-K |
|
Article IV |
Form 10-Q |
|
Article IV |
GAAP |
|
4.5(b) |
Governmental Entity |
|
4.4(c) |
Hazardous Substance |
|
4.13(e) |
Healthcare-Related Law |
|
4.15(n) |
HIPAA |
|
4.15(n) |
HSR Act |
|
7.2(a) |
IDM Pharma S.A. |
|
2.5 |
IDM Pharma S.A. Stock Options |
|
4.2(d) |
Indemnified Parties |
|
7.7(a) |
Independent Directors |
|
1.3(c) |
Insurance Policies |
|
4.18 |
Intellectual Property |
|
4.10(b) |
IRS |
|
4.14(b) |
June Warrants |
|
3.1(f) |
Letter of Transmittal |
|
1.1(c) |
Liens |
|
4.4(b) |
Merger |
|
Introduction |
Merger Consideration |
|
3.1(a)(iii) |
Minimum Condition |
|
Annex I |
Offer |
|
Introduction |
Offer Consideration |
|
1.1(a) |
Offer to Purchase |
|
1.1(c) |
Offer Documents |
|
1.1(c) |
Ordinary Course of Business |
|
4.2(h) |
- iv -
|
|
|
Orphan Product Designation |
|
4.15(d) |
Outside Date |
|
9.1(b) |
Parent |
|
Introduction |
Paying Agent |
|
3.2(a) |
Payment Fund |
|
3.2(a) |
Product Candidate |
|
4.15(o) |
Proxy Statement |
|
4.4(c) |
Purchaser |
|
Introduction |
Purchaser Designees |
|
1.3(a) |
Registered Intellectual Property |
|
4.10(a) |
Registrations |
|
4.15(e) |
Release |
|
4.13(d) |
Representatives |
|
7.1(a) |
Required Company Stockholder Vote |
|
4.4(d) |
RSU Consideration |
|
3.1(e) |
RSUs |
|
4.2(c) |
Sarbanes Act |
|
4.5(a) |
Schedule TO |
|
1.1(c) |
Schedule 14D-9 |
|
1.2(b) |
SEC |
|
1.1(b) |
Section 409A Guidance |
|
4.14(j) |
Securities Act |
|
4.2(f) |
Section 262 |
|
3.1(c) |
Share Exchange Agreement |
|
2.5 |
Shares |
|
Introduction |
Specified Time |
|
7.1(a) |
Stockholders’ Agreement |
|
Introduction |
Subsidiary |
|
4.3(a) |
Superior Proposal |
|
7.1(f) |
Surviving Corporation |
|
2.1 |
Taxes |
|
4.8(m)(i) |
Tax Returns |
|
4.8(m)(ii) |
Top-Up Option |
|
2.7(a) |
Top-Up Option Shares |
|
2.7(a) |
Trade Secrets |
|
4.10(b) |
- v -
AGREEMENT AND PLAN OF MERGER
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of May 18, 2009, is among
Takeda America Holdings, Inc., a New York corporation (the “Parent”), Jade Subsidiary Corporation,
a
Delaware corporation and a wholly owned Subsidiary of the Parent (the “Purchaser”), and
IDM
Pharma, Inc., a
Delaware corporation (the “Company”).
WHEREAS, the respective Boards of Directors of the Parent, the Purchaser and the Company have
determined that it would be advisable and in the best interests of their respective stockholders
for the Parent to acquire the Company upon the terms and subject to the conditions set forth in
this Agreement;
WHEREAS, in furtherance of such acquisition, the Purchaser will make a cash tender offer (as
it may be amended from time to time as permitted under this Agreement, the “Offer”) to purchase,
upon the terms and subject to the conditions set forth in this Agreement, all of the Company’s
issued and outstanding shares of common stock, $0.01 par value per share (the “Company Common
Stock”), at a price of $2.64 per share, net to the seller in cash, without interest thereon;
WHEREAS, to effectuate such acquisition, following consummation of the Offer, the Purchaser
will be merged with and into the Company, with the Company continuing as the surviving corporation
in such merger (the “Merger”);
WHEREAS, in connection with such acquisition, the Parent and the Purchaser have entered into a
tender and support agreement dated of even date herewith (the “Stockholders’ Agreement”) with
certain of the stockholders of the Company identified on Schedule A to this Agreement; and
WHEREAS, the Board of Directors of the Company has by unanimous vote (i) determined that the
Offer and the Merger are fair to, and in the best interest of, the Company and its stockholders;
(ii) approved this Agreement and the Stockholders’ Agreement and the transactions contemplated
hereby and thereby, including the Offer and the Merger, in accordance with the General Corporation
Law of the State of
Delaware (the “DGCL”) and (iii) declared the advisability of this Agreement and
resolved to recommend that the holders of Company Common Stock tender their shares into and accept
the Offer and adopt this Agreement;
NOW, THEREFORE, in consideration of the foregoing and the respective representations,
warranties, covenants and agreements set forth herein, the Parent, the Purchaser and the Company
agree as follows:
ARTICLE I
THE CASH TENDER OFFER
1.1 The Offer.
(a) Subject to the terms and conditions of this Agreement, as promptly as reasonably
practicable (but in no event more than seven business days) after the day on which the Purchaser’s
intention to make the Offer is publicly announced (which announcement will be made by the Parent on
May 18, 2009) (it being understood that the Purchaser’s obligation to commence the Offer within the
time period described in this sentence is conditioned upon the Company’s being prepared to file the
Schedule 14D-9 approximately contemporaneously with the commencement of the Offer as provided in
Section 1.2(b)), the Purchaser shall commence (within the meaning of Rule 14d-2 under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”)), the Offer to purchase any and
all outstanding shares of Company Common Stock at a price of $2.64 per share, net to the seller in
cash, without interest thereon (the “Offer Consideration”). On the terms and subject to the prior
satisfaction or waiver of the conditions of the Offer and this Agreement, the Purchaser shall
accept for payment all shares of Company Common Stock validly tendered and not properly withdrawn
pursuant to the Offer as soon as practicable after the expiration of the Offer and shall pay for
all such shares of Company Common Stock promptly after acceptance. The obligation of the Parent
and the Purchaser to commence the Offer and to accept for payment and pay for shares of Company
Common Stock validly tendered in the Offer and not properly withdrawn shall be subject to the
conditions set forth in Annex I to this Agreement.
(b) The initial expiration date of the Offer shall be the 20th business day after commencement
of the Offer (determined in accordance with Rules 14d-1(g)(3) and 14d-2 under the Exchange Act).
If on or prior to any then scheduled expiration date of the Offer, any of the conditions to the
Offer shall not have been satisfied, or waived by the Parent or the Purchaser if permitted
hereunder (other than any conditions which by their nature are to be satisfied at the Acceptance
Time), the Purchaser shall (and the Parent shall cause the Purchaser to) extend the Offer for
periods of up to 10 business days each until the earlier of (x) the date on which all of the
conditions and requirements set forth in Annex I are satisfied or waived or (y) the date on which
this Agreement is terminated in accordance with Section 9.1; provided, however,
that in no event shall the Offer be extended beyond the Outside Date without the prior written
consent of the Company. The Offer may not be terminated prior to its scheduled expiration (as such
expiration may be extended and re-extended in accordance with this Agreement), unless this
Agreement is terminated in accordance with Section 9.1. The Purchaser expressly reserves the
right, subject to compliance with the Exchange Act, to waive, amend or modify any term or condition
of the Offer in its sole discretion; provided, however, that, without the prior
written consent of the Company, the Purchaser shall not:
- 2 -
(i) change the form of consideration payable in the Offer, decrease the Offer
Consideration or decrease the number of shares of Company Common Stock sought
pursuant to the Offer;
(ii) extend the expiration date of the Offer except (A) as required by
applicable law (including for any period required by any rule, regulation,
interpretation or position of the United States Securities and Exchange Commission
(the “SEC”) or the staff thereof), (B) in accordance with the second sentence of
Section 1.1(b) or (C) in connection with an increase in the consideration to be
paid pursuant to the Offer so as to comply with applicable rules and regulations
of the SEC;
(iii) amend or waive the Minimum Condition;
(iv) amend any term of the Offer in any manner adverse to holders of shares
of Company Common Stock; or
(v) impose any condition to the Offer not set forth in Annex I.
If fewer than 90% of the number of outstanding shares of Company Common Stock are accepted for
payment pursuant to the Offer (excluding for this purpose as shares that are tendered for payment
pursuant to the Offer any shares that are tendered in the Offer pursuant to notices of guaranteed
delivery), the Purchaser may, without the consent of the Company, elect to provide a subsequent
offering period for the Offer in accordance with Rule 14d-11 of the Exchange Act following its
acceptance for payment of shares of Company Common Stock in the Offer.
(c) On the date of commencement of the Offer, the Parent and the Purchaser shall file with the
SEC a Tender Offer Statement on Schedule TO (together with all amendments and supplements thereto,
the “Schedule TO”) with respect to the Offer. The Schedule TO shall contain an offer to purchase
(the “Offer to Purchase”), a form of the related letter of transmittal (the “Letter of
Transmittal”), and ancillary documents and instruments pursuant to which the Offer will be made
(collectively, together with any supplements or amendments thereto, the “Offer Documents”). The
Parent and the Purchaser agree that the Offer Documents shall comply in all material respects with
the requirements of applicable U.S. federal securities laws and, on the date first filed with the
SEC and on the date first published, sent or given to the Company’s stockholders, shall not contain
any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading, except that no covenant, agreement, representation or
warranty is made by the Parent or the Purchaser with respect to information supplied by the Company
or any of its stockholders in writing for inclusion or incorporation by reference in the Offer
Documents. The Parent and the Purchaser shall take all steps necessary to cause the Offer
Documents to be disseminated to holders of shares of Company Common Stock, as and to the extent
required by applicable U.S. federal securities laws. Each of the Parent, the Purchaser and the
Company shall promptly correct any information
- 3 -
provided by it for use in the Schedule TO or the Offer Documents if and to the extent that
such information shall have become false or misleading in any material respect, and the Parent and
the Purchaser shall take all steps necessary to amend or supplement the Schedule TO and, as
applicable, the Offer Documents and to cause the Schedule TO as so amended and supplemented to be
filed with the SEC and the Offer Documents as so amended and supplemented to be disseminated to
holders of shares of Company Common Stock, in each case as and to the extent required by applicable
U.S. federal securities laws. The Company and its counsel shall be given reasonable opportunity to
review and comment upon the Offer Documents and any amendments thereto prior to the filing thereof
with the SEC or dissemination to the stockholders of the Company. The Parent and the Purchaser
shall provide the Company and its counsel with a copy of any written comments or telephonic
notification of any oral comments the Parent, the Purchaser or their counsel may receive from the
SEC or its staff with respect to the Offer promptly after the receipt thereof, shall consult with
the Company and its counsel prior to responding to any such comments, and shall provide the Company
and its counsel with a copy of any written responses thereto and telephonic notification of any
oral responses thereto of the Parent or the Purchaser or their counsel. Each of Parent and the
Purchaser shall respond promptly to any comments of the SEC or its staff with respect to the Offer
Documents or the Offer.
(d) The Parent shall provide or cause to be provided to the Purchaser on a timely basis the
funds necessary to purchase any and all shares of Company Common Stock that the Purchaser becomes
obligated to purchase pursuant to the Offer.
(e) The Purchaser shall be entitled to deduct and withhold from the consideration otherwise
payable pursuant to the Offer such amounts as the Purchaser reasonably determines that it is
required to deduct and withhold with respect to the making of such payment under the Internal
Revenue Code of 1986, as amended (the “Code”), or under any other applicable law.
1.2 Company Actions.
(a) The Company hereby approves of and consents to the Offer, the Merger and the other
transactions contemplated by this Agreement.
(b) Approximately contemporaneously with the commencement of the Offer (and in any event as
promptly as practicable on the day the Offer is commenced following the filing of the Schedule TO
with respect to the Offer), the Company shall file with the SEC a Solicitation/Recommendation
Statement on Schedule 14D-9 with respect to the Offer (together with all amendments and supplements
thereto, the “Schedule 14D-9”) and disseminate the Schedule 14D-9, to the extent required by Rule
14d-9 promulgated under the Exchange Act and any other applicable laws, to the stockholders of the
Company. Except and to the extent otherwise permitted pursuant to Section 7.1 below, the Offer
Documents and the Schedule 14D-9 shall contain the recommendation of the board of directors of the
Company (the “Company Board”) that the holders of Company Common Stock tender their shares into and
accept the
- 4 -
Offer and adopt this Agreement, and the Company hereby consents to the inclusion in the Offer
Documents of such recommendation. The Company agrees that the Schedule 14D-9 shall comply in all
material respects with the requirements of applicable U.S. federal securities laws and on the date
first filed with the SEC and on the date first published, sent or given to the Company’s
stockholders, shall not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading, except that no covenant,
agreement, representation or warranty is made by the Company with respect to information supplied
by the Parent or the Purchaser in writing for inclusion or incorporation by reference in the
Schedule 14D-9. Each of the Company, the Parent and the Purchaser shall promptly correct any
information provided by it for use in the Schedule 14D-9 if and to the extent that such information
shall have become false or misleading in any material respect, and the Company shall take all steps
necessary to amend or supplement the Schedule 14D-9 and to cause the Schedule 14D-9 as so amended
or supplemented to be filed with the SEC and disseminated to the Company’s stockholders, in each
case as and to the extent required by applicable U.S. federal securities laws. The Parent and its
counsel shall be given a reasonable opportunity to review and comment upon the Schedule 14D-9 and
any amendments thereto prior to the filing thereof with the SEC or dissemination to stockholders of
the Company. The Company shall provide the Parent and its counsel with a copy of any written
comments or telephonic notification of any oral comments the Company or its counsel may receive
from the SEC or its staff with respect to the Offer promptly after the receipt thereof, shall
consult with the Parent and its counsel prior to responding to any such comments, and shall provide
the Parent and its counsel with a copy of any written responses thereto and telephonic notification
of any oral responses thereto of the Company or its counsel. The Company shall respond promptly to
any comments of the SEC or its staff with respect to the Schedule 14D-9.
(c) The Company shall promptly supply to the Parent and the Purchaser in writing, for
inclusion in the Schedule TO and the Offer Documents, all information concerning the Company
required under applicable U.S. federal securities laws to be included in the Offer Documents or
that may be reasonably requested by the Parent and the Purchaser in connection with the preparation
of the Schedule TO or the Offer Documents or their obligations hereunder.
(d) The Company represents that each member of the Company Board and each executive officer of
the Company has advised the Company that his or her current intention is to tender all shares of
Company Common Stock, if any, beneficially owned by him or her pursuant to the Offer.
(e) In connection with the Offer and the Merger, the Company shall promptly furnish to the
Purchaser or its designated agent mailing labels containing the names and addresses of the record
holders of the shares of Company Common Stock as of a recent date and of those persons becoming
record holders subsequent to such date and, to the extent known, a list of the beneficial owners of
the shares of Company Common Stock as of a recent date, together with copies of all security
position listings and all other computer files and other information in
- 5 -
the Company’s possession or control regarding the beneficial owners of such shares, and shall
furnish to the Purchaser such information and assistance (including updated lists and information)
as the Purchaser may reasonably request for the purpose of communicating the Offer to the record
and beneficial owners of the shares of Company Common Stock. From and after the date of this
Agreement, all such information concerning the Company’s record and, to the extent known,
beneficial holders shall be made available to the Purchaser. Subject to the requirements of
applicable laws and except for such steps as are necessary to disseminate the Offer Documents and
any other documents necessary to consummate the Offer, the Merger and the other transactions
contemplated by this Agreement, the Parent and the Purchaser shall, until consummation of the
Offer, hold in confidence the information contained in any of such labels and lists, shall use such
information only in connection with the Offer, the Merger and the other transactions contemplated
by this Agreement and, if this Agreement shall be terminated in accordance with Section 9.1, shall,
upon request, deliver to the Company, or, at the Parent’s election, destroy, all copies of such
information then in their possession or under their control.
1.3 Directors.
(a) Promptly after the first time at which the Purchaser accepts for payment and pays for any
shares of Company Common Stock pursuant to the Offer (the “Acceptance Time”), and from time to time
thereafter as shares of Company Common Stock are accepted for payment and paid for by the
Purchaser, the Purchaser shall be entitled to designate such number of members of the Company Board
(the “Purchaser Designees”), rounded up to the nearest whole number, as will give the Purchaser
representation on the Company Board equal to the product of the total number of members of the
Company Board (after giving effect to the directors elected pursuant to this sentence) multiplied
by the percentage that the number of shares of Company Common Stock beneficially owned by the
Parent or the Purchaser at such time (including shares of Company Common Stock so accepted for
payment) bears to the total number of shares of Company Common Stock then outstanding; provided
that in no event shall the Purchaser Designees constitute less than a majority of the Company
Board. In furtherance thereof, the Company shall, upon the request of the Purchaser, use its
reasonable best efforts promptly (and in any event within one business day) either to increase the
size of the Company Board or to secure the resignations of such number of the Company’s incumbent
directors (and such incumbent directors have agreed to resign if required in order for the Company
to comply with this Section 1.3(a)), or both, as is necessary to enable the Purchaser Designees to
be so elected or appointed to the Company Board and the Company shall take all actions necessary to
cause the Purchaser Designees to be so elected or appointed. At such time, the Company shall, if
requested by the Purchaser, also take all action necessary to cause persons designated by the
Purchaser to constitute at least the same percentage (rounded up to the next whole number) as is on
the Company Board of (i) each committee of the Company Board, (ii) each board of directors (or
similar body) of each Subsidiary of the Company and (iii) each committee (or similar body) of each
such board. The provisions of this Section 1.3 are in addition to and shall not limit any rights
which the Purchaser, the Parent or any of their Affiliates may have as a holder or
- 6 -
beneficial owner of shares of Company Common Stock as a matter of applicable law with respect
to the election of directors or otherwise.
(b) The Company shall take all actions required in order to fulfill its obligations under
Section 1.3(a), including mailing to its stockholders the information required by Section 14(f) of
the Exchange Act and Rule 14f-1 promulgated thereunder as part of the Schedule 14D-9. The Parent
and the Purchaser shall supply to the Company in writing any information with respect to the Parent
and the Purchaser and the Purchaser Designees to the extent required by such Section 14(f) and Rule
14f-1.
(c) Notwithstanding the provisions of this Section 1.3, the parties hereto shall use their
respective reasonable best efforts to ensure that at least two of the members of the Company Board
shall, at all times prior to the Effective Time (as defined in Section 2.3 hereof), be directors of
the Company who were directors of the Company on the date hereof (the “Independent Directors”),
provided that, if there shall be in office less than two Independent Directors for any reason, the
Company Board shall cause the person designated by the remaining Independent Director to fill such
vacancy who shall be deemed to be an Independent Director for all purposes of this Agreement, or if
no Independent Directors then remain, the other directors of the Company then in office shall
designate two persons to fill such vacancies who will not be directors, officers, employees or
Affiliates of the Parent or the Purchaser and such persons shall be deemed to be Independent
Directors for all purposes of this Agreement. From and after the time, if any, that the Purchaser
Designees constitute a majority of the Company Board and prior to the Effective Time, subject to
the terms hereof, (i) any amendment or modification of this Agreement or any other consent or
action by the Company Board with respect to this Agreement or the Merger, (ii) any termination of
this Agreement by the Company, (iii) any extension of time for performance of any of the
obligations of the Parent or the Purchaser hereunder, (iv) any waiver of any covenant or agreement
of the Parent or the Purchaser hereunder, (v) any waiver of any condition to the Company’s
obligations hereunder or any of the Company’s rights, benefits or remedies hereunder, (vi) any
other action by the Company which is reasonably likely to adversely affect the right of the holders
of Company Common Stock (other than the Parent, the Purchaser and their Affiliates) to be paid the
Merger Consideration in the Merger, (vii) any Company Adverse Recommendation Change, or (viii) any
amendment to the Company’s certificate of incorporation or bylaws, in each case may be effected
only if there are in office one or more Independent Directors and such action is approved by a
majority of the Independent Directors then in office.
ARTICLE II
THE MERGER
2.1 The Merger. Upon the terms and subject to the conditions set forth in this
Agreement, and in accordance with the DGCL, the Purchaser shall merge with and into the Company at
the Effective Time. At the Effective Time, the separate corporate existence of the
- 7 -
Purchaser shall cease and the Company shall continue as the surviving corporation (the
“Surviving Corporation”) and shall succeed to and assume all the rights and obligations of the
Purchaser in accordance with the DGCL.
2.2 Closing. Upon the terms and subject to the conditions set forth in this
Agreement, the closing of the Merger (the “Closing”) shall take place at 10:00 a.m., eastern time,
on the second business day after the satisfaction or (to the extent permitted by applicable law)
waiver of the conditions set forth in Article VIII (other than those that by their terms cannot be
satisfied until the time of the Closing but subject to the fulfillment or waiver of such
conditions), at the offices of Xxxxxx Xxxxxx Xxxxxxxxx Xxxx and Xxxx LLP, 00 Xxxxx Xxxxxx, Xxxxxx,
XX 00000, or at such other time, date or place agreed to in writing by the Parent and the Company;
provided that if all the conditions set forth in Article VIII shall not have been satisfied or (to
the extent permitted by applicable law) waived on such second business day, then the Closing shall
take place on the first business day on which all such conditions shall have been satisfied or (to
the extent permitted by applicable law) waived. The date on which the Closing occurs is referred
to in this Agreement as the “Closing Date”.
2.3
Effective Time. Upon the terms and subject to the conditions set forth in this
Agreement, as soon as practicable on or after the Closing Date, a certificate of merger (or
certificate of ownership and merger, as the case may be) or other appropriate documents (in any
such case, the “Certificate of Merger”) shall be duly prepared, executed and acknowledged by the
parties in accordance with the relevant provisions of the DGCL and filed with the Secretary of
State of the State of
Delaware. The Merger shall become effective upon the filing of the
Certificate of Merger with the Secretary of State of the State of
Delaware or at such subsequent
time or date as the Parent and the Company shall agree and specify in the Certificate of Merger.
The time at which the Merger becomes effective is referred to in this Agreement as the “Effective
Time”.
2.4 Effects of the Merger. The Merger shall have the effects set forth in Section 259
of the DGCL.
2.5
Certificate of Incorporation and By-Laws. The Certificate of Incorporation of the
Company as in effect on the date of this Agreement shall, by virtue of the Merger, be amended at
the Effective Time in its entirety to read as set forth in
Exhibit A until thereafter
amended as provided under the DGCL. The By-laws of the Surviving Corporation as in effect
immediately prior to the Effective Time shall be amended to be the same as the By-laws of the
Purchaser effective immediately after the Effective Time until thereafter amended as provided under
the DGCL. Notwithstanding the other provisions of this Section 2.5, the Parent and the Surviving
Corporation shall ensure that the terms of such Certificate of Incorporation and By-laws will
comply with the requirements of Section 6.05 of that certain Share Exchange Agreement, dated March
15, 2005, by and among the Company (as successor to Epimmune, Inc., a
Delaware corporation) and the
shareholders of IDM Pharma S.A., a societe anonyme organized under the laws of France (and
predecessor to IDM, S.A., a societe anonyme organized under the laws of
- 8 -
France (“IDM Pharma S.A.”)) (as amended, the “Share Exchange Agreement”), for so long as such
requirements of the Share Exchange Agreement apply.
2.6 Directors and Officers. Effective as of the Effective Time, the directors of the
Purchaser immediately prior to the Effective Time will be the directors of the Surviving
Corporation, and the officers designated by the Parent prior to the Effective Time will be the
officers of the Surviving Corporation, in each case until their successors are elected and
qualified. Prior to the Effective Time, the Company shall cause each member of the Company Board,
other than the Purchaser Designees, to execute and deliver a letter effectuating his or her
resignation as a director of the Company effective upon the Effective Time.
2.7 Top-Up Option.
(a) Subject to Section 2.7(b) and Section 2.7(c), the Company grants to Purchaser an
irrevocable option (the “Top-Up Option”) to purchase from the Company the number of shares of
Company Common Stock (the “Top-Up Option Shares”) equal to the lesser of (i) the number of shares
of Company Common Stock that, when added to the number of shares of Company Common Stock owned by
Purchaser as of immediately prior to the exercise of the Top-Up Option, constitutes one share more
than 90% of the number of shares of Company Common Stock then outstanding on a fully diluted basis
(determined in accordance with Annex I) (assuming the issuance of the Top-Up Option Shares)
or (ii) the aggregate of the number of shares of Company Common Stock held as treasury shares by
the Company and its Subsidiaries and the number of shares of Company Common Stock that the Company
is authorized to issue under its certificate of incorporation but that are not issued and
outstanding (and are not reserved for issuance pursuant to the exercise of Company Stock Options or
Company Warrants) as of immediately prior to the exercise of the Top-Up Option.
(b) The Top-Up Option may be exercised by Purchaser, in whole or in part, at any time at or
after the Acceptance Time. The aggregate purchase price payable for the Top-Up Option Shares shall
be determined by multiplying the number of such Top-Up Option Shares by the Offer Consideration.
Such purchase price may be paid by Purchaser, at its election, either in cash or by executing and
delivering to the Company a promissory note having a principal amount equal to such purchase price,
or by any combination of cash and such promissory note. Any such promissory note shall bear
interest at the applicable federal rate determined under Section 1274(d) of the Code, shall mature
on the first anniversary of the date of execution and delivery of such promissory note and may be
prepaid without premium or penalty.
(c) In the event that Purchaser wishes to exercise the Top-Up Option, it shall deliver to the
Company a notice setting forth (i) the number of Top-Up Option Shares that it intends to purchase
pursuant to the Top-Up Option, (ii) the manner in which it intends to pay the applicable purchase
price and (iii) the place and time at which the closing of the purchase of the Top-Up Option Shares
by Purchaser is to take place. At the closing of the purchase of the Top-Up Option Shares,
Purchaser shall cause to be delivered to the Company the consideration
- 9 -
required to be delivered in exchange for such Top-Up Option Shares, and the Company shall
cause to be issued to Purchaser a certificate representing such shares.
(d) Parent and Purchaser acknowledge that the Top-Up Option Shares that Purchaser may acquire
upon exercise of the Top-Up Option will not be registered under the Securities Act and will be
issued in reliance upon an exemption thereunder for transactions not involving a public offering.
Parent and Purchaser represent and warrant to the Company that Purchaser is, or will be upon the
purchase of the Top-Up Option Shares, an “Accredited Investor”, as defined in Rule 501 of
Regulation D under the Securities Act. Purchaser agrees that the Top-Up Option and the Top-Up
Option Shares to be acquired upon exercise of the Top-Up Option are being and will be acquired by
Purchaser for the purpose of investment and not with a view to, or for resale in connection with,
any distribution thereof in violation of the Securities Act.
ARTICLE III
CONVERSION OF SECURITIES IN THE MERGER
3.1 Effect of Merger of Capital Stock.
(a) At the Effective Time, by virtue of the Merger and without any action on the part of the
Purchaser, the Company, the Surviving Corporation or the holder of any of the following securities:
(i) each share of the Purchaser’s capital stock issued and outstanding
immediately prior to the Effective Time shall be converted into and become one
validly issued, fully paid and nonassessable share of the same class of capital
stock of the Surviving Corporation;
(ii) each share of Company Common Stock issued and outstanding immediately
prior to the Effective Time that is owned by the Parent, the Purchaser or the
Company or any direct or indirect wholly-owned Subsidiary of the Parent, the
Purchaser or the Company, including all shares of Company Common Stock held by the
Company as treasury stock, shall automatically be cancelled, and no payment shall
be made with respect thereto; and
(iii) each share of Company Common Stock issued and outstanding immediately
prior to the Effective Time (other than shares of Company Common Stock to be
cancelled pursuant to clause (ii) above and any Dissenting Shares (as defined in
Section 3.1(c) hereof)) shall be automatically cancelled and extinguished and be
converted into and become the right to receive from the Surviving Corporation
$2.64 in cash per share (or any such higher price per share that may be paid in
the Offer) without any interest thereon (the “Merger Consideration”). As of the
Effective Time, all such shares of Company
- 10 -
Common Stock shall no longer be outstanding and shall be automatically
cancelled and shall cease to exist, and each holder of a certificate which
immediately prior to the Effective Time represented any such shares of Company
Common Stock (a “Certificate”), and each holder of record of uncertificated shares
of Company Common Stock represented by book entry as of immediately prior to the
Effective Time (“Book-Entry Shares”), shall cease to have any rights with respect
thereto, except the right to receive the Merger Consideration pursuant to this
Section 3.1(a)(iii) upon the surrender of such Certificate (or an agent’s message
in the case of Book-Entry Shares) in accordance with Section 3.2, without interest
and subject to any applicable withholding rights in accordance with Section
3.2(g).
(b) If, between the Acceptance Time and the Effective Time, the outstanding shares of Company
Common Stock are changed into a different number or class of shares by reason of any stock split,
division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares,
reclassification, recapitalization or other similar transaction, then the Merger Consideration
shall be appropriately adjusted.
(c) Notwithstanding anything in this Agreement to the contrary, shares of Company Common Stock
that are issued and outstanding immediately prior to the Effective Time and that are held by any
holder who is entitled to demand and properly demands appraisal of such shares (the “Dissenting
Shares”) pursuant to, and who complies in all respects with, the provisions of Section 262 of the
DGCL (“Section 262”) shall not be converted into the right to receive the Merger Consideration as
provided in Section 3.1(a)(iii), but instead such holder shall be entitled to payment of the fair
value of such Dissenting Shares in accordance with the provisions of Section 262. At the Effective
Time, all Dissenting Shares shall no longer be outstanding and shall automatically be cancelled and
shall cease to exist, and each holder of Dissenting Shares shall cease to have any rights with
respect thereto, except the right to receive the fair value of such shares in accordance with the
provisions of Section 262. Notwithstanding the foregoing, if any such holder shall fail to perfect
or otherwise shall waive, withdraw or lose the right to appraisal under Section 262 or a court of
competent jurisdiction shall determine that such holder is not entitled to the relief provided by
Section 262, then the right of such holder to be paid the fair value of such holder’s Dissenting
Shares under Section 262 shall cease and such Dissenting Shares shall be deemed to have been
converted at the Effective Time into, and shall have become, the right to receive the Merger
Consideration as provided in Section 3.1(a)(iii), without interest. The Company shall give the
Parent and the Purchaser prompt notice of any demands for payment, or notices of intent to demand
payment, received by the Company with respect to shares of Company Common Stock, and the Parent and
the Purchaser shall have the right to participate in and direct all negotiations and proceedings
with respect to such demands. Prior to the Effective Time, the Company shall not, except with the
prior written consent of the Parent and the Purchaser, make any payment with respect to, or settle,
or offer to settle, any such demands, or agree to do any of the foregoing.
- 11 -
(d) Prior to and contingent upon the occurrence of the Acceptance Time, the Company shall take
all action that may be necessary (under the plans and award agreements pursuant to which Company
Stock Options are outstanding and otherwise) to (i) accelerate the vesting and exercisability of
each unexpired and unexercised Company Stock Option then in effect so that each such Company Stock
Option shall be fully vested and exercisable prior to the Acceptance Time and (ii) ensure that each
such Company Stock Option (other than outstanding Company Stock Options for which Option Liquidity
Agreements (as defined in the Share Exchange Agreement) have been executed) includes a “net
exercise” or “cashless exercise” provision. The Company shall cause each outstanding Company Stock
Option (other than any Company Stock Options issuable pursuant to Option Liquidity Agreements and
any IDM Pharma S.A. Stock Options (collectively, the “Assumed French Options”)), to the extent not
exercised prior to the Effective Time, to be terminated as of immediately prior to the Effective
Time without any payment or Merger Consideration issuable with respect thereto.
(e) Prior to and contingent upon the occurrence of the Effective Time, in accordance with the
requirements of Treasury Regulation Section 1.409A-3(j)(4)(ix), the Company shall take all action
that may be necessary (under the plans and award agreements pursuant to which RSUs are outstanding
and otherwise) to accelerate the vesting of each RSU then in effect and provide for a cash payment
in consideration for the cancellation of each RSU, so that each such RSU shall be fully vested and
canceled at the Effective Time in exchange for a lump sum cash payment in lieu of an issuance of
shares in respect of such RSU. In exchange for each such canceled RSU, the holder shall be entitled
to a lump sum cash distribution payable by the Surviving Corporation in an amount determined by
multiplying the number of shares of Company Common Stock that would otherwise have been issued in
respect of such canceled RSU, whether vested or unvested, by the Merger Consideration (the “RSU
Consideration”). The RSU Consideration for each such canceled RSU shall be paid to the holder of
such canceled RSU in accordance with the Company’s standard payroll practices. In no event shall a
holder of an RSU receive both the RSU Consideration and an issuance of shares with respect to such
RSU.
(f) Purchaser shall, and shall cause the Company to, comply with the provisions of the Company
Warrants issued on or about June 20, 2007 (the “June Warrants”), including by agreeing to
subsequently adjust the June Warrants pursuant to Section 3(c) thereof upon the occurrence of a
subsequent transaction analogous to a “Fundamental Transaction” (as defined in the June Warrants).
The Company shall timely send to the holders of the June Warrants the notice required by Section
3(f) thereof.
(g) The Company represents and warrants that the Company Warrants issued on or about February
20, 2007 (the “February Warrants”) shall terminate pursuant to Section 7 of the February Warrants
as of immediately prior to the Effective Time without any Merger Consideration issuable with
respect thereto, unless exercised before such time. In the event that any February Warrant
terminates pursuant to the immediately preceding sentence, the Surviving Corporation shall comply
with the provisions of such February Warrant, including by purchasing the remaining unexercised
portion of such February Warrant from the holder thereof for cash
- 12 -
equal to the Black-Scholes Value (as defined in such February Warrant) of the remaining
unexercised portion of such February Warrant within five days after the Closing pursuant to Section
7 of such February Warrant.
(h) Prior to and contingent upon the occurrence of the Acceptance Time, in accordance with the
requirements of Treasury Regulation Section 1.409A-3(j)(4)(ix), the Company shall take all
irrevocable action that may be necessary to terminate the Company’s Directors’ Deferred
Compensation Plan and provide for the accelerated payment of all Directors’ Deferred Compensation
Plan accounts.
3.2 Surrender of Certificates. The procedures for exchanging outstanding shares of
Company Common Stock for Merger Consideration pursuant to the Merger are as follows:
(a) Paying Agent. Prior to the Effective Time, the Parent shall select a bank or
trust company reasonably acceptable to the Company to act as agent (the “Paying Agent”) for the
payment after the Effective Time of the Merger Consideration upon surrender of Certificates or
Book-Entry Shares. From time to time after the Effective Time, the Parent shall provide, or cause
the Surviving Corporation to provide, to the Paying Agent, on a timely basis as and when needed,
cash necessary for payment of the Merger Consideration pursuant to Section 3.1(a)(iii) upon
surrender of Certificates or Book-Entry Shares (such cash being hereinafter referred to as the
“Payment Fund”).
(b) Exchange Procedures. As soon as reasonably practicable after the Effective Time,
the Paying Agent shall mail to each holder of record of a Certificate and each holder of record of
Book-Entry Shares (i) a Letter of Transmittal (which, in the case of shares of Company Common Stock
formerly represented by a Certificate, shall specify that delivery shall be effected, and risk of
loss and title to the Certificate shall pass, only upon delivery of the Certificate to the Paying
Agent and shall be in such form and have such other provisions as the Parent may reasonably
specify) and (ii) instructions for use in effecting the surrender of the Certificate or Book-Entry
Shares in exchange for the Merger Consideration. Upon surrender of a Certificate for cancellation
to the Paying Agent or to such other agent or agents as may be appointed by the Parent (or upon
receipt of an agent’s message in the case of Book-Entry Shares), together with such Letter of
Transmittal, duly completed and properly executed, and such other documents as may reasonably be
required by the Paying Agent, the holder of such Certificate or Book-Entry Shares shall be entitled
to receive in exchange therefor an amount of cash equal to the Merger Consideration that such
holder has the right to receive pursuant to Section 3.1(a)(iii), and the Certificate or Book-Entry
Shares so surrendered shall forthwith be cancelled. In the event of a transfer of ownership of
Company Common Stock that is not registered in the stock transfer records of the Company, payment
may be made to a person other than the person in whose name the Certificate or Book-Entry Shares so
surrendered is or are registered if, in the case of shares formerly represented by a Certificate,
such Certificate shall be properly endorsed or otherwise be in proper form for transfer and, in the
case of shares formerly represented by a Certificate or Book-Entry Shares, the person requesting
such payment shall pay
- 13 -
any transfer or other taxes required by reason of the payment to a person other than the
registered holder of such Certificate or Book-Entry Shares or establish to the satisfaction of the
Parent that such tax has been paid or is not applicable. Until surrendered as contemplated by this
Section 3.2, each Certificate and all Book-Entry Shares shall be deemed at any time after the
Effective Time to represent only the right to receive upon such surrender the amount of cash,
without interest, into which the shares of Company Common Stock formerly represented by such
Certificate have been converted pursuant to Section 3.1(a)(iii). No interest shall be paid or
shall accrue on the cash payable upon surrender of any Certificate.
(c) No Further Ownership Rights in Company Common Stock. The Merger Consideration
paid upon the surrender for exchange of Certificates or Book-Entry Shares in accordance with the
terms hereof shall be deemed to have been paid in full satisfaction of all rights pertaining to
such shares of Company Common Stock, and from and after the Effective Time, the stock transfer
books of the Company shall be closed, and there shall be no further registration of transfers on
the stock transfer books of the Surviving Corporation of shares of Company Common Stock that were
outstanding immediately prior to the Effective Time. If, after the Effective Time, any
Certificates (or an agent’s message in the case of Book-Entry Shares) are presented to the
Surviving Corporation or the Paying Agent for any reason, they shall be cancelled and exchanged as
provided in this Article III.
(d) Termination of Payment Fund. Any portion of the Payment Fund that remains
undistributed to the holders of Certificates and Book-Entry Shares for six months after the
Effective Time shall be delivered by the Paying Agent to the Parent, upon demand, and any holder of
a Certificate who has not theretofore complied with this Article III (or delivered an agent’s
message, in the case of Book-Entry Shares) shall thereafter look only to the Parent for payment of
the Merger Consideration which the holder has the right to receive pursuant to Section 3.1(a)(iii),
but shall have no greater rights against the Parent than may be accorded to general unsecured
creditors of the Parent under applicable law.
(e) No Liability. None of the Parent, the Purchaser, the Company, the Surviving
Corporation or the Paying Agent shall be liable to any person in respect of any cash from the
Payment Fund delivered to a public official pursuant to any applicable abandoned property, escheat
or similar law. If any Certificate has not been surrendered (or, in the case of Book-Entry Shares,
an agent’s message has not been delivered) prior to two years after the Effective Time (or
immediately prior to such earlier date on which the Merger Consideration in respect of such
Certificate would otherwise escheat to or become the property of any Governmental Entity (as
defined in Section 4.4)), any such Merger Consideration shall, to the extent permitted by
applicable law, become the property of the Surviving Corporation, free and clear of all claims or
interest of any person previously entitled thereto.
(f) Investment of Payment Fund. The Paying Agent shall invest any cash included in
the Payment Fund as directed by the Parent. Any interest and other income resulting from such
investments shall be paid to and be the property of the Parent.
- 14 -
(g) Withholding Rights. The Parent, the Surviving Corporation and the Paying Agent
shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this
Agreement such amounts as any of them reasonably determines that it is required to deduct and
withhold with respect to the making of such payment under the Code or any other applicable law. To
the extent that amounts are so withheld and paid over to the appropriate taxing authority by the
Parent, the Surviving Corporation or the Paying Agent, such withheld amounts shall be treated for
all purposes of this Agreement as having been paid to the holder of the shares of Company Common
Stock in respect of which such deduction and withholding was made by the Parent, the Surviving
Corporation or the Paying Agent.
(h) Lost Certificates. If any Certificate shall have been lost, stolen or destroyed,
the Paying Agent shall pay to such holder the Merger Consideration required pursuant to Section
3.1(a)(iii) in exchange for such lost, stolen or destroyed Certificate, upon the making of an
affidavit of that fact by the holder thereof with such assurances as the Parent or Paying Agent, in
its discretion and as a condition precedent to the payment of the Merger Consideration, may require
of the holder of such lost, stolen or destroyed Certificate.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to the Parent and the Purchaser that the statements contained
in this Article IV are true and correct, except (i) as set forth herein, (ii) as disclosed in the
Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 or in the Form
10-K/A filed by the Company on April 30, 2009 (such Form 10-K and Form 10-K/A taken together, the
“Form 10-K”) or in the Form 10-Q filed by the Company on May 11, 2009 (the “Form 10-Q”), but
excluding any information in the “Risk Factors” sections of the Form 10-K and Form 10-Q, any
forward-looking statements contained in the Form 10-K and Form 10-Q that are of a nature that they
speculate about future developments, and other than any changes made to the Form 10-K or Form 10-Q
by amendment of the Form 10-K or Form 10-Q, as applicable, on or after the date hereof and (iii) in
the disclosure schedule delivered by the Company to the Parent on or before the date of this
Agreement (the “Company Disclosure Schedule”). The Company Disclosure Schedule shall be arranged
in paragraphs corresponding to the numbered and lettered paragraphs contained in this Article IV
and the disclosure in any paragraph of the Company Disclosure Schedule shall qualify (1) the
corresponding paragraph in this Article IV and (2) the other paragraphs in this Article IV only to
the extent that it is reasonably apparent from a reading of such disclosure that it also qualifies
or applies to such other paragraphs.
4.1
Organization, Standing and Power. The Company is a corporation duly organized,
validly existing and in good standing under the laws of the State of
Delaware, has all requisite
corporate power and authority to own, lease and operate its properties and assets and to carry on
its business as now being conducted and to manufacture for commercial sale, market,
- 15 -
sell and otherwise commercialize the Company’s MEPACT product candidate in the EU Territory
(as defined below), and is duly qualified to do business and is in good standing as a foreign
corporation in each jurisdiction listed in Section 4.1 of the Company Disclosure Schedule, which
jurisdictions constitute the only jurisdictions in which the character of the properties it owns,
operates or leases or the nature of its activities makes such qualification necessary, except for
such failures to be so organized, qualified or in good standing that have not had, and would not
reasonably be expected to result in, a Company Material Adverse Effect. For purposes of this
Agreement, the term “Company Material Adverse Effect” means any change, event, circumstance,
development or effect (each, a “Change”) that, individually or in the aggregate with all other
Changes occurring or existing prior to the determination of a Company Material Adverse Effect, has
a material adverse effect on (i) the business, assets, liabilities, capitalization, condition
(financial or other), or results of operations of the Company and its Subsidiaries, taken as a
whole, (ii) the current or future manufacturing for commercial sale, marketing, sale or other
commercialization by the Company and its Subsidiaries of the Company’s MEPACT product candidate in
the EU Territory, or (iii) the ability of the Company to consummate the transactions contemplated
by this Agreement; provided, however, that none of the following (to the extent
arising after the date hereof) shall be deemed to be or to constitute a Company Material Adverse
Effect, or taken into account when determining whether a Company Material Adverse Effect has
occurred or would occur:
|
(A) |
|
any Change to the extent resulting from general
economic conditions in the United States or any other country or region in
the world (in each case other than Changes that affect the Company and its
Subsidiaries, taken as a whole, in a disproportionate manner as compared
to the Company’s industry peers); |
|
|
(B) |
|
any Change to the extent resulting from conditions in
the industries in which the Company and its Subsidiaries conduct business
(in each case other than Changes that affect the Company and its
Subsidiaries, taken as a whole, in a disproportionate manner as compared
to the Company’s industry peers); |
|
|
(C) |
|
any Change to the extent resulting from acts of
terrorism, war, sabotage, national or international calamity or any other
similar event in the United States or any other country or region in the
world (in each case other than Changes that affect the Company and its
Subsidiaries, taken as a whole, in a disproportionate manner as compared
to the Company’s industry peers); |
|
|
(D) |
|
any Change to the extent resulting from the pendency
or announcement of the Offer, the Merger or the transactions contemplated
by this Agreement, including any disruption in (or |
- 16 -
|
|
|
loss of) supplier, distributor, partner or similar relationships or
loss of employees (but not, for the avoidance of doubt, any direct
legal or contractual consequence of the Company’s execution, delivery
and performance of this Agreement or the Stockholders’ Agreement and
consummation of the transactions contemplated hereby or thereby); |
|
|
(E) |
|
any Change to the extent resulting from any failure
by the Company to meet any public or internal estimates or expectations of
the Company’s revenue, income or losses or other financial performance or
results of operations for any period, in and of itself (it being
understood that any Changes giving rise to or contributing to such failure
to meet estimates or expectations may be deemed to constitute, and be
taken into account in determining whether there has been or would be, a
Company Material Adverse Effect); |
|
|
(F) |
|
any Change to the extent resulting from the taking of
any action required by this Agreement (other than in the first sentence of
Section 6.1), or the failure to take any action prohibited by this
Agreement (other than the first sentence of Section 6.1); |
|
|
(G) |
|
any Change to the extent resulting from changes in
the Company’s stock price or trading volume of the Company’s stock, in and
of itself or as it may affect the value of the Company Warrants (as
defined below) (it being understood that any Changes giving rise to or
contributing to such changes in the Company’s stock price or trading
volume or the value of the Company Warrants may be deemed to constitute,
and be taken into account in determining whether there has been or would
be, a Company Material Adverse Effect); |
|
|
(H) |
|
any Change to the extent resulting from any actions
taken, or failure to take action, in each case which the Parent has
requested in writing or approved in writing or to which the Parent has
consented in writing; |
|
|
(I) |
|
any Change to the extent resulting from changes in
law or other legal or regulatory conditions (in each case other than
Changes that affect the Company and its Subsidiaries, taken as a whole, in
a disproportionate manner as compared to the Company’s industry peers); |
|
|
(J) |
|
any Change to the extent resulting from changes in
GAAP (in each case other than Changes that affect the Company and its |
- 17 -
|
|
|
Subsidiaries, taken as a whole, in a disproportionate manner as
compared to the Company’s industry peers); |
|
|
(K) |
|
any Change to the extent resulting from fluctuations
in the value of any currency; |
|
|
(L) |
|
any Change to the extent resulting from the failure
by the Company to maintain a particular amount of operating cash and cash
equivalents (as such term is defined under GAAP); |
|
|
(M) |
|
any Change to the extent resulting from the failure
by the Company to maintain the listing of the Company Common Stock on the
NASDAQ Global Market or failure to list the Company Common Stock on the
NASDAQ Capital Market; |
|
|
(N) |
|
any Change to the extent resulting from any
Governmental Entity or any panel or advisory body empowered or appointed
by any Governmental Entity with respect to the approval, non-approval,
disapproval, withdrawal, manufacture, design, initiation, suspension or
termination of the Company’s IDM-2101 product candidate or the Company’s
UVIDEM product candidate; and |
|
|
(O) |
|
any Change to the extent resulting from the
introduction, commercial success or trial results of, or action by any
Governmental Entity with respect to, any product or product candidate (in
each case of a person other than the Company or any of its Subsidiaries)
similar to or potentially competitive with any of the Product Candidates. |
For the avoidance of doubt, the parties agree that the terms “material”, “materially” or
“materiality” as used in this Agreement with an initial lower case “m” shall have their respective
customary and ordinary meanings, without regard to the meanings ascribed to Company Material
Adverse Effect in the prior sentence of this paragraph. The Company has made available to the
Parent copies of the Certificate of Incorporation and Bylaws of the Company.
4.2 Capitalization.
(a) The authorized capital stock of the Company consists of 55,000,000 shares of Company
Common Stock and 10,000,000 shares of preferred stock, $.01 par value per share (“Company Preferred
Stock”). The rights and privileges of each class of the Company’s capital stock are as set forth
in the Company’s Certificate of Incorporation. As of May 17, 2009, (i) 25,273,935 shares of
Company Common Stock were issued and outstanding, (ii) no shares of Company Common Stock were held
in the treasury of the Company or by Subsidiaries of the Company, and (iii) no shares of Company
Preferred Stock were issued or outstanding.
- 18 -
(b) Section 4.2(b) of the Company Disclosure Schedule lists all issued and outstanding shares
of Company Common Stock that constitute restricted stock or that are otherwise subject to a
repurchase or redemption right or right of first refusal in favor of the Company, indicating the
name of the applicable stockholder, the vesting schedule for any such shares, including the extent
to which any such repurchase or redemption right or right of first refusal has lapsed as of the
date of this Agreement, whether (and to what extent) the vesting will be accelerated in any way by
the transactions contemplated by this Agreement or by termination of employment or change in
position following consummation of the Merger, and whether such holder has the sole power to vote
and dispose of such shares.
(c) Section 4.2(c) of the Company Disclosure Schedule lists all issued and outstanding
restricted stock unit awards granted under any Company Stock Plan (“RSUs”), indicating with respect
to each such RSU the name of the holder thereof, the Company Stock Plan under which it was granted,
the number of shares of Company Common Stock subject to such RSU, the date of grant, and the
vesting schedule, including whether (and to what extent) the vesting will be accelerated in any way
by the Merger or by termination of employment or change in position following consummation of the
Merger. The Company has made available to the Parent complete and accurate copies of forms of
award agreements evidencing RSUs.
(d) Section 4.2(d) of the Company Disclosure Schedule sets forth a list, as of the date of
this Agreement, of: (i) all plans or other arrangements under which Company Stock Options (as
defined below) and IDM Pharma S.A. Stock Options (as defined below) were granted (collectively, the
“Company Stock Plans”), indicating for each Company Stock Plan, as of the close of business on the
business day prior to the date of this Agreement, the number of shares of Company Common Stock
issued to date under such Plan, the number of shares of Company Common Stock subject to outstanding
options under such Plan, including where applicable whether the shares of Company Common Stock are
issuable pursuant to Option Liquidity Agreements (such outstanding options, collectively, the
“Company Stock Options”), the number of ordinary shares of IDM Pharma, S.A. subject to outstanding
options under such Plan (such outstanding options, the “IDM Pharma S.A. Stock Options”) and the
number of shares of Company Common Stock reserved for future issuance under such Plan; and (ii) all
outstanding Company Stock Options and IDM Pharma S.A. Stock Options, indicating with respect to
each such Company Stock Option and IDM Pharma S.A. Stock Option the name of the holder thereof, the
Company Stock Plan under which it was granted or is issuable, the number of shares of Company
Common Stock subject to such Company Stock Option or ordinary shares of IDM Pharma S.A. subject to
such IDM Pharma S.A. Stock Option, as applicable, the exercise price, the date of grant, and the
vesting schedule, including whether (and to what extent) the vesting will be accelerated in any way
by the Merger or by termination of employment or change in position following consummation of the
Merger. The Company has made available to the Parent copies of all Company Stock Plans and the
forms of all stock option agreements and Option Liquidity Agreements evidencing or applicable to
Company Stock Options.
- 19 -
(e) Section 4.2(e) of the Company Disclosure Schedule shows the number of shares of Company
Common Stock reserved for future issuance pursuant to each warrant or other outstanding right
(other than Company Stock Options and IDM Pharma S.A. Stock Options) to purchase shares of Company
Common Stock (such outstanding warrants or other rights, “Company Warrants”) outstanding as of the
date of this Agreement and the agreement or other document under which such Company Warrants were
granted and sets forth a list of all holders of Company Warrants indicating the number of shares of
Company Common Stock subject to each Company Warrant, and the exercise price, the date of grant and
the expiration date thereof. The Company has made available to the Parent the forms of all
agreements or other documents evidencing all Company Warrants.
(f) Except (x) as set forth in this Section 4.2, (y) as reserved for future grants under
Company Stock Plans as of the date of this Agreement, and (z) as set forth on Section 4.2(f) of the
Company Disclosure Schedule, (A) there are no equity securities of any class of the Company, or any
security exchangeable into or exercisable for such equity securities, issued, reserved for issuance
or outstanding and (B) there are no options, warrants, equity securities, calls, rights,
commitments or agreements of any character to which the Company or any of its Subsidiaries is a
party or by which the Company or any of its Subsidiaries is bound obligating the Company or any of
its Subsidiaries to issue, exchange, transfer, deliver or sell, or cause to be issued, exchanged,
transferred, delivered or sold, additional shares of capital stock or other equity interests of the
Company or any security or rights convertible into or exchangeable or exercisable for any such
shares or other equity interests, or obligating the Company or any of its Subsidiaries to grant,
extend, accelerate the vesting of, otherwise modify or amend or enter into any such option,
warrant, equity security, call, right, commitment or agreement. Except as set forth on Section
4.2(f) of the Company Disclosure Schedule, the Company does not have any outstanding stock
appreciation rights, phantom stock, performance based stock or equity rights or similar stock or
equity rights or obligations. Other than the Stockholders’ Agreement, neither the Company nor any
of its Affiliates is a party to or is bound by any, and to the knowledge of the Company, there are
no, agreements or understandings with respect to the voting (including voting trusts and proxies)
or sale or transfer (including agreements imposing transfer restrictions) of any shares of capital
stock or other equity interests of the Company. For purposes of this Agreement, the term
“Affiliate” when used with respect to any party shall mean any person who is an “affiliate” of that
party within the meaning of Rule 405 promulgated under the Securities Act of 1933, as amended (the
“Securities Act”). Except as contemplated by this Agreement or as set forth on Section 4.2(f) of
the Company Disclosure Schedule, there are no registration rights, and there is no rights
agreement, “poison pill” anti-takeover plan or other similar agreement or understanding to which
the Company or any of its Subsidiaries is a party or by which it or they are bound with respect to
any equity security of any class of the Company.
(g) All outstanding shares of Company Common Stock are, and all shares of Company Common Stock
subject to issuance as specified in Sections 4.2(c) and 4.2(d) above, upon issuance on the terms
and conditions specified in the instruments pursuant to which they are issuable, will be, duly
authorized, validly issued, fully paid and nonassessable and not subject
- 20 -
to or issued in violation of any purchase option, call option, right of first refusal,
preemptive right, subscription right or any similar right under any provision of the DGCL, the
Company’s Certificate of Incorporation or By-laws or any agreement to which the Company is a party
or is otherwise bound.
(h) There are no obligations, contingent or otherwise, of the Company or any of its
Subsidiaries to (i) repurchase, redeem or otherwise acquire any shares of Company Common Stock or
the capital stock of the Company or any of its Subsidiaries, (ii) provide funds to or make any
investment (in the form of a loan, capital contribution or otherwise) in the Company or any
Subsidiary of the Company or (iii) make any investment (in the form of a loan or capital
contribution) in any other entity, other than, in the case of clause (ii), guarantees of bank
obligations of Subsidiaries of the Company entered into in the ordinary course of business
consistent with past practice (the “Ordinary Course of Business”) and listed in Section 4.2(h) of
the Company Disclosure Schedule.
(i) No consent of the holders of Company Stock Options, RSUs or Company Warrants is required
in connection with the actions contemplated by clauses (c), (d) and (e) of Section 3.1, except that
the Assumed French Options may not be terminated by the Company’s unilateral action.
4.3 Subsidiaries.
(a) Section 4.3 of the Company Disclosure Schedule sets forth, for each Subsidiary of the
Company: (i) its name; (ii) the number and type of outstanding equity securities and a list of the
holders thereof; and (iii) the jurisdiction of organization or formation. For purposes of this
Agreement, the term “Subsidiary” means, with respect to any party, any corporation, partnership,
trust, limited liability company or other non-corporate business enterprise in which such party (or
another Subsidiary of such party) holds stock or other ownership interests representing (A) more
than 50% of the voting power of all outstanding stock or ownership interests of such entity or (B)
the right to receive more than 50% of the net assets of such entity available for distribution to
the holders of outstanding stock or ownership interests upon a liquidation or dissolution of such
entity.
(b) Each Subsidiary of the Company is an entity duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization or formation, has all requisite
power and authority to own, lease and operate its properties and assets and to carry on its
business as now being conducted and to manufacture for commercial sale, market, sell and otherwise
commercialize the Company’s MEPACT product candidate in the EU Territory, and is duly qualified to
do business and is in good standing as a foreign entity in each jurisdiction where the character of
its properties owned, operated or leased or the nature of its activities makes such qualification
necessary, except for such failures to be so organized, qualified or in good standing that have not
had, and would not reasonably be expected to result in, a Company Material Adverse Effect. All of
the outstanding shares of capital stock and other equity securities or interests of each Subsidiary
of the Company are duly authorized, validly
- 21 -
issued, fully paid, nonassessable and free of preemptive rights and all such shares (other
than directors’ qualifying shares in the case of non-U.S. Subsidiaries, all of which the Company
has the power to cause to be transferred for no or nominal consideration to the Company or the
Company’s designee), except as set forth on Section 4.3(b) of the Company Disclosure Schedule, are
owned, of record and beneficially, by the Company or another of its Subsidiaries free and clear of
all security interests, liens, claims, pledges, agreements, limitations in the Company’s voting
rights, charges or other encumbrances of any nature. Except for the IDM Pharma S.A. Stock Options,
there are no outstanding or authorized options, warrants, rights, agreements or commitments to
which the Company or any of its Subsidiaries is a party or which are binding on any of them
providing for the issuance, disposition or acquisition of any capital stock of any Subsidiary of
the Company. There are no outstanding stock appreciation, phantom stock or similar rights with
respect to any Subsidiary of the Company. There are no voting trusts, proxies or other agreements
or understandings with respect to the voting of any capital stock of any Subsidiary of the Company.
(c) The Company has made available to the Parent copies of the charter, by-laws or other
organizational documents of each Subsidiary of the Company.
(d) The Company does not control directly or indirectly or have any direct or indirect equity
participation or similar interest in any corporation, partnership, limited liability company, joint
venture, trust or other business association or entity which is not a Subsidiary of the Company.
Except as set forth in Section 4.3(d) of the Company Disclosure Schedule, there are no obligations,
contingent or otherwise, of the Company or any of its Subsidiaries to repurchase, redeem or
otherwise acquire any shares of capital stock of any Subsidiary of the Company or to provide funds
to or make any investment (in the form of a loan, capital contribution or otherwise) in any
Subsidiary of the Company or any other entity, other than guarantees of bank obligations of
Subsidiaries of the Company entered into in the Ordinary Course of Business.
4.4 Authority; No Conflict; Required Filings and Consents.
(a) The Company has all requisite corporate power and authority to enter into this Agreement,
perform its obligations hereunder and, subject only to the adoption of this Agreement (the “Company
Voting Proposal”) by the Company’s stockholders under the DGCL (the “Company Stockholder
Approval”), to the extent required by applicable law, to consummate the transactions contemplated
by this Agreement. Without limiting the generality of the foregoing, the Company Board, at a
meeting duly called and held, by the unanimous vote of all directors (i) determined that the
Merger, the Offer and this Agreement are fair to and in the best interests of the Company and its
stockholders, (ii) approved the Merger, the Offer and this Agreement and declared their
advisability in accordance with the provisions of the DGCL, (iii) directed that this Agreement be
submitted to the stockholders of the Company for their adoption and resolved to recommend that the
stockholders of the Company vote in favor of the adoption of this Agreement, to the extent required
by applicable law, (iv) to the extent necessary, adopted
- 22 -
resolutions having the effect of causing the Company not to be subject to any takeover law or
similar law that might otherwise apply to this Agreement, the Stockholders’ Agreement, the Merger,
the Offer or any other transactions contemplated by this Agreement or the Stockholders’ Agreement
and (v) recommended that the holders of Company Common Stock tender their shares into and accept
the Offer. The execution and delivery of this Agreement and the consummation of the transactions
contemplated by this Agreement by the Company have been duly authorized by all necessary corporate
action on the part of the Company, subject only to the required receipt of the Company Stockholder
Approval to the extent required by applicable law. This Agreement has been duly executed and
delivered by the Company and constitutes the valid and binding obligation of the Company,
enforceable in accordance with its terms, except to the extent that such enforceability (A) may be
limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to
creditors’ rights generally, and (B) is subject to general principles of equity. Each member of
the Company Board (1) is a “Continuing Director” defined in the Certificate of Incorporation of the
Company) and (2) is not an “Interested Stockholder” defined in the Certificate of Incorporation of
the Company) or affiliated with an “Interested Stockholder”. The Company is not subject to Section
2115 of the California Corporations Code.
(b) The execution and delivery of this Agreement by the Company do not, and the consummation
by the Company of the transactions contemplated by this Agreement shall not, (i) conflict with, or
result in any violation or breach of, any provision of the Certificate of Incorporation or By-laws
of the Company or of the charter, by-laws, or other organizational document of any Subsidiary of
the Company, (ii) conflict with, or result in any violation or breach of, or constitute (with or
without notice or lapse of time, or both) a default (or give rise to a right of termination,
cancellation or acceleration of any obligation or loss of any material benefit) under, require a
consent or waiver under, constitute a change in control under, require the payment of a penalty
under or result in the imposition of any mortgage, security interest, pledge, lien, charge or
encumbrance of any nature, whether arising by contract or by operation of law (“Liens”) on the
Company’s or any of its Subsidiary’s assets under, any of the terms, conditions or provisions of
any note, bond, mortgage, indenture, lease, license, contract or other agreement, instrument or
obligation to which the Company or any of its Subsidiaries is a party or by which any of them or
any of their properties or assets may be bound, or (iii) subject to obtaining the Company
Stockholder Approval (to the extent required by applicable law) and compliance with the
requirements specified in clauses (i) through (iv) of Section 4.4(c), conflict with or violate any
permit, concession, franchise, license, judgment, injunction, order, decree, statute, law,
ordinance, rule or regulation applicable to the Company or any of its Subsidiaries or any of its or
their properties or assets, except in the case of clauses (ii) and (iii) of this Section 4.4(b) for
any such conflicts, violations, breaches, defaults, terminations, cancellations, accelerations or
losses that have not had, and would not reasonably be expected to result in, a Company Material
Adverse Effect. Section 4.4(b) of the Company Disclosure Schedule lists all consents, waivers and
approvals under any of the Company’s or any of its Subsidiaries’ agreements, licenses or leases
required to be obtained in connection with the consummation of the transactions contemplated
hereby, except for any such consents, waivers or approvals that
- 23 -
relate to agreements, licenses and leases (A) that, neither individually nor in the aggregate,
are material to the operations of the Company and its Subsidiaries, taken as a whole, (B) under
which the unpaid obligations of any party to such agreement, license or lease does not exceed, as
of the date of this Agreement $10,000 individually or $100,000 in the aggregate and (C) that do not
by their terms provide for the payment of any financial penalty as a result of the failure to
obtain any such consent, waiver of approval.
(c) No consent, approval, license, permit, order or authorization of, or registration,
declaration, notice or filing with, any foreign or domestic court, arbitrational tribunal,
administrative agency or commission or other governmental, regulatory or administrative authority,
agency, commission or instrumentality or any stock market or stock exchange on which shares of
Company Common Stock are listed for trading (a “Governmental Entity”) is required by or with
respect to the Company or any of its Subsidiaries in connection with the execution and delivery of
this Agreement by the Company or the consummation by the Company of the transactions contemplated
by this Agreement, except for (i) the filing of the Certificate of Merger with the
Delaware
Secretary of State and appropriate corresponding documents with the appropriate authorities of
other states in which the Company is qualified as a foreign corporation to transact business, (ii)
the filing of the Schedule TO, Offer Documents, Schedule 14D-9 and (if required by applicable law)
the proxy or information statement (the “Proxy Statement”) with respect to the Company Meeting (as
defined below) with the SEC in accordance with the Exchange Act, (iii) the filing of such reports,
schedules or materials under Section 13 of or Rule 14a-12 under the Exchange Act and materials
under Rule 165 and Rule 425 under the Securities Act as may be required in connection with this
Agreement and the transactions contemplated hereby, (iv) such consents, approvals, orders,
authorizations, registrations, declarations and filings as may be required under applicable state
securities laws and the securities laws of any foreign country and the NASDAQ Marketplace Rules,
and (v) such other consents, approvals, licenses, permits, orders, authorizations, registrations,
declarations, notices and filings which, if not obtained or made, have not had, and would not
reasonably be expected to result in, a Company Material Adverse Effect.
(d) To the extent stockholder approval is required by applicable law, the affirmative vote for
adoption of the Company Voting Proposal by the holders of a majority of the outstanding shares of
Company Common Stock on the record date for the meeting of the Company’s stockholders (the “Company
Meeting”) to consider the Company Voting Proposal (the “Required Company Stockholder Vote”) is the
only vote of the holders of any class or series of the Company’s capital stock or other securities
necessary for the adoption of this Agreement and for the consummation by the Company of the
transactions contemplated by this Agreement. There are no bonds, debentures, notes or other
indebtedness of the Company having the right to vote (or convertible into, or exchangeable for,
securities having the right to vote) on any matters on which stockholders of the Company may vote.
- 24 -
4.5 SEC Filings; Financial Statements; Information Provided.
(a) The Company has filed all registration statements, forms, reports, certifications and
other documents required to be filed by the Company with the SEC since it became an SEC reporting
company, and has made available to the Parent copies of all registration statements, forms,
reports, certifications and other documents filed by the Company with the SEC since January 1,
2006, including all certifications and statements required by (i) Rule 13a-14 or 15d-14 of the
Exchange Act or (ii) 18 U.S.C. §1350 (Section 906 of the Xxxxxxxx-Xxxxx Act of 2002 (the “Sarbanes
Act”)). All such registration statements, forms, reports, certifications and other documents
(including those that the Company may file after the date hereof until the Closing) are referred to
herein as the “Company SEC Documents.” All of the Company SEC Documents are publicly available on
the SEC’s XXXXX system. The Company has made available to the Parent copies of all comment letters
received by the Company from the staff of the SEC since January 1, 2006 and all responses to such
comment letters by or on behalf of the Company. The Company SEC Documents (A) were or will be
filed on a timely basis, (B) at the time filed, were or will be prepared in compliance as to form
in all material respects with the applicable requirements of the Securities Act and the Exchange
Act, as the case may be, and the rules and regulations of the SEC thereunder applicable to such
Company SEC Documents, and (C) did not or will not at the time they were or are filed contain any
untrue statement of a material fact or omit to state a material fact required to be stated in such
Company SEC Documents or necessary in order to make the statements in such Company SEC Documents,
in the light of the circumstances under which they were made, not misleading. No Subsidiary of the
Company is subject to the reporting requirements of Section 13 or Section 15(d) of the Exchange
Act. As used in this Section 4.5, the term “file” shall be broadly construed to include any manner
in which a document or information is furnished, supplied or otherwise made available to the SEC.
(b) Each of the consolidated financial statements (including, in each case, any related notes
and schedules) contained or to be contained in the Company SEC Documents at the time filed (i)
complied or will comply as to form in all material respects with applicable accounting requirements
and the published rules and regulations of the SEC with respect thereto (including Regulation S-X),
(ii) were or will be prepared in accordance with United States generally accepted accounting
principles (“GAAP”) applied on a consistent basis throughout the periods involved and at the dates
involved (except as may be indicated in the notes to such financial statements or, in the case of
unaudited statements, as permitted by the SEC on Form 10-Q under the Exchange Act), and (iii)
fairly presented in all material respects or will fairly present in all material respects the
consolidated financial position of the Company and its Subsidiaries as of the dates thereof and the
consolidated results of its operations and cash flows for the periods indicated, consistent with
the books and records of the Company and its Subsidiaries, except that the unaudited interim
financial statements were or are subject to normal and recurring year-end adjustments which were
not or will not be material in amount or effect. The consolidated, unaudited balance sheet of the
Company as of March 31, 2009 is referred to herein as the “Company Balance Sheet.”
- 25 -
(c) To the Company’s knowledge, Ernst & Young LLP, the Company’s current auditors, is and has
been at all times since its engagement by the Company (i) “independent” with respect to the Company
within the meaning of Regulation S-X and (ii) in compliance with subsections (g) through (l) of
Section 10A of the Exchange Act (to the extent applicable) and the related rules of the SEC and the
Public Company Accounting Oversight Board.
(d) The information to be supplied in writing by or on behalf of the Company for inclusion or
incorporation by reference in the Schedule TO or the Offer Documents, on the date the Schedule TO
is filed with the SEC and on the date the Offer Documents are first published, sent or given to
stockholders of the Company shall not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make the statements
therein not misleading. The Proxy Statement (if required) to be sent to the stockholders of the
Company in connection with the Company Meeting, on the date the Proxy Statement is first published,
sent or given to stockholders of the Company and at the time of the Company Meeting, shall comply
in all material respects with the provisions of applicable securities laws and shall not contain
any statement which, at such time and in light of the circumstances under which it shall be made,
is false or misleading with respect to any material fact, or omit to state any material fact
necessary in order to make the statements made in the Proxy Statement not false or misleading in
light of the circumstances under which they were or shall be made; or omit to state any material
fact necessary to correct any statement in any earlier communication with respect to the
solicitation of proxies for the Company Meeting which has become false or misleading; provided that
no representation or warranty is made pursuant to this Section 4.5(d) with respect to any written
information provided by or on behalf of the Parent or the Purchaser for inclusion in the Proxy
Statement. If at any time prior to the Effective Time any fact or event relating to the Company or
any of its Affiliates, officers or directors should be discovered by the Company which should be
set forth in an amendment to the Schedule TO or a supplement to the Offer Documents or the Proxy
Statement, the Company shall promptly inform the Parent.
4.6 No Undisclosed Liabilities; Indebtedness.
(a) Neither the Company nor any of its Subsidiaries has any obligations or liabilities
(whether or not accrued, contingent or otherwise, and whether or not required to be reflected in
financial statements in accordance with GAAP), except for: (i) liabilities disclosed in the
financial statements contained in the Company SEC Documents filed with the SEC on the SEC’s XXXXX
system at least three business days prior to the date hereof; (ii) liabilities incurred in the
Ordinary Course of Business since the date of the Company Balance Sheet; (iii) liabilities that
have not had, and would not reasonably be expected to result in, a Company Material Adverse Effect;
and (iv) liabilities set forth on Section 4.6(a) of the Company Disclosure Schedule.
- 26 -
(b) Section 4.6(b) of the Company Disclosure Schedule sets forth a list of all loan or credit
agreements, notes, bonds, mortgages, indentures and other agreements and instruments pursuant to
which any indebtedness for borrowed money of the Company or any of its Subsidiaries in an aggregate
principal amount in excess of $25,000 is outstanding or may be incurred and the respective
principal amounts outstanding thereunder as of the date of this Agreement. For purposes of this
Section 4.6(b), “indebtedness” means, with respect to any person, without duplication, (i) all
obligations of such person for borrowed money, or with respect to deposits or advances of any kind
to such person, (ii) all obligations of such person evidenced by bonds, debentures, notes or
similar instruments, (iii) all obligations of such person upon which interest charges are
customarily paid, (iv) all obligations of such person under conditional sale or other title
retention agreements relating to property purchased by such person, (v) all obligations of such
person issued or assumed as the deferred purchase price of property or services (excluding
obligations of such person or creditors for raw materials, inventory, services and supplies
incurred in the Ordinary Course of Business), (vi) all capitalized lease obligations of such
person, (vii) all obligations of others secured by any lien on property or assets owned or acquired
by such person, whether or not the obligations secured thereby have been assumed, (viii) all
obligations of such person under interest rate or currency hedging transactions (valued at the
termination value thereof), (xi) all letters of credit issued for the account of such person, and
(x) all guarantees and arrangements having the economic effect of a guarantee by such person of any
indebtedness of any other person. All of the outstanding indebtedness of the type described in
this Section 4.6(b) of the Company and each of its Subsidiaries may be prepaid by the Company or
its Subsidiary at any time without the consent or approval of, or prior notice to, any other
person, and without payment of any premium or penalty.
4.7 Absence of Certain Changes or Events. Since the date of the Company Balance
Sheet, the Company and its Subsidiaries have conducted their respective businesses only in the
Ordinary Course of Business and, since such date and through the date of this Agreement, there has
not been (i) any Change that has had, or would reasonably be expected to result in, a Company
Material Adverse Effect; or (ii) any other action or event that would have required the consent of
the Parent pursuant to Section 6.1 of this Agreement (other than subsections (a)(3), (b), (l), (m),
(n) and (r) of Section 6.1) had such action or event occurred after the date of this Agreement.
4.8 Taxes.
(a) Each of the Company and its Subsidiaries has properly filed or caused to be filed on a
timely basis all material Tax Returns that it was required to file, and all such Tax Returns were
true, correct and complete in all material respects. Except as set forth in Section 4.8(a) of the
Company Disclosure Schedule, each of the Company and its Subsidiaries has paid or caused to be paid
on a timely basis all material Taxes that were due and payable by it. The unpaid Taxes of the
Company and each of its Subsidiaries for Tax periods through the date of the Company Balance Sheet
do not exceed the accruals and reserves for Taxes (excluding accruals and reserves for deferred
Taxes established to reflect timing differences between book and Tax
- 27 -
income) set forth on the Company Balance Sheet and all unpaid Taxes of the Company and each of
its Subsidiaries for all Tax periods commencing after the date of the Company Balance Sheet arose
in the Ordinary Course of Business and are of a type and amount commensurate with Taxes
attributable to prior similar periods. Neither the Company nor any of its Subsidiaries (i) has any
actual or potential liability under Treasury Regulations Section 1.1502-6 (or any comparable or
similar provision of federal, state, local or foreign law), as a transferee or successor, pursuant
to any contractual obligation, or otherwise for any Taxes of any person other than the Company or
any of its Subsidiaries, or (ii) is a party to or bound by any Tax indemnity, Tax sharing, Tax
allocation or similar agreement. All material Taxes that the Company or any of its Subsidiaries
was required by law to withhold or collect have been duly withheld or collected and, to the extent
required, have been properly paid to the appropriate Governmental Entity.
(b) The Company has made available to the Parent (i) copies of all material Tax Returns of the
Company and any of its Subsidiaries relating to Taxes for all taxable periods for which the
applicable statute of limitations has not yet expired, and (ii) copies of all private letter
rulings, revenue agent reports, information document requests, notices of proposed deficiencies,
deficiency notices, protests, petitions, notices of assessment, closing agreements, settlement
agreements, pending ruling requests and any similar documents submitted by, received by, or agreed
to by or on behalf of the Company or any of its Subsidiaries relating to any material Taxes for all
taxable periods for which the statute of limitations has not yet expired. The federal income Tax
Returns of the Company and each of its Subsidiaries have been audited by the Internal Revenue
Service or are closed by the applicable statute of limitations for all taxable years through the
taxable year specified in Section 4.8(b) of the Company Disclosure Schedule. Except as set forth
in Section 4.8(b) of the Company Disclosure Schedule, no examination or audit of any Tax Return of
the Company or any of its Subsidiaries by any Governmental Entity is currently in progress or, to
the knowledge of the Company or any of its Subsidiaries, threatened or contemplated. Neither the
Company nor any of its Subsidiaries has been informed by any jurisdiction that the jurisdiction
believes that the Company or any of its Subsidiaries was required to file any Tax Return that was
not filed. Except as set forth in Section 4.8(b) of the Company Disclosure Schedule neither the
Company nor any of its Subsidiaries has (A) waived any statute of limitations with respect to
material Taxes or agreed to extend the period for assessment or collection of any material Taxes,
which extension is still in effect, (B) requested any extension of time within which to file any
material Tax Return, which Tax Return has not yet been filed, or (C) executed or filed any power of
attorney with any taxing authority, which power of attorney is still in effect.
(c) Neither the Company nor any of its Subsidiaries is or, to the knowledge of the Company,
has ever been a member of a group of corporations with which it has filed (or been required to
file) consolidated, combined or unitary Tax Returns, other than a group the common parent of which
is the Company.
- 28 -
(d) Neither the Company nor any of its Subsidiaries is obligated to make any payment that will
not be fully deductible as a result of the application of Section 162(m) of the Code.
(e) There are no Liens with respect to Taxes upon any of the assets or properties of the
Company or any of its Subsidiaries, other than with respect to Taxes not yet due and payable or
being contested in good faith.
(f) There are no adjustments under Section 481 of the Code (or any similar adjustments under
any provision of the Code or the corresponding foreign, state or local Tax laws) that are required
to be taken into account by the Company or any of its Subsidiaries in any period ending after the
Closing Date by reason of a change in method of accounting in any taxable period ending on or
before the Closing Date or as a result of the consummation of the transactions contemplated by this
Agreement.
(g) Neither the Company nor any of its Subsidiaries has distributed to its shareholders or
security holders stock or securities of a controlled corporation, nor has stock or securities of
the Company or any of its Subsidiaries been distributed, in a transaction to which Section 355 of
the Code applies (i) in the two years prior to the date of this Agreement or (ii) in a distribution
that could otherwise constitute part of a “plan” or “series of related transactions” (within the
meaning of Section 355(e) of the Code) that includes the transactions contemplated by this
Agreement.
(h) Section 4.8(h) of the Company Disclosure Schedule sets forth each jurisdiction (other than
United States federal) in which the Company or any of its Subsidiaries files, is required to file
or has been required to file a material Tax Return or is or has been liable for any material Taxes
on a “nexus” basis.
(i) Neither the Company nor any of its Subsidiaries is or has been a passive foreign
investment company within the meaning of Sections 1291 through 1297 of the Code.
(j) Neither the Company nor any of its Subsidiaries has incurred (or been allocated) an
“overall foreign loss” as defined in Section 904(f)(2) of the Code which has not been previously
recaptured in full as provided in Sections 904(f)(1) and/or 904(f)(3) of the Code.
(k) Neither the Company nor any of its Subsidiaries is a party to a gain recognition agreement
under Section 367 of the Code.
(l) Neither the Company nor any of its Subsidiaries has engaged in a “reportable transaction”
as set forth in Treasury Regulation Section 1.6011-4(b), or any transaction that is the same as or
substantially similar to one of the types of transactions that the IRS has determined to be a tax
avoidance transaction and identified by notice, regulation or other form of published guidance as a
“listed transaction” as set forth in Treasury Regulation Section 1.6011-4(b)(2).
- 29 -
(m) As used in this Agreement:
(i) “Taxes” shall mean any and all taxes, charges, fees, levies or other
similar assessments or liabilities in the nature of a tax, including income, gross
receipts, ad valorem, premium, value-added, net worth, capital stock, capital
gains, documentary, recapture, alternative or add-on minimum, disability,
estimated, registration, recording, excise, real property, personal property,
sales, use, license, lease, service, service use, transfer, withholding,
employment, unemployment, insurance, employment insurance, social security,
business license, business organization, environmental, worker’s compensation,
pension, payroll, profits, severance, stamp, occupation, windfall profits,
customs, duties, franchise and other taxes of any kind whatsoever imposed by the
United States of America or any state, local or foreign government, or any agency
or political subdivision thereof, and any interest, fines, penalties, assessments
or additions to tax imposed with respect to such items or any contest or dispute
thereof, and
(ii) “Tax Returns” shall mean any and all reports, returns, or declarations
relating to Taxes (including any schedule or attachment thereto, including any
amendment thereof) filed or required to be filed with any Governmental Entity.
4.9 Owned and Leased Real Properties.
(a) Neither the Company nor any of its Subsidiaries owns or, to the knowledge of the Company,
has ever owned any real property.
(b) Section 4.9(b) of the Company Disclosure Schedule sets forth a list of all real property
leased, subleased or licensed by the Company or any of its Subsidiaries (collectively “Company
Leases”) and the location of the premises. Neither the Company nor any of its Subsidiaries nor, to
the Company’s knowledge, any other party to any Company Lease, is in default under any of the
Company Leases, except where the existence of such defaults, individually or in the aggregate, has
not had, and would not reasonably be expected to result in, a Company Material Adverse Effect.
Each of the Company Leases is in full force and effect and is enforceable (except to the extent
such enforceability (i) may be limited by bankruptcy, insolvency, reorganization, moratorium or
other similar laws relating to creditors’ rights generally, and (ii) is subject to general
principles of equity) against the Company or the applicable Subsidiary of the Company, as the case
may be, and, to the Company’s knowledge, against each other party thereto, in accordance with its
terms and shall not cease to be in full force and effect as a result of the transactions
contemplated by this Agreement. Neither the Company nor any of its Subsidiaries leases, subleases
or licenses any real property to any person other than the Company and its Subsidiaries. The
Company has made available to the Parent copies of all Company Leases.
- 30 -
4.10 Intellectual Property.
(a) Section 4.10(a) of the Company Disclosure Schedule lists all patents, patent applications,
trademark applications and registrations for trademarks, copyrights and other forms of Intellectual
Property included in the Company Intellectual Property (as defined below) that is the subject of
any application, registration, filing, certificate, or other document issued by, filed with, or
recorded by any Governmental Entity (“Registered Intellectual Property”) , in each case enumerating
specifically the applicable filing or registration number, title, jurisdiction in which filing was
made or from which registration issued, date of filing or issuance, names of all current
applicant(s) and registered owners(s), as applicable. All material Registered Intellectual
Property is subsisting (or, in the case of applications thereof that have not yet been granted, is
pending) and has not expired or been cancelled or abandoned. All assignments of Registered
Intellectual Property to the Company or any of its Subsidiaries related to the Company’s MEPACT
product candidate and IDM-2101 product candidate have been properly executed and recorded, other
than any failure to properly execute and record such assignments that is not material to the
Company and its Subsidiaries, taken as a whole. To the knowledge of the Company, all issued
Registered Intellectual Property is valid and enforceable, all pending patent and trademark
applications included in the Registered Intellectual Property if issued would be valid and
enforceable, and all issuance, renewal, maintenance and other payments that are or have become due
with respect to all Registered Intellectual Property related to the Company’s MEPACT product
candidate and IDM-2101 product candidate have been timely paid by or on behalf of the Company.
(b) The Company and its Subsidiaries own, license, sublicense or otherwise possess legally
enforceable rights to use all Intellectual Property material to the conduct of the business of the
Company and its Subsidiaries, taken as a whole, as currently conducted and to the manufacturing for
commercial sale, marketing and sale of the Company’s MEPACT product candidate in the EU Territory
(in each case excluding generally commercially available, off-the-shelf software programs). For
purposes of this Agreement, the term “Intellectual Property” means all proprietary rights of every
kind and nature throughout the world owned or used or planned to be used by the Company or any of
its Subsidiaries in the operation of the business of the Company or its Subsidiaries as it is
currently conducted and in the manufacturing for commercial sale, marketing and sale of the
Company’s MEPACT product candidate in the EU Territory, including all rights and interests
pertaining to or deriving from (i) patents, patent rights, patent applications (including all
provisional applications, utility applications, reissues, reexaminations, divisionals,
continuations, continuations-in-part and extensions of any patent or patent application and all
counterparts thereof in any country in the world), supplementary protection certificates,
inventions, discoveries, improvements, innovations, industrial designs, and all applications for
registration of the foregoing; (ii) copyrights, registrations and applications for copyrights,
works, derivative works, software (including all executables, libraries, controls and source code),
software documentation, database rights, mask works, domain names, domain name registrations, web
sites, web pages, moral rights, rights of privacy and publicity, and all applications for
registration of the foregoing; (iii) trade secrets, know-how,
- 31 -
processes, methods, data, formulae, and information (including ideas, research and
development, compositions and techniques, designs, drawings, specifications, customer and supplier
lists, pricing and cost information, business and marketing plans and proposals, documentation and
manuals) (collectively, “Trade Secrets”); and (iv) trademarks, trade names, logos, designs, brand
names, trade dress, and slogans (including the name of the Company and each Subsidiary and any
fictitious names used by the Company or any Subsidiary) and all goodwill associated with any of the
foregoing, and all applications for registration of the foregoing.
(c) Except as set forth in Section 4.10(c) of the Company Disclosure Schedule, there are no
inventorship challenges, opposition or nullity proceedings or interferences declared or commenced
or, to the knowledge of the Company, threatened, and the Company has no knowledge of any material
fact that is reasonably likely to result in an inventorship challenge, opposition or nullity
proceeding or interference, with respect to any patents, patent rights, patent applications
(including all provisional applications, utility applications, reissues, reexaminations,
divisionals, continuations, continuations-in-part and extensions of any patent or patent
application), trademarks or trademark applications included in the Registered Intellectual
Property. The Company and its Subsidiaries have complied with their duty of candor and disclosure
to the United States Patent and Trademark Office and any relevant patent offices in countries
outside the United States with respect to all patent and trademark applications within the
Registered Intellectual Property filed by or on behalf of the Company or any of its Subsidiaries
and have made no material misrepresentation in such applications.
(d) Except as set forth in Section 4.10(d) of the Company Disclosure Schedule, the Company or
a Subsidiary of the Company is the sole and exclusive owner of all Intellectual Property owned or
purported to be owned by the Company or one of its Subsidiaries (the “Company Intellectual
Property”), free and clear of any Liens.
(e) Except as set forth in Section 4.10(e) of the Company Disclosure Schedule, the execution
and delivery of this Agreement by the Company and the consummation by the Company of the Merger
will not result in the breach or termination of, or create on behalf of any third party the right
to terminate or modify, (i) any material license, sublicense or other agreement relating to any
Company Intellectual Property, or (ii) any material license, sublicense and other agreement as to
which the Company or any of its Subsidiaries is a party and pursuant to which the Company or any of
its Subsidiaries is authorized to use any third party Intellectual Property, excluding generally
commercially available, off-the-shelf software programs.
(f) The conduct of the business of the Company and its Subsidiaries, taken as a whole, as
currently conducted, does not to the knowledge of the Company, in any material respect, infringe,
violate or constitute a misappropriation of any Intellectual Property of any third party. Neither
the Company nor any of its Subsidiaries has received any written claim or notice from any Person
(i) alleging any such infringement, violation or misappropriation, or (ii) advising that such
Person is challenging or threatening to challenge the ownership, use, legality, validity or
enforceability of any Company Intellectual Property. To the knowledge of the
- 32 -
Company, none of the manufacturing for commercial sale, marketing or sale of any of the
Product Candidates (as defined below) would infringe, violate or constitute a misappropriation of
any Intellectual Property of any third party.
(g) The Company and each of its Subsidiaries has implemented commercially reasonable measures
to maintain the confidentiality of the Company Intellectual Property of a nature that the Company
intends to keep confidential.
(h) To the Company’s knowledge, no third party is infringing, violating or misappropriating
any of the Company Intellectual Property.
(i) Each employee of the Company or any of its Subsidiaries and each independent contractor of
the Company or any of its Subsidiaries has executed a valid and binding written agreement expressly
assigning to the Company or such Subsidiary all right, title and interest in any inventions and
works of authorship, whether or not patentable, invented, created, developed, conceived and/or
reduced to practice during the term and in the course of such employee’s employment or such
independent contractor’s work for the Company or its relevant Subsidiary, and all Intellectual
Property rights therein, and has waived all moral rights therein to the extent legally permissible.
4.11 Agreements; Government Contracts.
(a) Section 4.11(a) of the Company Disclosure Schedules sets forth a list of all agreements
(collectively, the “Company Material Contracts”), that are material to the business, assets,
liabilities, capitalization, condition (financial or otherwise) or results of operations of the
Company and its Subsidiaries, taken as a whole, or to the current or future manufacturing for
commercial sale, marketing, sale or other commercialization by the Company and its Subsidiaries of
the Company’s MEPACT product candidate in the EU Territory. The Company has made available to the
Parent a copy of each Company Material Contract. Each Company Material Contract is in full force
and effect and is enforceable (except to the extent that such enforceability (A) may be limited by
bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to creditors’
rights generally, and (B) is subject to general principles of equity) in accordance with its terms
against the Company or the applicable Subsidiary of the Company, as the case may be, and, to the
Company’s knowledge, against each other party thereto. Neither the Company nor any of its
Subsidiaries nor, to the Company’s knowledge, any other party to any Company Material Contract is
in violation of or in default under (nor does there exist any condition which, upon the passage of
time or the giving of notice or both, would cause such a violation of or default under) (i) any
loan or credit agreement, note, bond, mortgage, indenture, lease, permit, concession, franchise,
license or other contract, arrangement or understanding to which it is a party or by which it or
any of its properties or assets is bound, except for violations or defaults that have not had, and
would not reasonably be expected to result in, a Company Material Adverse Effect or (ii) any
Company Material Contract.
- 33 -
(b) Section 4.11(b) of the Company Disclosure Schedule sets forth a list of each agreement to
which the Company or any of its Subsidiaries is a party or bound with any Affiliate of the Company
(other than any Subsidiary which is a direct or indirect wholly owned Subsidiary of the Company).
Copies of all the agreements listed in Section 4.11(b) of the Company Disclosure Schedule have
heretofore been made available to the Parent. Neither the Company nor any of its Subsidiaries has
entered into any transaction with any Affiliate of the Company or any of its Subsidiaries or any
transaction that has not been disclosed in any Company SEC Documents filed prior to the date hereof
and that would be subject to proxy statement disclosure pursuant to Item 404 of Regulation S-K.
(c) There is no non-competition or other similar agreement, judgment, injunction or order to
which the Company or any of its Subsidiaries is a party or is subject that has or would reasonably
be expected to result in the effect of prohibiting or impairing the conduct of the business of the
Company or any of its Subsidiaries as currently conducted or the manufacturing for commercial sale,
marketing or sale of the Company’s MEPACT product candidate in the EU Territory. Except as set
forth on Section 4.11(c) of the Company Disclosure Schedule, neither the Company nor any of its
Subsidiaries has entered into (or is otherwise bound by) any agreement under which it is now, or
following the Effective Time the Parent or any of the Parent’s Affiliates (including the Company or
any of its Subsidiaries) would be, restricted from selling, licensing or otherwise distributing any
of their respective technology or Product Candidates to customers or potential customers or any
class of customers, in any geographic area, during any period of time or any segment of the market
or line of business.
(d) Neither the Company nor any of its Subsidiaries is a party to any agreement under which a
third party would be entitled to receive a license or any other right to Intellectual Property of
the Parent or any of the Parent’s Affiliates following the Closing.
(e) Neither the Company nor any of its Subsidiaries is or has been suspended or debarred from
bidding on contracts or subcontracts with any Governmental Entity; no such suspension or debarment
has been initiated or, to the Company’s knowledge, threatened; and the consummation of the
transactions contemplated by this Agreement will not result in any such suspension or debarment.
Neither the Company nor any of its Subsidiaries has since January 1, 2002 been audited or
investigated or is now being audited or, to the Company’s knowledge, investigated by the U.S.
Government Accounting Office, the U.S. Department of Defense or any of its agencies, the Defense
Contract Audit Agency, the U.S. Department of Justice, the Inspector General of any U.S.
Governmental Entity, any similar agencies or instrumentalities of any foreign Governmental Entity,
or any prime contractor with a Governmental Entity nor, to the Company’s knowledge, has any such
audit or investigation been threatened. To the Company’s knowledge, there is no valid basis for
(i) the suspension or debarment of the Company or any of its Subsidiaries from bidding on contracts
or subcontracts with any Governmental Entity or (ii) any claim pursuant to an audit or
investigation by any of the entities named in the foregoing sentence. Neither the Company nor any
of its Subsidiaries has any agreements which require it to obtain or maintain a security clearance
with any Governmental Entity.
- 34 -
4.12 Litigation. There is no action, suit, proceeding, claim, arbitration or
investigation pending and served or, to the knowledge of the Company, pending and not served or
threatened against or affecting the Company or any of its Subsidiaries that, individually or
together with any other actions, suits, proceedings, claims, arbitrations or investigations, is
material to the Company and its Subsidiaries, taken as a whole. There are no judgments, orders or
decrees outstanding against the Company or any of its Subsidiaries that, individually or in the
aggregate, are material to the Company and its Subsidiaries, taken as a whole. No claims have been
asserted or, to the knowledge of the Company, threatened against the Company or any of its
Subsidiaries relating to any of the Product Candidates. There is no action, suit, proceeding,
claim, arbitration or investigation pending and (where service or process is applicable) served,
or, to the knowledge of the Company, pending and (where service or process is applicable) not
served or threatened against or affecting the Company or any of its Subsidiaries by any current or
former director, officer or employee of the Company or any of its Subsidiaries.
4.13 Environmental Matters.
(a) Except for such matters that have not had, and would not reasonably be expected to result
in, a Company Material Adverse Effect:
(i) the Company and each of its Subsidiaries, to the knowledge of the Company
have at all times complied with, and are not currently in violation of, any
applicable Environmental Laws;
(ii) the Company and each of its Subsidiaries have all permits, licenses and
approvals required under Environmental Laws to operate and conduct their
respective businesses as currently operated and conducted;
(iii) there is no Contamination of or at the properties currently owned,
leased or operated by the Company or any of its Subsidiaries (including soils,
groundwater, surface water, buildings or other structures);
(iv) to the knowledge of the Company, there was no Contamination of or at the
properties formerly owned, leased or operated by the Company or any of its
Subsidiaries prior to or during the period of time such properties were owned,
leased or operated by the Company or any of its Subsidiaries;
(v) to the knowledge of the Company, neither the Company nor any of its
Subsidiaries is subject to liability for a Release of any Hazardous Substance or
Contamination on the property of any third party;
(vi) neither the Company nor any of its Subsidiaries has Released any
Hazardous Substance into the environment;
- 35 -
(vii) neither the Company nor any of its Subsidiaries has received any
notice, demand, letter, claim or request for information, nor are the Company or
any of its Subsidiaries aware of any pending or threatened notice, demand, letter,
claim or request for information, alleging that the Company or any of its
Subsidiaries may be in violation of, liable under or have obligations under any
Environmental Law;
(viii) neither the Company nor any of its Subsidiaries is subject to any
orders, decrees, injunctions or other arrangements with any Governmental Entity or
is subject to any indemnity or other agreement with any third party relating to
liability or obligation under any Environmental Law or relating to Hazardous
Substances;
(ix) to the knowledge of the Company, there are no circumstances or
conditions involving the Company or any of its Subsidiaries that would reasonably
be expected to result in any claims, liability, obligations, investigations, costs
or restrictions on the ownership, use or transfer of any property of the Company
or any of its Subsidiaries pursuant to any Environmental Law;
(x) none of the properties currently or, to the knowledge of the Company,
formerly owned, leased or operated by the Company or any of its Subsidiaries is
listed in the National Priorities List or any other list, schedule, log, inventory
or record maintained by any federal, state or local governmental agency with
respect to sites from which there is or has been a Release of any Hazardous
Substance or any Contamination;
(xi) none of the properties currently or, to the knowledge of the Company,
formerly owned, leased or operated by the Company or any of its Subsidiaries is
used, nor was ever used, (A) as a landfill, dump or other disposal, storage,
transfer or handling area for Hazardous Substances, excepting, however, for the
routine storage and use of Hazardous Substances from time to time in the Ordinary
Course of Business, in compliance with Environmental Laws and in compliance with
good commercial practice; (B) for industrial, military or manufacturing purposes;
or (C) as a gasoline service station or a facility for selling, dispensing,
storing, transferring or handling petroleum and/or petroleum products;
(xii) there are no underground or above ground storage tanks (whether or not
currently in use), urea-formaldehyde materials, asbestos, asbestos containing
materials, polychlorinated biphenyls (PCBs) or nuclear fuels or wastes, located on
or under any of the properties currently or, to the knowledge of the Company,
formerly owned, leased or operated by the Company or any of
- 36 -
its Subsidiaries, and no underground tank previously located on these
properties has been removed therefrom; and
(xiii) there are no Liens against any of the properties currently owned,
leased or operated by the Company or any of its Subsidiaries arising under any
Environmental Law.
(b) For purposes of this Agreement, “Environmental Law” means any federal, state or local law,
statute, rule or regulation or the common law relating to the environment or occupational health
and safety, including any statute, regulation, administrative decision or order pertaining to
(i) treatment, storage, disposal, generation and transportation of industrial, toxic, infectious,
biological, radioactive or hazardous materials or substances or solid, medical, mixed or hazardous
waste; (ii) air, water and noise pollution; (iii) groundwater and soil contamination; (iv) the
release or threatened release into the environment of industrial, toxic, infectious, biological,
radioactive or hazardous materials or substances, or solid, medical, mixed or hazardous waste,
including emissions, discharges, injections, spills, escapes or dumping of pollutants, contaminants
or chemicals; (v) the protection of wild life, marine life and wetlands, including all endangered
and threatened species; (vi) storage tanks, vessels, containers, abandoned or discarded barrels and
other closed receptacles; (vii) health and safety of employees and other persons; or (viii)
manufacturing, processing, using, distributing, treating, storing, disposing, transporting or
handling of materials regulated under any law as pollutants, contaminants, toxic, infectious,
biological, radioactive or hazardous materials or substances or oil or petroleum products or solid,
medical, mixed or hazardous waste.
(c) For purposes of this Agreement, “Contamination” means the presence of, or Release on,
under, from or to, any property of any Hazardous Substance, except the routine storage and use of
Hazardous Substances from time to time in the Ordinary Course of Business, in compliance with
Environmental Laws and in compliance with good commercial practice.
(d) For purposes of this Agreement, “Release” or “Released” means the spilling, leaking,
disposing, discharging, emitting, depositing, injecting, leaching, escaping or any other release,
however defined, and whether intentional or unintentional, of any Hazardous Substance. The term
“Release” shall include any threatened release.
(e) For purposes of this Agreement, “Hazardous Substance” means any substance that is: (i)
listed, classified, regulated or which falls within the definition of a “hazardous substance,”
“hazardous waste” or “hazardous material” pursuant to any Environmental Law; (ii) any petroleum
product or by-product, asbestos-containing material, lead-containing paint, pipes or plumbing,
polychlorinated biphenyls, radioactive materials or radon; (iii) any infectious, biological or
medical waste, including biohazards, radioactive materials and blood-borne pathogens; or (iv) any
other substance which is the subject of regulatory action by any Governmental Entity pursuant to
any Environmental Law.
- 37 -
(f) Section 4.13(f) of the Company Disclosure Schedule sets forth a list of all documents
(whether in hard copy or electronic form) that contain any environmental, human health and safety,
or natural resources reports, investigations and audits relating to premises currently or, to the
knowledge of the Company, previously owned or operated by the Company or any of its Subsidiaries
(whether conducted by or on behalf of the Company or any of its Subsidiaries or a third party, and
whether done at the initiative of the Company or any of its Subsidiaries or directed by a
Governmental Entity or other third party) which were issued or conducted during the past five years
and of which the Company or any of its Subsidiaries has possession or to which the Company or any
of its Subsidiaries has access. A copy of each such document has been made available to the
Parent.
4.14 Employee Benefit Plans.
(a) Section 4.14(a) of the Company Disclosure Schedule sets forth a list of all Employee
Benefit Plans maintained, or contributed to, by the Company, any of the Company’s Subsidiaries or
any of their ERISA Affiliates (together, the “Company Employee Plans”), including a written summary
of any unwritten Employee Benefit Plan. For purposes of this Agreement, the following terms shall
have the following meanings: (i) “Employee Benefit Plan” means any “employee pension benefit plan”
(as defined in Section 3(2) of ERISA), any “employee welfare benefit plan” (as defined in Section
3(1) of ERISA), and any other written or oral plan, agreement or arrangement involving direct or
indirect compensation, including insurance coverage, severance benefits, disability benefits,
deferred compensation, bonuses, stock options, stock purchase, phantom stock, stock appreciation or
other forms of incentive compensation or post-retirement compensation and all unexpired severance
agreements, written or otherwise, for the benefit of, or relating to, any current or former
employee of the Company or any of its Subsidiaries or an ERISA Affiliate; (ii) “ERISA” means the
Employee Retirement Income Security Act of 1974, as amended; and (iii) “ERISA Affiliate” means any
entity which is, or at any applicable time was, a member of (1) a controlled group of corporations
(as defined in Section 414(b) of the Code), (2) a group of trades or businesses under common
control (as defined in Section 414(c) of the Code), or (3) an affiliated service group (as defined
under Section 414(m) of the Code or the regulations under Section 414(o) of the Code), any of which
includes or included the Company or a Subsidiary.
(b) With respect to each Company Employee Plan, the Company has made available to the Parent,
a copy of (i) such Company Employee Plan (or a written summary of any unwritten plan), (ii) the
most recent annual report (Form 5500) filed with the Internal Revenue Service (the “IRS”), if any,
required under ERISA or the Code, (iii) each trust agreement, group annuity contract and summary
plan description, if any, relating to such Company Employee Plan, (iv) the most recent financial
statements for each Company Employee Plan that is funded, (v) all personnel, payroll and employment
manuals and policies, (vi) all employee handbooks and (vii) for each Company Employee Plan intended
to be qualified under Section 401(a) of the Code, all reports regarding the satisfaction of the
nondiscrimination requirements of Sections 410(b), 401(k) and 401(m) of the Code for the three most
recent plan years.
- 38 -
(c) To the knowledge of the Company, each Company Employee Plan has been administered in all
material respects in accordance with ERISA, the Code and all other applicable laws and the
regulations thereunder and in accordance with its terms and each of the Company, the Company’s
Subsidiaries and their ERISA Affiliates has in all material respects met its obligations with
respect to such Company Employee Plan and has made all required contributions thereto (or reserved
such contributions on the Company Balance Sheet). To the knowledge of the Company, the Company,
each Subsidiary of the Company, each ERISA Affiliate and each Company Employee Plan are in
compliance in all material respects with the currently applicable provisions of ERISA and the Code
and the regulations thereunder (including Section 4980B of the Code, Subtitle K, Chapter 100 of the
Code and Sections 601 through 608 and Section 701 et seq. of ERISA). All filings and reports as to
each Company Employee Plan required to have been submitted to the Internal Revenue Service or to
the United States Department of Labor have been timely submitted. To the knowledge of the Company,
with respect to the Company Employee Plans, no event has occurred, and there exists no condition or
set of circumstances in connection with which the Company or any of its Subsidiaries could be
subject to any material liability under ERISA, the Code or any other applicable law.
(d) With respect to the Company Employee Plans, there are no benefit obligations for which
contributions have not been made or properly accrued and there are no benefit obligations which
have not been accounted for by reserves, or otherwise properly footnoted in accordance with GAAP,
on the financial statements of the Company. The assets of each Company Employee Plan which is
funded are reported at their fair market value on the books and records of such Employee Benefit
Plan.
(e) Each Company Employee Plan that is intended to be qualified under Section 401(a) of the
Code has received a favorable determination letter (or opinion letter, if applicable) from the
Internal Revenue Service to the effect that such Company Employee Plans are qualified and the plans
and trusts related thereto are exempt from federal income taxes under Sections 401(a) and 501(a),
respectively, of the Code, no such determination letter or opinion letter has been revoked and
revocation has not been threatened, and no such Employee Benefit Plan has been amended or operated
since the date of its most recent determination letter or application therefor in any respect, and
no act or omission has occurred, that would reasonably be expected to adversely affect its
qualification. Each Company Employee Plan which is required to satisfy Section 401(k)(3) or
Section 401(m)(2) of the Code has been tested for compliance with, and satisfies the requirements
of Section 401(k)(3) and Section 401(m)(2) of the Code, as the case may be, for each plan year
ending prior to the Closing Date.
(f) Neither the Company, any of the Company’s Subsidiaries nor any of their ERISA Affiliates
has (i) ever maintained a Company Employee Plan which was ever subject to Section 412 of the Code
or Title IV of ERISA or (ii) ever been obligated to contribute to a “Multiemployer Plan” (as
defined in Section 4001(a)(3) of ERISA). No Company Employee Plan is funded by, associated with or
related to a “voluntary employees’ beneficiary association” within the meaning of Section 501(c)(9)
of the Code. Except as set forth in Section 4.14(f) of the
- 39 -
Company Disclosure Schedule, no Company Employee Plan holds securities issued by the Company,
any of the Company’s Subsidiaries or any of their ERISA Affiliates.
(g) Except with respect to the Assumed French Options, each Company Employee Plan is amendable
and terminable unilaterally by the Company and any of the Company’s Subsidiaries which are a party
thereto or covered thereby at any time without liability to the Company or any of its Subsidiaries
as a result thereof (other than for benefits accrued through the date of termination or amendment
and reasonable administrative expenses related thereto) and no Company Employee Plan, plan
documentation or agreement, summary plan description or other written communication distributed
generally to employees by its terms prohibits the Company or any of its Subsidiaries from amending
or terminating any such Company Employee Plan. The investment vehicles used to fund the Company
Employee Plans may be changed at any time without incurring a sales charge, surrender fee or other
similar expense.
(h) Section 4.14(h) of the Company Disclosure Schedule lists each agreement between the
Company or any of its Subsidiaries, on the one hand, and any current or former employee, director
or officer of the Company or any of its Subsidiaries, providing for any payment to be made to any
such employee, director or officer as a result of the consummation of the Offer or the Merger or as
a result of any termination of employment (whether before or after consummation of the Offer or the
Merger), setting forth in each case the name of each such current or former employee, director or
officer, any amount payable and the circumstances under which such payment will be made. Neither
the Company nor any of its Subsidiaries is a party to any other oral or written (i) agreement with
any stockholders, director, executive officer or other key employee of the Company or any of its
Subsidiaries (A) the benefits of which are contingent, or the terms of which are altered, upon the
occurrence of a transaction involving the Company or any of its Subsidiaries of the nature of any
of the transactions contemplated by this Agreement, (B) providing any term of employment or
compensation guarantee or (C) providing severance benefits or other benefits after the termination
of employment of such director, executive officer or key employee; (ii) agreement, plan or
arrangement under which any person may receive payments from the Company or any of its Subsidiaries
that may be subject to the tax imposed by Section 4999 of the Code or included in the determination
of such person’s “parachute payment” under Section 280G of the Code, without regard to Section
280G(b)(4); or (iii) agreement or plan binding the Company or any of its Subsidiaries, including
any stock option plan, stock appreciation right plan, restricted stock plan, stock purchase plan or
severance benefit plan, any of the benefits of which shall be increased, or the vesting of the
benefits of which shall be accelerated, by the occurrence of any of the transactions contemplated
by this Agreement or the value of any of the benefits of which shall be calculated on the basis of
any of the transactions contemplated by this Agreement. The Company has made available to the
Parent the information necessary to accurately calculate any excise tax due under Section 4999 of
the Code as a result of the transactions contemplated by this Agreement for which the Company or
the Parent may directly or indirectly become liable and the amount of deductions that may be
- 40 -
disallowed under Section 280G of the Code as a result of the transactions contemplated by this
Agreement.
(i) None of the Company Employee Plans promises or provides retiree medical or other retiree
welfare benefits to any person, except as required by COBRA or other applicable law.
(j) Each Company Employee Plan that is a “nonqualified deferred compensation plan” (as defined
in Section 409A(d)(1) of the Code) (i) has been operated in reasonable good faith compliance with
Section 409A of the Code, the Treasury Regulations promulgated thereunder and any other guidance
issued with respect to Section 409A of the Code (such regulations and guidance, the “Section 409A
Guidance”) at all times since January 1, 2005 through December 31, 2008, (ii) has been operated in
compliance with Section 409A of the Code and the Section 409A Guidance at all times since December
31, 2008, and (iii) has been in documentary compliance within the meaning of Section 409A of the
Code and the Section 409A Guidance at all times on or after December 31, 2008. Except as set forth
in Section 4.14(j) of the Company Disclosure Schedule, no Company Employee Plan that is a
“nonqualified deferred compensation plan” that was in existence as of October 3, 2004 has been
materially modified (as determined under Section 409A of the Code and the Section 409A Guidance)
after October 3, 2004. No event has occurred that would be treated by Section 409A(b) of the Code
as a transfer of property for purposes of Section 83 of the Code. No stock option or equity unit
option granted under any Company Employee Plan had an exercise price that was or may have been less
than the fair market value of the underlying stock or equity units (as the case may be) as of the
date such option was granted, or has any feature for the deferral of compensation other than the
deferral of recognition of income until the later of exercise or disposition of such option. The
Company’s past and current stock option grant practices (i) complied with all applicable Company
Stock Plans, stock exchange rules and applicable laws, (ii) have been fairly presented in
accordance with GAAP in the Company’s financial statements, and (iii) are not and have not been the
subject of any internal investigation, review or inquiry. The Company has not granted, and there
is no and has been no Company policy or practice to grant, stock options prior to, or otherwise
coordinate the grant of stock options with, the release or other public announcement of material
information regarding the Company or any of its Subsidiaries or their financial results or
prospects.
4.15 Compliance With Laws.
(a) The Company and each of its Subsidiaries is in compliance, and not in violation of, in any
material respect, any applicable provisions of any statute, law or regulation with respect to the
conduct of its business, or the ownership or operation of its properties or assets. Since January
1, 2000, the Company and each of its Subsidiaries has complied with, and not been in violation of,
all applicable provisions of all statutes, laws and regulations with respect to the conduct of its
business and the ownership and operation of its properties or assets, except for such violations
and failures to comply that have not had, and would not reasonably be
- 41 -
expected to result in, a Company Material Adverse Effect. Except as set forth in Section
4.15(a) of the Company Disclosure Schedule, since January 1, 2000, none of the Company or any of
its Subsidiaries has received any written notice alleging any material violation with respect to
any applicable provisions of any statute, law or regulation with respect to the conduct of its
business, or the ownership or operation of its properties or assets.
(b) Each of the Product Candidates is being, and at all times has been, developed, tested,
manufactured, processed, labeled, stored, transported, and distributed, as applicable, in
compliance in all material respects with all applicable Healthcare-Related Laws (as defined below),
including those requirements relating to good manufacturing practices, good laboratory practices,
and good clinical practices.
(c) The Company has not marketed, commercially distributed or sold any of its Product
Candidates, or any other pharmaceutical, biologic or medical device, anywhere in the world.
(d) The Company’s MEPACT (mifamurtide) product candidate (i) has received Community Marketing
Authorization (the “EU Approval”) under Regulation (EC) No. 726/2004 from the European Medicines
Agency (“EMEA”), which allows MEPACT to be marked in all member states of the European Union, as
well as Iceland, Liechtenstein and Norway (such member states of the European Union and other
countries collectively, the “EU Territory”) and (ii) has received an “orphan medicinal product
designation” (the “Orphan Product Designation”) by the EMEA. Each of the EU Approval and the
Orphan Product Designation is valid and subsisting in full force and effect and shall not cease to
be in full force and effect as a result of the consummation of the transactions contemplated by
this Agreement.
(e) Each of the Company and each of its Subsidiaries has all Registrations from the U.S. Food
and Drug Administration (“FDA”) and the EMEA, or any other comparable Governmental Entity, required
to conduct the development, investigation, testing, manufacture and distribution of each of the
Product Candidates (and any other product candidates of the Company or any of its Subsidiaries)
previously conducted by or on behalf of the Company or such Subsidiary. Each of the Registrations
(as defined below) is valid and subsisting in full force and effect and shall not cease to be in
full force and effect as a result of the consummation of the transactions contemplated by this
Agreement. To the Company’s knowledge, none of the FDA, the EMEA or any other comparable
Governmental Entity is, or is considering, limiting, suspending, or revoking any such Registrations
that are relevant to the Company’s MEPACT product candidate, including the EU Approval. No product
applications or other materials submitted by the Company or its Subsidiaries to the FDA, the EMEA
or any other Governmental Entity contained an untrue statement of material fact, or omitted a
material fact required to be stated therein or necessary in order to make the statements contained
therein, in light of the circumstances under which they were made, not misleading. The Company and
its Subsidiaries have fulfilled and performed their obligations under each Registration in all
material respects, and no event has occurred or condition or state of facts exists which would
constitute a material
- 42 -
breach or default or would cause revocation, suspension, limitation or termination of any such
Registration or would result in any other material impairment of the rights of the holder of any
such Registration. No loss or expiration of any Registration is pending or, to the knowledge of
the Company, threatened, other than the expiration of any Registration in accordance with the terms
thereof. Except as set forth in Section 4.15(e) of the Company Disclosure Schedule, to the
Company’s knowledge, each third party that is a supplier, manufacturer, or contractor for the
Company or any of its Subsidiaries is in compliance with all Registrations of the FDA, the EMEA or
any comparable Governmental Entity. For purposes of this Agreement, “Registrations” means
authorizations, approvals, licenses, permits, certificates, or exemptions issued by any
Governmental Entity (including pre-market approval applications, pre-market notifications,
investigational new drug applications, new drug applications, biologic license applications,
manufacturing approvals and authorizations, XX Xxxxx, pricing and reimbursement approvals, labeling
approvals or their foreign equivalent) held by the Company or any of its Subsidiaries and that are
required for the research, development, manufacture, processing, labeling, distribution, marketing,
storage, transportation, use and sale of any Product Candidate.
(f) The pre-clinical and clinical trials conducted by or on behalf of the Company or its
Subsidiaries were at the time conducted, and if still pending, are, being conducted in all material
respects in accordance with all clinical protocols, informed consent requirements, institutional
review board requirements and applicable Healthcare-Related Laws, including regulations relating to
good clinical practice, good laboratory practice and clinical trial disclosure requirements. The
Company has made available to the Parent (i) complete and accurate descriptions of the pre-clinical
and clinical trials conducted or currently being conducted by or on behalf of the Company or its
Subsidiaries with respect to the Company’s MEPACT product candidate, (ii) the protocols for such
pre-clinical and clinical trials and (iii) the data and other results of such pre-clinical and
clinical trials. There have been no studies or trials performed by or on behalf of the Company the
results of which are materially inconsistent with or otherwise materially call into question the
data and other results of the pre-clinical and clinical trials made available to the Parent
pursuant to the immediately preceding sentence.
(g) None of the Company or any of its Subsidiaries is subject to any obligation arising under
an administrative or regulatory action, inspection, warning letter, report of inspection
observations, establishment inspection report, notice of violation, or other notice, response or
commitment made to or with the FDA, EMEA or any comparable Governmental Entity or otherwise
pursuant to any Healthcare-Related Law.
(h) None of the Company or any of its Subsidiaries is subject to any investigation that is
pending and of which the Company has been notified or, to the Company’s knowledge, which has been
threatened, by (i) the EMEA, (ii) the FDA, the Department of Health and Human Services Office of
Inspector General or Department of Justice, or (iii) any comparable Governmental Entity, or subject
to any determination by a Governmental Entity excluding, suspending, debarring or otherwise
restricting or proposing to restrict the Company or any of its Subsidiaries from participation in
any healthcare program.
- 43 -
(i) None of the Company or any of its Subsidiaries or, to the Company’s knowledge, any of the
Company’s or its Subsidiaries’ officers, employees, contractors or agents, has committed any act,
made any statement or failed to make any statement that would reasonably be expected to provide a
basis for the FDA to invoke its policy with respect to “Fraud, Untrue Statements of Material Facts,
Bribery, and Illegal Gratuities” set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any
amendments thereto, or for the EMEA or any other Governmental Entity to invoke substantially
similar policies.
(j) None of the Company or any of its Subsidiaries or, to the Company’s knowledge, any of the
Company’s or its Subsidiaries’ officers, employees, contractors, or agents who performed work
related to any Product Candidate, has been convicted of any crime or engaged in any conduct that
has resulted, or would reasonably be expected to result, in debarment under 21 U.S.C. § 335a or any
similar law or regulation of the EMEA or any other Governmental Entity. None of the Company or any
of its Subsidiaries has used, employed, hired or contracted with any clinical investigator with
regard to activities relating to any Product Candidate who has been disqualified under 21 C.F.R. §
312.70 or who has engaged in any conduct that would reasonably be expected to result in
disqualification as a clinical investigator under 21 C.F.R. § 312.70, or in each case any
comparable law or regulation of the EMEA or any other Governmental Entity. To the knowledge of the
Company, none of the Company or any of its Subsidiaries has used, employed, hired or contracted
with any institution or IRB that has been disqualified under 21 C.F.R. § 56.121 or who has engaged
in any conduct that would reasonably be expected to result in disqualification under 21 C.F.R. §
56.121, or in each case any comparable law or regulation of the EMEA or any other Governmental
Entity.
(k) None of the Company or any of its Subsidiaries has submitted, or had submitted on its
behalf, any claim seeking payment directly or indirectly from any healthcare payment program
anywhere in the world in connection with any of the Product Candidates.
(l) None of the Company or any of its Subsidiaries has failed to comply in any material
respect with any applicable security and privacy standards regarding protected health information
under HIPAA (as defined below), or any applicable foreign, federal, state or local privacy laws, or
any contractual requirement relating to the privacy or security of individually identifiable health
information.
(m) The Company has made available to the Parent complete and accurate copies of (i) each
investigational new drug applications or new drug applications submitted to the FDA, the EMEA or
any other Governmental Entity by or on behalf of the Company or its Subsidiaries, including any
supplements thereto, (ii) all final study results and/or reports relating to the Company’s MEPACT
product candidate, (iii) all correspondence to or from the FDA, the EMEA or any comparable
Governmental Entities, including meeting minutes and records of material contacts, in each case
relating to the Company’s MEPACT product candidate, (iv) all documents in the Company’s and its
Subsidiaries’ possession related to inspections by the FDA, the EMEA or comparable Governmental
Entities, in each case relating to the Company’s
- 44 -
MEPACT product candidate and (v) all information
relating to adverse drug experiences obtained or otherwise received by the Company or its
Subsidiaries from any source with respect to any Product Candidate.
(n) As used in this Agreement, the term “Healthcare-Related Law” means (i) the Federal Food,
Drug and Cosmetic Act, (ii) the Public Health Service Act, (iii) the Federal Healthcare Program
Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b) (known as the “Anti-Kickback Statute”)), (iv) the
Medicare statute, federal and state Medicaid statutes, Sections 1128, 1128A, 1128B, 1128C and 1877
of the Social Security Act (42 U.S.C. §§ 0000x-0, 0000x-0x, 0000x-0x, 0000x-0x xxx 0000xx), (x)
statutes governing TRICARE (10 U.S.C. § 1071 et seq.) or any other government employee healthcare
programs, (vi) the civil False Claims Act (31 U.S.C. § 3729 et seq.), (vii) criminal false claims
and false statements statutes (e.g., 18 U.S.C. §§ 287 and 1001), (viii) the Program Fraud Civil
Remedies Act (31 U.S.C. § 3801 et seq.), (ix) the Health Insurance Portability and Accountability
Act of 1996 (Pub. L. 104-191) (“HIPAA”), (x) Section 353 of the Public Health Services Act (42
U.S.C. § 263a) as revised by the Clinical Laboratory Improvement Amendments of 1988, (xi) all laws
of the European Union or any member state relating to the subject matter of any of the
Healthcare-Related Laws described in clause (i)-(x) of this definition, (xii) all regulations,
guidances, rules, standards, guidelines, policies and orders promulgated under or relating to any
Healthcare-Related Law described in clauses (i)-(xi) of this definition or otherwise administered
or issued by the FDA, the EMEA or any comparable Governmental Entity and (xiii) all other foreign,
federal, state and local statutes, laws, regulations, directives, rules, standards, guidelines,
policies and orders relating to the subject matter of any of the matters described in clauses
(i)-(xii) of this definition.
(o) As used in this Agreement, the “Product Candidates” means (i) the Company’s MEPACT
(mifamurtide) product candidate, (ii) the Company’s IDM-2101 product candidate and (iii) the
Company’s UVIDEM product candidate.
4.16 Permits. The Company and each of its Subsidiaries have all permits, licenses and
franchises from Governmental Entities required to conduct their businesses as now being conducted
and to manufacture for commercial sale, market, sell and otherwise commercialize the Company’s
MEPACT product candidate in the EU Territory, and in each case that are material to the Company and
its Subsidiaries, taken as a whole (the “Company Permits”). The Company and each of its
Subsidiaries are in compliance with the terms of the Company Permits. No Company Permit shall
cease to be effective as a result of the consummation of the transactions contemplated by this
Agreement.
4.17 Labor Matters.
(a) Section 4.17(a)(i) of the Company Disclosure Schedule contains a list of all employees of
the Company and each of its Subsidiaries, along with the position and the annual base salary of,
and expected cash bonus payments to, each such person. Section 4.17(a)(ii) of the Company
Disclosure Schedule contains a list of all former employees of the Company and each of its
Subsidiaries whose primary place of employment was in France or in
- 45 -
Canada and whose employment by
the Company or one of its Subsidiaries terminated on or after April 1, 2007, along with the
position of each such person and the aggregate compensation paid to each such person during the
2007 and 2008 calendar years (stated separately). Each current or past employee of the Company or
any of its Subsidiaries has entered into a confidentiality and
assignment of inventions agreement with the Company, a copy or form of which has previously
been made available to the Parent. All of the agreements referenced in the preceding sentence will
continue to be legal, valid, binding and enforceable and in full force and effect immediately
following the Effective Time in accordance with the terms thereof as in effect immediately prior to
the Effective Time, except to the extent that such enforceability (A) may be limited by bankruptcy,
insolvency, reorganization, moratorium or other similar laws relating to creditors’ rights
generally, and (B) is subject to general principles of equity. Neither the Company nor any of its
Subsidiaries is a party to or otherwise bound by any collective bargaining agreement, contract or
other agreement or understanding with a labor union or labor organization. Neither the Company nor
any of its Subsidiaries is the subject of any proceeding asserting that the Company or any of its
Subsidiaries has committed an unfair labor practice or is seeking to compel it to bargain with any
labor union or labor organization, nor is there pending or, to the knowledge of the Company,
threatened, any labor strike, dispute, walkout, work stoppage, slow-down or lockout involving the
Company or any of its Subsidiaries. The Company and each of its Subsidiaries are in material
compliance with all applicable laws relating to the hiring, employment, and termination of
employees. There are no employees of the Company employed in the United States who are not
citizens of the United States.
(b) Except as set forth on Section 4.17(b) of the Company Disclosure Schedule, no employee of
the Company or any of its Subsidiaries (i) has an employment agreement, (ii) to the Company’s
knowledge is in violation of any term of any patent disclosure agreement, non-competition
agreement, or any restrictive covenant to a former employer relating to the right of any such
employee to be employed by the Company or any of its Subsidiaries because of the nature of the
business conducted or presently proposed to be conducted by the Company or any of its Subsidiaries
or to the use of trade secrets or proprietary information of others, or (iii) in the case of any
key employee or group of key employees, has given notice to the Company or any of its Subsidiaries
that such employee or any employee in a group of key employees intends to terminate his or her
employment with the Company.
(c) Section 4.17(c) of the Company Disclosure Schedule contains a list of all independent
contractors and consultants currently engaged by the Company or any of its Subsidiaries, along with
the position, date of retention and rate of remuneration for each such person or entity. Except as
set forth in Section 4.17(c) of the Company Disclosure Schedule, none of such independent
contractors or consultants is a party to a written agreement or contract with either the Company or
any of its Subsidiaries. Each such independent contractor and consultant has entered into a
confidentiality and assignment of inventions agreement (or substantive equivalent thereto) with the
Company or any of its Subsidiaries, a copy or form of which has previously been made available to
the Parent. Except as set forth in Section 4.17(c) of the Company Disclosure Schedule, there are
no, and at no time have been, any independent
- 46 -
contractors or consultants who have provided services
to the Company for a period of six (6) consecutive months or longer. Neither the Company nor any
of its Subsidiaries has ever had any temporary or leased employees.
(d) Neither the Company nor any of its Subsidiaries has caused or will cause any “employment
loss” (as that term is defined or used in the Worker Adjustment Retraining Notification Act) at any
time from the date that is 90 days immediately preceding the date of this Agreement and continuing
through the Closing Date.
4.18 Insurance. Section 4.18 of the Company Disclosure Schedule lists each of the
insurance policies of the Company and its Subsidiaries currently in effect (the “Insurance
Policies”). Each Insurance Policy is in full force and effect and is valid, outstanding and
enforceable, and all premiums due thereon have been paid in full. The Company and each of its
Subsidiaries have complied in all material respects with the provisions of each Insurance Policy
under which it is the insured party. No insurer under any Insurance Policy has cancelled or
generally disclaimed liability under any such policy or indicated any intent to do so or not to
renew any such policy. All pending claims under the Insurance Policies have been filed in a timely
fashion.
4.19 No Existing Discussions. As of the date of this Agreement, neither the Company
nor any of its Subsidiaries is engaged, directly or indirectly, in any discussions or negotiations
with any other party with respect to an Acquisition Proposal.
4.20 Opinion of Financial Advisor. The financial advisor of the Company, JMP
Securities, LLC (the “Financial Advisor”), has delivered to the Company an opinion dated May 17,
2009 to the effect that, as of such date, the consideration to be paid to the holders of Company
Common Stock in the Offer and the Merger is fair to the holders of Company Common Stock from a
financial point of view, a signed copy of which opinion will be made available to the Parent
promptly on or following the date hereof.
4.21 Section 203 of the DGCL Not Applicable. The Company Board has taken all actions
necessary so that the restrictions contained in Section 203 of the DGCL applicable to a “business
combination” with an “interested stockholder” (each as defined in Section 203) shall not apply to
the execution, delivery or performance of this Agreement, the Stockholders’ Agreement or the
consummation of the Offer, the Merger or the other transactions contemplated by this Agreement or
the Stockholders’ Agreement.
4.22 Brokers; Schedule of Fees and Expenses.
(a) No agent, broker, investment banker, financial advisor or other firm or person is or shall
be entitled, as a result of any action or agreement of the Company or any of its Affiliates, to any
broker’s, finder’s, financial advisor’s or other similar fee or commission in connection with any
of the transactions contemplated by this Agreement, except the Financial Advisor, whose fees and
expense shall be paid by the Surviving Corporation. The Company has
- 47 -
made available to the Parent a
copy of all agreements pursuant to which the Financial Advisor is entitled to any fees and expenses
in connection with any of the transactions contemplated by this Agreement.
(b) Section 4.22(b) of the Company Disclosure Schedule sets forth a list of the estimated fees
and expenses incurred and to be incurred by the Company and any of its Subsidiaries in connection
with this Agreement and the transactions contemplated by this Agreement (including the fees and
expenses of the Financial Advisor and of the Company’s legal counsel and accountants).
4.23 Rule 14d-10. The Company Board has determined that each of the members of the
Compensation Committee of the Company Board (the “Compensation Committee”) are, and the Company
represents and warrants that each of the members of the Compensation Committee are and at the
Acceptance Time will be, “independent directors” as defined in Rule 5605(a)(2) of the NASDAQ
Marketplace Rules and eligible to serve on the Compensation Committee under the Exchange Act and
the rules and regulations thereunder and all applicable NASDAQ Marketplace Rules. On or prior to
the date hereof, the Compensation Committee approved each Company Compensation Arrangement (as
defined in this Section 4.23) as an “employment compensation, severance or other employee benefit
arrangement” within the meaning of Rule 14d-10(d)(1) under the Exchange Act (an “Approved Company
Compensation Arrangement”), and has taken all other action necessary to satisfy the requirements of
the non-exclusive safe-harbor with respect to such Company Compensation Arrangements in accordance
with Rule 14d-10(d)(2) under the Exchange Act. The Company has provided copies of all resolutions
adopted or actions taken in connection with all Approved Company Compensation Arrangements. Each
Approved Company Compensation Arrangement in existence as of the date hereof is listed on Section
4.23 of the Company Disclosure Schedule. As used in this Agreement, “Company Compensation
Arrangement” means (i) any employment agreement, severance agreement or change of control agreement
between the Company or any of its Subsidiaries, on the one hand, and any officer, director or other
stockholder of the Company or any of its Subsidiaries, on the other hand, and any amendments
thereto entered into during the 12 months immediately prior to the date hereof and (ii) any Company
Stock Options.
4.24 Controls and Procedures, Certifications and Other Matters Relating to the Sarbanes
Act.
(a) The Company and each of its Subsidiaries maintains accurate books and records reflecting
its assets and liabilities and maintains proper and adequate internal control over financial
reporting which provide assurance that (i) transactions are executed with management’s
authorization, (ii) transactions are recorded as necessary to permit preparation of the
consolidated financial statements of the Company and to maintain accountability for the Company’s
consolidated assets, (iii) access to assets of the Company and its Subsidiaries is permitted only
in accordance with management’s authorization, (iv) the reporting of assets of the Company and its
Subsidiaries is compared with existing assets at regular intervals, and (v)
- 48 -
accounts, notes and
other receivables and inventory were recorded accurately, and proper and adequate procedures are
implemented to effect the collection thereof on a current and timely basis.
(b) The Company maintains disclosure controls and procedures required by Rules 13a-15 or
15d-15 under the Exchange Act, and such controls and procedures are effective to ensure that all
material information concerning the Company and its Subsidiaries is made known on a timely basis to
the individuals responsible for the preparation of the Company’s filings with the SEC and other
public disclosure documents. The Company has disclosed, based on its most recent evaluation of
such disclosure controls and procedures prior to the date of this Agreement, to the Company’s
auditors and the audit committee of the Company Board and on Section 4.24(b) of the Company
Disclosure Schedule (i) any significant deficiencies and material weaknesses in the design or
operation of internal controls over financial reporting that are reasonably likely to adversely
affect in any material respect the Company’s ability to record, process, summarize and report
financial information and (ii) any fraud, whether or not material, that involves management or
other employees who have a significant role in the Company’s internal controls over financial
reporting.
(c) Except as set forth in Section 4.24(c) of the Company Disclosure Schedule, since January
1, 2005 through the date of this Agreement, (i) neither the Company nor any of its Subsidiaries
nor, to the knowledge of the Company, any director, officer, employee, auditor, accountant or
representative of the Company or any of its Subsidiaries has received or otherwise had or obtained
knowledge of any material complaint, allegation, assertion or claim, whether written or oral,
regarding the accounting or auditing practices, procedures, methodologies or methods of the Company
or any of its Subsidiaries or their respective internal accounting controls, including any material
complaint, allegation, assertion or claim that the Company or any of its Subsidiaries has engaged
in questionable accounting or auditing practices, and (ii) no attorney representing the Company or
any of its Subsidiaries, whether or not employed by the Company or any of its Subsidiaries, has
reported evidence of a material violation of securities laws, breach of fiduciary duty or similar
violation by the Company or any of its officers, directors, employees or agents to the Board of
Directors of the Company or any committee thereof or to any director or officer of the Company.
(d) Neither the Company nor any of its officers has received notice from any Governmental
Entity questioning or challenging the accuracy, completeness or manner of filing or submission of
any filing with the SEC, including any certifications required by Section 906 of the Sarbanes Act.
(e) Except as set forth in Section 4.24(e) of the Company Disclosure Schedule, the Company has
not, since July 30, 2002, extended or maintained credit, arranged for the extension of credit,
modified or renewed an extension of credit, in the form of a personal loan or otherwise, to or for
any director or executive officer of the Company. Section 4.24(e) of the
- 49 -
Company Disclosure
Schedule identifies any loan or extension of credit maintained by the Company to which the second
sentence of Section 13(k)(1) of the Exchange Act applies.
ARTICLE V
REPRESENTATIONS AND WARRANTIES
OF THE PARENT AND THE PURCHASER
The Parent and the Purchaser each represents and warrants to the Company as follows:
5.1 Organization, Standing and Power. Each of the Parent and the Purchaser is a
corporation duly organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation, has all requisite corporate power and authority to own, lease
and operate its properties and assets and to carry on its business as now being conducted, and is
duly qualified to do business and is in good standing as a foreign corporation in each jurisdiction
where the failure to be so qualified or in good standing, individually or in the aggregate, would
not reasonably be expected to materially impair the ability of the Parent or the Purchaser to
consummate the transactions contemplated hereunder.
5.2 Authority; No Conflict; Required Filings and Consents.
(a) Each of the Parent and the Purchaser has all requisite corporate power and authority to
enter into this Agreement, perform its obligations hereunder and to consummate the transactions
contemplated by this Agreement. The execution and delivery of this Agreement by the Parent and the
Purchaser and the consummation by the Parent and the Purchaser of the transactions contemplated by
this Agreement have been duly authorized by all necessary corporate action on the part of each of
the Parent and the Purchaser (other than the adoption of this Agreement by the Parent in its
capacity as the sole stockholder of the Purchaser, which shall occur prior to the Effective Time).
This Agreement has been duly executed and delivered by each of the Parent and the Purchaser and
constitutes the valid and binding obligation of each of the Parent and the Purchaser, enforceable
in accordance with its terms, except to the extent that such enforceability (A) may be limited by
bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to creditors’
rights generally, and (B) is subject to general principles of equity.
(b) The execution and delivery of this Agreement by each of the Parent and the Purchaser do
not, and the consummation by the Parent and the Purchaser of the transactions contemplated by this
Agreement shall not, (i) conflict with, or result in any violation or breach of, any provision of
the Certificate of Incorporation or By-laws of the Parent or the Purchaser, (ii) conflict with, or
result in any violation or breach of, or constitute (with or without notice or lapse of time, or
both) a default (or give rise to a right of termination, cancellation or acceleration of any
obligation or loss of any material benefit) under, or require a consent or waiver under, any of the
terms, conditions or provisions of any note, bond, mortgage, indenture, lease, license, contract or
other agreement, instrument or obligation to which the Parent or the Purchaser is a
- 50 -
party or by
which either of them or any of their properties or assets may be bound, or (iii) subject to
compliance with the requirements specified in clauses (i) through (iv) of Section 5.2(c), conflict
with or violate any permit, concession, franchise, license, judgment, injunction, order, decree,
statute, law, ordinance, rule or regulation applicable to the Parent or the Purchaser or any
of their properties or assets, except in the case of clauses (ii) and (iii) of this Section
5.2(b) for any such conflicts, violations, breaches, defaults, terminations, cancellations,
accelerations or losses which, individually or in the aggregate, would not reasonably be expected
to materially impair the ability of the Parent or the Purchaser to consummate the transactions
contemplated hereunder.
(c) No consent, approval, license, permit, order or authorization of, or registration,
declaration, notice or filing with any Governmental Entity is required by or with respect to the
Parent or the Purchaser in connection with the execution and delivery of this Agreement or the
consummation by the Parent or the Purchaser of the transactions contemplated by this Agreement,
except for (i) the filing of the Certificate of Merger with the
Delaware Secretary of State and
appropriate corresponding documents with the appropriate authorities of other states in which the
Company is qualified as a foreign corporation to transact business, (ii) required filings under the
Securities Act and the Exchange Act, (iii) such consents, approvals, orders, authorizations,
registrations, declarations and filings as may be required under applicable “takeover” or state
securities laws and the securities laws of any foreign country, and (iv) such other consents,
approvals, licenses, permits, orders, authorizations, registrations, declarations, notices and
filings, the failure of which to make or obtain would not individually or in the aggregate,
reasonably be expected to materially impair the ability of the Parent or the Purchaser to
consummate the transactions contemplated hereunder.
5.3 Information Provided. The information to be supplied in writing by or on behalf
of the Parent for inclusion in the Schedule 14D-9, on the date the Schedule 14D-9 is filed with the
SEC, and on the date the Schedule 14D-9 is first published, sent or given to stockholders of the
Company, shall not contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading.
5.4 Interim Operations of the Purchaser. The Purchaser is a wholly-owned Subsidiary
of the Parent and was formed solely for the purpose of engaging in the transactions contemplated by
this Agreement, has not engaged in any other business activities and has conducted its operations
only as contemplated hereby.
5.5 Funds. Parent has available cash resources in an amount sufficient to consummate
the Offer and the Merger.
5.6
Not an Interested Stockholder. Neither Parent nor any of its Affiliates is an
“interested stockholder” (as such term is defined in Section 203 of
Delaware Law) of the Company.
- 51 -
5.7 Absence of Litigation. There is no action, suit, proceeding, claim, arbitration
or investigation pending and served or, to the knowledge of Takeda Pharmaceutical Company Limited
or the Parent, pending and not served or threatened against or affecting Takeda Pharmaceutical
Company Limited, the Parent or the Purchaser that would materially and adversely affect the
Parent’s or the Purchaser’s ability to consummate the Merger and the
transactions contemplated hereby. None of Takeda Pharmaceutical Company Limited, the Parent
or the Purchaser is subject to any continuing judgment, order or decree with, or, to the knowledge
of the Parent, continuing investigation by, any Governmental Entity, or any judgment, order or
decree of any Governmental Entity that would materially and adversely affect the Parent’s or the
Purchaser’s ability to consummate the Merger and the transactions contemplated hereby.
ARTICLE VI
CONDUCT OF BUSINESS
6.1 Conduct Prior to Effective Time. Except as expressly consented to in writing by
the Parent (which consent shall not be unreasonably withheld, delayed or conditioned) or as listed
on Section 6.1 of the Company Disclosure Schedule or otherwise required by the terms of this
Agreement, from and after the date of this Agreement until the earlier of the termination of this
Agreement in accordance with its terms or the Effective Time, the Company shall, and shall cause
each of its Subsidiaries to, act and carry on its business in the usual, regular and ordinary
course in substantially the same manner as previously conducted, pay its debts and Taxes and
perform its other obligations when due (subject to good faith disputes over such debts, Taxes or
obligations), comply in all material respects with all applicable laws, rules and regulations, and
use its reasonable best efforts, consistent with past practices, to maintain and preserve its and
each of its Subsidiaries’ business organization, assets, and properties, keep available the
services of its present officers and employees and preserve its advantageous business relationships
with strategic partners, suppliers, distributors and others having business dealings with it to the
end that its goodwill and ongoing business shall be unimpaired at and after the Effective Time.
Without limiting the generality of the foregoing, from and after the date of this Agreement until
the earlier of the termination of this Agreement in accordance with its terms or the Effective
Time, except as specifically set forth in Section 6.1 of the Company Disclosure Schedule or
otherwise required by the terms of this Agreement, the Company shall not, and shall not permit any
of its Subsidiaries to, directly or indirectly, do any of the following without the prior written
consent of the Parent:
(a) (i) declare, set aside or pay any dividends on, or make any other distributions (whether
in cash, securities or other property) in respect of, any of its capital stock (other than
dividends and distributions by a direct or indirect wholly owned Subsidiary of the Company to its
parent); (ii) split, combine or reclassify any of its capital stock or, except for the issuance of
shares of Company Common Stock upon the exercise of any Company Stock Options, IDM Pharma S.A.
Stock Options or Company Warrants outstanding on the date of this
- 52 -
Agreement, issue or authorize the
issuance of any other securities in respect of, in lieu of or in substitution for shares of its
capital stock or any of its other securities; or (iii) purchase, redeem or otherwise acquire any
shares of its capital stock or any other of its securities or any rights, warrants or options to
acquire any such shares or other securities except, in the case of this clause (iii), for (A) the
acquisition of shares of Company Common Stock from holders of Company Stock Options in full or
partial payment of the exercise price payable by such holder upon
exercise of Company Stock Options to the extent required under the terms of such Company Stock
Options as in effect on the date hereof; (B) the acquisition of shares of IDM Pharma S.A. from
holders of Company Stock Options subject to Option Liquidity Agreements in full or partial payment
of the transfer consideration payable by such holder upon exercise of Company Stock Options subject
to Option Liquidity Agreements to the extent required under the terms of such Company Stock Options
and Option Liquidity Agreements as in effect on the date hereof; or (C) from former employees,
directors and consultants in accordance with agreements providing for the repurchase of shares in
connection with any termination of services to the Company or any of its Subsidiaries;
(b) issue, deliver, sell, grant, pledge or otherwise dispose of or encumber any shares of its
capital stock, any other voting securities or any securities convertible into or exchangeable for,
or any rights, warrants or options to acquire, any such shares, voting securities or convertible or
exchangeable securities, other than the issuance of shares of Company Common Stock upon the
exercise of Company Stock Options, IDM Pharma S.A. Stock Options or Company Warrants outstanding on
the date of this Agreement in accordance with their present terms;
(c) amend its certificate of incorporation, by-laws or other comparable charter or
organizational documents, except as expressly provided by this Agreement;
(d) acquire (i) by merging or consolidating with, or by purchasing all or a substantial
portion of the assets or any stock of, or by any other manner, any business or any corporation,
partnership, joint venture, limited liability company, association or other business organization
or division thereof or (ii) any assets that are material, in the aggregate, to the Company and its
Subsidiaries, taken as a whole;
(e) except in the Ordinary Course of Business, sell, lease, license, pledge, or otherwise
dispose of or encumber any properties or assets of the Company or of any of its Subsidiaries;
(f) whether or not in the Ordinary Course of Business, sell, dispose of, license, or otherwise
transfer any assets material to the Company and its Subsidiaries, taken as a whole (including any
accounts, leases, contracts or Intellectual Property or any assets or the stock of any
Subsidiaries);
(g) adopt or implement any stockholder rights plan;
- 53 -
(h) except for a confidentiality agreement as permitted by Section 7.1, enter into an
agreement with respect to any merger, consolidation, liquidation or business combination, or any
acquisition or disposition of all or any material portion of the assets or securities of the
Company or any of its Subsidiaries;
(i) (i) incur or suffer to exist any indebtedness for borrowed money other than such
indebtedness which existed as of March 31, 2009 as reflected on the Company Balance
Sheet or guarantee any such indebtedness of another person, (ii) issue, sell or amend any debt
securities or warrants or other rights to acquire any debt securities of the Company or any of its
Subsidiaries, guarantee any debt securities of another person, enter into any “keep well” or other
agreement to maintain any financial statement condition of another person or enter into any
arrangement having the economic effect of any of the foregoing, (iii) make any loans, advances
(other than routine advances to employees of the Company and its Subsidiaries in the Ordinary
Course of Business) or capital contributions to, or investments in, any other person, other than
the Company or any of its direct or indirect wholly owned Subsidiaries, or (iv) enter into any
hedging agreement or other financial agreement or arrangement designed to protect the Company or
its Subsidiaries against fluctuations in commodities prices, exchange rates or interest rates;
(j) make any individual capital expenditure or other expenditure with respect to property,
plant or equipment in excess of $10,000, or make capital expenditures or other expenditures with
respect to property, plan or equipment in excess of $50,000 in the aggregate for the Company and
its Subsidiaries, taken as a whole;
(k) except as may be required by a change in GAAP, make any change in accounting methods,
principles or practices, or change any assumption underlying, or method of calculating, any bad
debt, contingency or other reserve;
(l) pay, discharge, settle or satisfy any claims, liabilities or obligations (whether
absolute, accrued, asserted or unasserted, contingent or otherwise), other than (i) the payment,
discharge or satisfaction, in the Ordinary Course of Business or in accordance with their terms as
in effect on the date of this Agreement, of claims, liabilities or obligations reflected or
reserved against in, or contemplated by, the most recent consolidated financial statements (or the
notes thereto) of the Company included in the Company SEC Reports filed prior to the date of this
Agreement (to the extent so reflected or reserved against) or (ii) claims, liabilities or
obligations incurred since the date of such financial statements in the Ordinary Course of Business
and consistent with the limitations set forth in this Agreement;
(m) modify, amend or terminate any Company Material Contract, or knowingly waive, release or
assign any material rights or claims (including any write-off or other compromise of any accounts
receivable of the Company or any of its Subsidiaries) with respect to the foregoing;
(n) (i) enter into any material contract or agreement, (ii) enter into any agreement that is
not terminable upon 90 days’ prior notice or does not terminate within 90 days
- 54 -
after the date
hereof, in each case without prepayment or penalty, or (iii) license any material Intellectual
Property Rights to or from any third party;
(o) except as required to comply with applicable law or agreements, plans or arrangements
existing on the date hereof or as provided in Section 3.1(d), (e) and (h) of this Agreement or as
provided in Section 6.1 of the Company Disclosure Schedule, (i) take any action with respect to,
adopt, enter into, terminate or amend any employment, severance or similar agreement or benefit
plan for the benefit or welfare of any current or former director,
officer, employee or consultant or any collective bargaining agreement, (ii) increase the
compensation or fringe benefits of, or pay any bonus to, any director, officer, employee or
consultant, (iii) amend or accelerate the payment, right to payment or vesting of any compensation
or benefits, including any outstanding options or restricted stock awards, (iv) pay any material
benefit not provided for as of the date of this Agreement under any benefit plan, (v) grant any
awards under any bonus, incentive, performance or other compensation plan or arrangement or benefit
plan, including the grant of stock options, stock appreciation rights, stock based or stock related
awards, performance units or restricted stock, or the removal of existing restrictions in any
benefit plans or agreements or awards made thereunder, or (vi) take any action other than in the
Ordinary Course of Business to fund or in any other way secure the payment of compensation or
benefits under any employee plan, agreement, contract or arrangement or benefit plan;
(p) hire any new employees or, except as provided in Section 6.1 of the Company Disclosure
Schedule, terminate any employees other than for cause;
(q) make or rescind any Tax election, settle or compromise any Tax liability or amend any Tax
return;
(r) commence any offering of shares of Company Common Stock pursuant to the ESPP;
(s) initiate, compromise or settle any material litigation or arbitration proceeding;
(t) open or close any facility or office;
(u) with respect to any insurance policies, fail to (i) pay all premiums due thereunder, (ii)
renew any expiring insurance policies or (iii) comply with obligations under insurance policies;
(v) take any action that would cause any Company Compensation Arrangement not to satisfy the
requirements of the non-exclusive safe-harbor in Rule 14d-10(d)(2) under the Exchange Act;
- 55 -
(w) initiate any pre-clinical trials, clinical trials or any other program, study,
investigation or collaboration (or make any filing or application with any Governmental Entity with
respect thereto) or materially alter ongoing activities or currently planned activities with
respect to ongoing pre-clinical trials, clinical trials, programs, studies, investigations or
collaborations (or related filings or applications) of the Company or any of its Subsidiaries, each
of which is ongoing or planned activity is set forth on in Section 6.1(w) of the Company Disclosure
Schedule;
(x) promote, market or commercially distribute any Product Candidate anywhere in the world; or
(y) authorize any of, or commit or agree, in writing or otherwise, to take any of, (i) the
foregoing actions or (ii) any other action with the knowledge that such action would make any
representation or warranty of the Company set forth in this Agreement untrue or incorrect in any
material respect (without giving effect to any qualifications or limitations as to materiality or
Company Material Adverse Effect set forth therein), or would materially impair the ability to
satisfy, or prevent the satisfaction of, any condition in Annex I or Article VIII.
6.2 Certain Communications. The Company shall notify the Parent within 24 hours after
the Company or any of its Subsidiaries has first received or otherwise learned of any notice or
other communication from any Governmental Entity or quasi-governmental authority concerning the
Company’s MEPACT product candidate, or any notice or other communication from any supplier of the
active pharmaceutical ingredient or drug product for MEPACT. None of the Company or any of its
Subsidiaries shall respond to any such notice or other communication without first consulting with
the Parent and giving due consideration to any recommendations made by the Parent as to such
response.
6.3 Confidentiality. The parties acknowledge that the Parent and the Company have
previously executed a confidentiality agreement, dated as of December 8, 2006 (the “Confidentiality
Agreement”), which Confidentiality Agreement shall continue in full force and effect in accordance
with its terms.
ARTICLE VII
ADDITIONAL AGREEMENTS
7.1 No Solicitation.
(a) Except as set forth in this Section 7.1, the Company shall not, nor shall it authorize or
permit any of its Subsidiaries or any of its or their directors, officers, employees, investment
bankers, attorneys, accountants or other advisors, agents or representatives (such directors,
officers, employees, investment bankers, attorneys, accountants, other advisors, agents and
representatives, collectively, “Representatives”) to directly or indirectly:
- 56 -
(i) solicit, initiate, knowingly encourage or knowingly facilitate any
inquiries or the making of any proposal or offer that constitutes, or would
reasonably be expected to lead to, any Acquisition Proposal, including (A)
approving any transaction under Section 203 of the DGCL, (B) approving any person
becoming an “interested stockholder” under Section 203 of the DGCL or (C) amending
or granting any waiver or releasing any material benefits of, modifying in any
respect adverse to Parent or the Purchaser, failing to enforce, or consenting to
any matter with respect to which its consent is required under, any
confidentiality, standstill or similar agreement to which the Company or any of
its Subsidiaries is a party or entered into on their behalf; or
(ii) enter into, continue or otherwise participate in any discussions or
negotiations regarding, furnish to any person any information with respect to,
knowingly assist, or participate in any effort or attempt by any person with
respect to, or otherwise cooperate in any way with, any Acquisition Proposal.
Notwithstanding the foregoing, prior to the acceptance for payment of any shares of Company Common
Stock pursuant to the Offer (the “Specified Time”), the Company may, to the extent the Company
Board determines in good faith, after consultation with outside counsel, that the failure to take
such action would be inconsistent with the fiduciary duties of the Company Board to the Company’s
stockholders under applicable law, in response to a bona fide, unsolicited written Acquisition
Proposal made or received after the date of this Agreement that the Company Board reasonably
determines in good faith after consultation with outside counsel and the Financial Advisor or a
nationally recognized independent financial advisor is, or may reasonably be expected to lead to, a
Superior Proposal, in each case that did not result from a breach by the Company of this Section
7.1, and subject to compliance with Section 7.1(c), (x) furnish information with respect to the
Company to the person making such Acquisition Proposal and its Representatives pursuant to a
customary confidentiality agreement not less restrictive of the other party than the
Confidentiality Agreement other than any standstill restrictions and (y) participate in discussions
or negotiations (including solicitation of a revised Acquisition Proposal) with such person and its
Representatives regarding any Acquisition Proposal. In addition, notwithstanding the foregoing,
prior to the Specified Time, the Company may, to the extent the Company Board determines in good
faith, after consultation with outside counsel, that the failure to take such action would be
inconsistent with the fiduciary duties of the Company Board to the Company’s stockholders under
applicable law, grant a waiver or release under any confidentiality, standstill or similar
agreement to which the Company or any of its Subsidiaries is a party for the sole purpose of
allowing the other party to such agreement to submit an Acquisition Proposal that constitutes, or
may reasonably be expected to lead to, a Superior Proposal, in each case that did not result from a
breach by the Company of this Section 7.1. Without limiting the foregoing, it is agreed that any
violation of the restrictions set forth in this Section 7.1(a) by any Representative of the Company
or any of its Subsidiaries, whether or not such person is purporting to act on behalf of the
Company or otherwise, shall be deemed to be a breach of this Section 7.1(a) by the Company.
- 57 -
(b) Neither the Company Board nor any committee thereof shall:
(i) except as set forth in this Section 7.1(b) withdraw or modify, or propose
to withdraw or modify, in a manner adverse to the Parent or the Purchaser, the
approval or recommendation by the Company Board or any such committee of this
Agreement, the Offer or the Merger or that the stockholders of the Company tender
their shares into and accept the Offer;
(ii) cause or permit the Company to enter into any letter of intent,
memorandum of understanding, agreement in principle, acquisition agreement,
merger
agreement or similar agreement (an “Acquisition Agreement”)
constituting or relating to any Acquisition Proposal (other than a
confidentiality agreement referred to in Section 7.1(a) entered into in the
circumstances referred to in Section 7.1(a));
(iii) withdraw or modify, or propose to withdraw or modify, the approval by
the Compensation Committee of the Company Compensation Arrangements as Approved
Company Compensation Arrangements for purposes of satisfying the requirements of
the non-exclusive safe-harbor in accordance to Rule 14d-10(d)(2) under the
Exchange Act; or
(iv) adopt, approve or recommend, or propose to adopt, approve or recommend,
any Acquisition Proposal.
Notwithstanding the foregoing, provided the Company shall not have breached its obligations under
Section 7.1(a), the Company Board may withdraw or modify the recommendation by the Company Board or
any committee thereof of this Agreement, the Offer or the Merger if (1) (A) the Company Board
determines in good faith, after consultation with outside counsel, that the failure to take such
action would be inconsistent with the fiduciary duties of the Company Board to the Company’s
stockholders under applicable law, but only at a time that is prior to the Specified Time and is
after the fourth business day following the Parent’s receipt of written notice (an “Adverse
Recommendation Notice”) advising the Parent that the Company Board intends to withdraw or modify
the recommendation (and the manner and timing in which it intends to do so), and (B) the Company
provides the Parent with a reasonable opportunity to make adjustments in the terms and conditions
of this Agreement and negotiates in good faith with the Parent with respect thereto during the four
business day period after the Parent has received the Adverse Recommendation Notice, in each case
as would enable the Company Board or committee thereof to maintain in effect its recommendation in
favor of this Agreement, the Offer and the Merger, (2) if such withdrawal is due to the existence
of a Superior Proposal, (x) the Company has complied with the requirements of Section 7.1(c),
including specifying the material terms and conditions of such Superior Proposal and identifying
the person making such Superior Proposal, and (y) the Parent shall not have within four business
days of the receipt of the Adverse Recommendation Notice made an offer or proposal that the Company
Board determines in good faith (after consultation with its financial and legal advisors) to be at
least as
- 58 -
favorable to the Company’s stockholders from a financial point of view as such Superior
Proposal, and (3) if such withdrawal is not due to the existence of a Superior Proposal, the Parent
shall not have within four business days of the receipt of the Adverse Recommendation Notice made
an offer or proposal that the Company Board determines in good faith (after consultation with its
financial and legal advisors) would enable the Company Board or committee thereof to maintain in
effect its recommendation in favor of this Agreement, the Offer and the Merger. Any Company
Adverse Recommendation Change shall not change the approval of this Agreement or any other approval
of the Company Board, nor shall any Company Adverse Recommendation Change, have the effect of
causing any state (including Delaware) corporate takeover statute or other similar statute to be
applicable to the transactions contemplated hereby or thereby, including the Offer and the Merger.
(c) The Company shall promptly, and in any event within one business day, advise the Parent
orally, with written confirmation to follow within 24 hours, of any Acquisition Proposal or any
request for nonpublic information in connection with any Acquisition Proposal, or any inquiry with
respect to, or that may reasonably be expected to lead to any Acquisition Proposal, the material
terms and conditions of any such Acquisition Proposal or inquiry and the identity of the person
making any such Acquisition Proposal or inquiry. The Company shall (i) keep the Parent reasonably
informed, on a current basis, of the status and details (including any change to the terms) of any
such Acquisition Proposal or inquiry, (ii) provide to the Parent as soon as reasonably practicable
after receipt or delivery thereof copies of all correspondence and other written material sent or
provided to the Company, including those provided by electronic mail, from any third party in
connection with any Acquisition Proposal or sent or provided by the Company to any third party in
connection with any Acquisition Proposal and (iii) if the Parent shall make a counterproposal,
consider in good faith the terms of such counterproposal. Contemporaneously with providing any
information to a third party in connection with any such Superior Proposal or inquiry, the Company
shall furnish a copy of such information to the Parent.
(d) Nothing contained in Section 7.1 shall be deemed to prohibit the Company from taking and
disclosing to its stockholders a position with respect to a tender offer contemplated by Rule
14e-2(a) promulgated under the Exchange Act or from making any required disclosure to the Company’s
stockholders if, in the good faith judgment of the Company Board, after consultation with outside
counsel, failure so to disclose would be inconsistent with its obligations under applicable law;
provided, however, that, in no event shall the Company Board or any committee
thereof take, or agree or resolve to take, any action prohibited by Section 7.1(b).
(e) The Company shall, and shall cause its Subsidiaries and its and their Representatives to,
cease immediately all discussions and negotiations regarding any proposal that constitutes, or may
reasonably be expected to lead to, an Acquisition Proposal. The Company shall use its reasonable
best efforts to have all copies of all nonpublic information it or
- 59 -
its Subsidiaries and its and
their Representatives have distributed on or prior to the date of this Agreement to other potential
purchasers returned to the Company as soon as possible.
(f) For purposes of this Agreement:
“Acquisition Proposal” means (i) any inquiry, proposal or offer for a merger, consolidation,
dissolution, sale of substantial assets, tender offer, recapitalization, share exchange or other
business combination involving the Company or any of its Subsidiaries, (ii) any proposal for the
issuance by the Company or any of its Subsidiaries of 15% or more of its equity securities or (iii)
any proposal or offer to acquire in any manner, directly or indirectly, 15% or more of the equity
securities or consolidated total assets of the Company, in each case other than the transactions
contemplated by this Agreement.
“Superior Proposal” means any unsolicited, bona fide written proposal made by a third party to
acquire all the equity securities or all or substantially all of the assets of the
Company, pursuant to a tender or exchange offer, a merger, or a sale of its assets, (i) on terms
which the Company Board determines in its good faith judgment to be materially more favorable from
a financial point of view to the holders of Company Common Stock than the transactions contemplated
by this Agreement (after consultation with its legal counsel and the Financial Advisor or another
nationally recognized independent financial advisor), taking into account all relevant factors,
including the terms and conditions of such proposal, including price, form of consideration,
closing conditions, the ability to finance the proposal and other aspects of the proposal that the
Company Board reasonably deems relevant, and this Agreement (including any proposal by the Parent
to amend the terms of this Agreement) and (ii) that is reasonably capable of being completed on the
terms proposed, taking into account all financial, regulatory, legal and other aspects of such
proposal; provided, however, that no Acquisition Proposal shall be deemed to be a Superior
Proposal if any financing required to consummate the Acquisition Proposal is not committed.
7.2 Efforts; Consents, Notices and Approvals.
(a) Subject to the terms hereof, including Section 7.2(b), the Company and the Parent shall
each use reasonable best efforts to (i) take, or cause to be taken, all actions, and do, or cause
to be done, and to assist and cooperate with the other parties in doing, all things necessary,
proper or advisable to consummate and make effective the transactions contemplated hereby as
promptly as practicable, (ii) as promptly as practicable, obtain from any Governmental Entity or
any other third party any consents, licenses, permits, waivers, approvals, authorizations, or
orders required to be obtained or made by the Company or the Parent or any of their Subsidiaries in
connection with the authorization, execution and delivery of this Agreement and the consummation of
the Offer, the Merger and the other transactions contemplated hereby, (iii) as promptly as
practicable, make all necessary filings, and thereafter make any other required submissions, with
respect to this Agreement, the Offer and the Merger required under (A) the Securities Act and the
Exchange Act, and any other applicable federal or state securities laws, (B) the Xxxx-Xxxxx-Xxxxxx
Antitrust Improvements Act of 1976 (the “HSR Act”) and any related
- 60 -
governmental request thereunder,
and (C) any other applicable law and (iv) execute or deliver any additional instruments necessary
to consummate the transactions contemplated by, and to fully carry out the purposes of, this
Agreement. The Company and the Parent shall cooperate with each other in connection with the
making of all such filings and shall use reasonable best efforts to furnish to each other all
information required for any application or other filing to be made pursuant to the rules and
regulations of any applicable law (including all information required to be included in the Offer
Documents) in connection with the transactions contemplated by this Agreement. For the avoidance
of doubt, the Parent and the Company agree that nothing contained in this Section 7.2(a) shall
modify or affect their respective rights and responsibilities under Section 7.2(b).
(b) Subject to the terms hereof, the Parent and the Company agree, and shall cause each of
their respective Subsidiaries, to cooperate and to use reasonable best efforts to obtain any
government clearances or approvals and the expiration of any waiting periods required for
consummation of the Offer under the HSR Act, the Xxxxxxx Antitrust Act, as
amended, the Xxxxxxx Act, as amended, the Federal Trade Commission Act, as amended, and any
other federal, state, or foreign law or, regulation or decree designed to prohibit, restrict or
regulate actions for the purpose or effect of monopolization or restraint of trade (collectively
“Antitrust Laws”), and to respond to any government requests for information under any Antitrust
Law. The parties hereto will consult and cooperate with one another, and consider in good faith
the views of one another, in connection with any analyses, appearances, presentations, memoranda,
briefs, arguments, opinions and proposals made or submitted by or on behalf of any party hereto in
connection with proceedings under or relating to any Antitrust Law. The Parent shall be entitled
to direct any proceedings or negotiations with any Governmental Entity relating to any of the
foregoing, provided that it shall afford the Company a reasonable opportunity to participate
therein. Notwithstanding anything in this Agreement to the contrary, neither the Parent nor any of
its Affiliates shall be under any obligation to make proposals, execute or carry out agreements or
submit to orders providing for the sale or other disposition or holding separate (through the
establishment of a trust or otherwise) of any assets of the Parent or any of its Affiliates or the
Company or any of its Affiliates or the holding separate of the shares of Company Common Stock (or
shares of stock of the Surviving Corporation) or imposing or seeking to impose any limitation on
the ability of the Parent or any of its Affiliates to conduct their business or own such assets or
to acquire, hold or exercise full rights of ownership of the shares of Company Common Stock (or
shares of stock of the Surviving Corporation). Each of the parties hereto agrees to cooperate and
use its reasonable best efforts, until the earlier of the Effective Time or the termination of this
Agreement in accordance with its terms, to contest and resist any actions, and to have vacated,
lifted, reversed or overturned any order, executive order, stay, decree, judgment or injunction
(preliminary or permanent) that is in effect, and in each case that seeks to impose any of the
remedies described in the condition set forth in clause (iii)(a) of Annex I.
(c) The Company shall confer with the Parent on a regular and frequent basis as reasonably
requested by the Parent concerning operational matters and promptly advise the
- 61 -
Parent orally and in
writing of any Change having, or which, insofar as reasonably can be foreseen, could result in, a
Company Material Adverse Effect. The Company shall promptly deliver to the Parent (or its counsel)
copies of all filings made by the Company with any Governmental Entity in connection with this
Agreement and the transactions contemplated hereby.
(d) Neither the Company nor any of its Affiliates shall make any settlement offers or, except
as directed by the Parent, negotiate any consent decree or consent order with any Governmental
Entity relating to the transactions contemplated by this Agreement. The Parent alone shall be
responsible for making any settlement offers and negotiating any consent decree or consent order
with any Governmental Entity relating to the transactions contemplated by this Agreement. The
Parent shall promptly communicate to the Company if any Governmental Entity suggests or proffers
any settlement, consent decree or consent order, including the material terms thereof (and any
written documentation provided by such Governmental Entity reflecting the same). The Parent may
accept or reject any settlement, consent decree or consent order proposed by any Governmental
Entity in its sole discretion.
(e) Without limiting the generality of Section 7.2, if any “fair price” or “control share
acquisition” or “anti-takeover” statute, or other similar statute or regulation or any state “blue
sky” statute shall become applicable to the transactions contemplated by this Agreement or by the
Stockholders’ Agreement, the Company and the Company Board shall grant such approvals and take such
actions as are necessary so that the transactions contemplated hereby and thereby may be
consummated as promptly as practicable on the terms contemplated hereby and thereby, and otherwise
act to minimize the effects of such statute or regulation on the transactions contemplated hereby
or thereby.
7.3 Notification of Certain Matters.
(a) The Company shall give prompt notice to the Parent if, at any time prior to the Acceptance
Time (i) any Change occurs or exists that would result in any representation or warranty of the
Company contained in this Agreement that is qualified as to materiality not being true and accurate
in any respect as if such representation or warranty were made at such time, or any such
representation or warranty that is not so qualified not being true and accurate in any material
respect as if such representation or warranty were made at such time, or (ii) the Company fails to
comply with or satisfy in any material respect any covenant, condition or agreement to be complied
with or satisfied by it under this Agreement; provided, however, that no such
notification shall be deemed to cure any breach or otherwise affect the representations,
warranties, covenants or agreements of the Company or the conditions to the obligations of the
parties hereunder. Without limiting the foregoing, the Company shall, within 24 hours after it has
notice of any of the following, notify the Parent of:
(i) any notice or other communication from any person alleging that the
consent of such person is or may be required in connection with the transactions
contemplated by this Agreement;
- 62 -
(ii) any notice or other communication from any Governmental Entity in
connection with the transactions contemplated by this Agreement; and
(iii) any actions, suits, claims, investigations or proceedings commenced or,
to the best of its knowledge, threatened against, relating to or involving or
otherwise affecting the Company or any of its Subsidiaries which, if pending on
the date of this Agreement would have been required to have been disclosed
pursuant to this Agreement or which relate to the consummation of the transaction
contemplated hereby.
(b) The Parent shall give prompt notice to the Company if, at any time prior to the Acceptance
Time (i) any Change occurs or exists that would result in any representation or warranty of the
Parent or the Purchaser contained in this Agreement that is qualified as to materiality not being
true and accurate in any respect as if such representation or warranty were made at such time, or
any such representation or warranty that is not so qualified not being true and accurate in any
material respect as if such representation or warranty were made at such time, or (ii) the Parent
or the Purchaser fails to comply with or satisfy in any material respect any
covenant, condition or agreement to be complied with or satisfied by them under this
Agreement; provided, however, that no such notification shall be deemed to cure any
breach or otherwise affect the representations, warranties, covenants or agreements of the Parent
or the Purchaser or the conditions to the obligations of the parties hereunder.
7.4 Company Stockholder Approval of the Merger.
(a) If the adoption of this Agreement by the stockholders of the Company is required under the
DGCL in order to consummate the Merger, the Company shall, acting through the Company Board, at the
Parent’s request, as soon as practicable following the acceptance for payment of, and payment for,
shares of Company Common Stock by the Purchaser in the Offer (coordinating the timing thereof with
the Parent), duly call, give notice of, convene and hold the Company Meeting for the purpose of
obtaining such stockholder approval. Subject to Section 7.1, to the fullest extent permitted by
law, the Company shall, through the Company Board, recommend to its stockholders that they adopt
this Agreement. Without limiting the generality of the foregoing, the Company agrees that its
obligations pursuant to the first sentence of this Section 7.4(a) shall not be affected by (i) the
commencement, public proposal, public disclosure or communication to the Company of any Acquisition
Proposal or (ii) the withdrawal or modification by the Company Board of its approval or
recommendation of this Agreement, the Offer or the Merger. Notwithstanding the foregoing, if the
Purchaser or any other Subsidiary of the Parent shall acquire at least 90% of the outstanding
shares of Company Common Stock, the parties shall take all necessary and appropriate action to
cause the Merger to become effective as soon as practicable after the expiration of the Offer
without a stockholders meeting in accordance with Section 253 of the DGCL.
(b) If the adoption of this Agreement by the stockholders of the Company is required under the
DGCL in order to consummate the Merger, the Company shall, at the Parent’s
- 63 -
request, as soon as practicable following the acceptance for payment of, and payment for, shares of
Company Common Stock by the Purchaser in the Offer, prepare and file with the SEC the Proxy
Statement in accordance with the Exchange Act and any other applicable laws, and will use its
reasonable best efforts to respond to any comments of the SEC or its staff and to cause the Proxy
Statement to be mailed to the Company’s stockholders as promptly as practicable after responding to
all such comments to the satisfaction of the staff. The Company shall notify the Parent promptly
upon the receipt of any comments from the SEC or its staff or any other government officials and of
any request by the SEC or its staff or any other government officials for amendments or supplements
to the Proxy Statement or for additional information, and shall supply the Parent with copies of
all correspondence between the Company or any of its representatives, on the on hand, and the SEC,
or its staff, or any other government officials on the other hand with respect to the Proxy
Statement. The Company shall consult with the Parent and its counsel prior to responding to any
comments from the SEC or its staff or any other government officials. If at any time prior to the
Company Meeting there shall occur any event that should be set forth in an amendment or supplement
to the Proxy Statement, the Company shall promptly prepare and mail to its stockholders and file
with the SEC any such amendment or supplement. The Company shall not mail any Proxy Statement, or
any amendment or supplement thereto, to the Company’s stockholders unless it has first obtained the
consent of the Parent to such mailing, which consent shall not be unreasonably withheld,
conditioned or delayed.
(c) The Parent shall cause all shares of Company Common Stock purchased by the Purchaser
pursuant to the Offer and all other shares of Company Common Stock owned by the Parent or the
Purchaser or any other Subsidiary of the Parent to be voted in favor of the adoption of this
Agreement.
7.5 Access to Information. The Company shall, and shall cause each of its
Subsidiaries and the Company’s and such Subsidiaries’ Representatives to, upon reasonable advance
notice to the Company, afford to the Parent and its Representatives reasonable access, at all
reasonable times, during the period prior to the Effective Time, to the Company’s and any of its
Subsidiaries’ properties, books, records, agreements and personnel and shall furnish the Parent all
financial, operating and other data and information as the Parent may reasonably request;
provided, however, that any such access shall be conducted at Parent’s expense,
under the supervision of appropriate personnel of the Company and in such a manner as not to
unreasonably interfere with the normal operation of the business of the Company. Unless otherwise
required by law, the Parent will hold any such information which is nonpublic in confidence in
accordance with the Confidentiality Agreement. Without limiting the generality of the foregoing,
the Company shall, within two business days of any request therefor, provide to the Parent the
information described in Rule 14a-7(a)(2)(ii) under the Exchange Act and any information to which a
holder of Company Common Stock would be entitled under Section 220 of the DGCL (assuming such
holder met the requirements of such section). The Company shall use its reasonable best efforts to
secure for the Company access to and copies of the workpapers of its independent public
accountants. No information or knowledge obtained in any
- 64 -
investigation pursuant to this Section 7.5 or otherwise shall affect or be deemed to modify any
representation or warranty contained in the Agreement or the conditions to the obligations of
the parties to consummate the Offer or the Merger.
7.6 Public Disclosure. Except as may be required by law or stock market regulations,
(a) the press release announcing the execution of this Agreement shall be issued only in such form
as shall be mutually agreed upon by the Company and the Parent and (b) the Parent and the Company
shall each use its respective reasonable best efforts to consult with the other party before
issuing, and provide each other with a reasonable opportunity to review and comment upon, any other
press release or otherwise making any public statement with respect to the transactions
contemplated by this Agreement, including the Offer and the Merger; provided,
however, that these restrictions shall not apply to any Company communications regarding
either (i) an Acquisition Proposal that the Company Board determines in good faith (after
consultation with outside counsel and the Financial Advisor or another independent nationally
recognized financial advisor) constitutes or may reasonably likely lead to a Superior Proposal, or
(ii) a Company Adverse Recommendation Change, in each case made in accordance with the provisions
of Section 7.1 of this Agreement.
7.7 Indemnification.
(a) From and after the Effective Time, the Parent and the Purchaser shall, to the fullest
extent permitted by law, cause the Surviving Corporation, (i) for a period of six years from the
Effective Time, to honor all of the Company’s obligations to indemnify and hold harmless each
present and former director and officer of the Company (the “Indemnified Parties”), against any
costs or expenses (including attorneys’ fees), judgments, fines, losses, claims, damages,
liabilities or amounts paid in settlement incurred in connection with any claim, action, suit,
proceeding or investigation, whether civil, criminal, administrative or investigative, arising out
of or pertaining to matters existing or occurring at or prior to the Effective Time, whether
asserted or claimed prior to, at or after the Effective Time, to the extent that such obligations
to indemnify and hold harmless exist on the date of this Agreement, and (ii) to honor all of the
Company’s obligations (including to indemnify and maintain the directors’ and officers’ liability
insurance policy for its former directors and officers) in accordance with Section 6.05 of the
Share Exchange Agreement.
(b) For a period of six years after the Effective Time, the Parent and the Purchaser shall
cause the Surviving Corporation to maintain (to the extent available in the market) in effect a
directors’ and officers’ liability insurance policy covering those persons who are currently
covered by the Company’s directors’ and officers’ liability insurance policy (a copy of which has
been made available to the Parent prior to the date of this Agreement) with coverage in amount and
scope at least as favorable to such persons as the Company’s existing coverage; provided, that in
no event shall the Parent or the Surviving Corporation be required to expend in any one year in
excess of 200% of the annual premium currently paid by the Company for such coverage. At the
Parent’s option, the Parent may purchase prior to the Effective Time a
- 65 -
six-year prepaid “tail policy” covering those persons who are currently covered by the
Company’s directors’ and officers’ liability insurance policy, in which case the Parent and
the Purchaser shall be relieved of their obligations pursuant to the immediately preceding
sentence. The Company represents and warrants that the annual premium currently paid by the
Company for directors’ and officers’ liability insurance coverage is as set forth on Section 7.7(b)
of the Company Disclosure Schedule.
(c) The provisions of this Section 7.7 are intended to be in addition to the rights otherwise
available to the current officers and directors of the Company by law, certificate of
incorporation, by-law or agreement, and shall operate for the benefit of, and shall be enforceable
by, each of the Indemnified Parties, their heirs and their representatives.
7.8 Employee Stock Purchase Plan and 401(k) Plan. Prior to and contingent upon the
occurrence of the Acceptance Time, the Company shall take all actions necessary or required to
ensure that, except for the 24-month offering period under the Company’s 2001 Employee Stock
Purchase Plan (the “ESPP”) that commenced on January 1, 2009, no additional offering under the ESPP
shall be authorized or commenced, and the ESPP shall terminate effective as of and contingent upon
the occurrence of the Effective Time. The rights of participants in the ESPP with respect to any
offering period then underway under the ESPP shall be determined by treating the last business day
prior to the date on which the Effective Time occurs as the last day of such offering period and by
making such other pro-rata adjustments as may be necessary to reflect the shortened offering period
but otherwise treating such shortened offering period as a fully effective and completed offering
period for all purposes under the ESPP. Prior to the Effective Time, the Company Board or, if
appropriate, any committee administering the Company’s 401(k) plan, shall adopt such resolutions
and take such other actions as are required to terminate such plan contingent upon the occurrence
of the Effective Time.
7.9 Employee Benefits. Parent agrees that all employees of the Company and its
Subsidiaries who continue employment with Parent, the Surviving Corporation or any Subsidiary of
the Surviving Corporation on the first business day after the date on which the Effective Time
occurs (“Continuing Employees”) shall be eligible to continue to participate in the Surviving
Corporation’s health and welfare benefit plans; provided, however, that (i) nothing
in this Section 7.9 or elsewhere in this Agreement shall limit the right of Parent or the Surviving
Corporation to amend or terminate any such health or welfare benefit plan at any time, and (ii) if
Parent or the Surviving Corporation terminates any such health or welfare benefit plan, then (upon
expiration of any appropriate transition period), the Continuing Employees shall be eligible to
participate in Parent’s health and welfare benefit plans, to substantially the same extent as
similarly situated employees of Parent. To the extent that service is relevant for eligibility,
vesting or allowances (including flexible time off) under any health or welfare benefit plan of
Parent and/or the Surviving Corporation, then Parent shall ensure that such health or welfare
benefit plan shall, for purposes of eligibility, vesting and allowances (including flexible time
off) but not for purposes of benefit accrual or where providing service credit will result in
duplication of benefits, credit Continuing Employees for service prior to the Effective Time with
- 66 -
the Company and its Subsidiaries to the same extent that such service was recognized prior to the
Effective Time under the corresponding health or welfare benefit plan of the Company. Parent
shall use its reasonable best efforts to (i) cause to be waived any pre-existing condition
limitation and eligibility waiting periods under any group health plan of Parent with respect to
Continuing Employees and their eligible dependents, and (ii) to the extent it is commercially
reasonable to do so, cause each Continuing Employee to be given credit toward applicable
deductibles and annual out-of-pocket limits under any group health plan of Parent for all amounts
paid prior to Closing and during the respective plan year in which the Effective Time occurs in
satisfaction of co-payments and deductibles under any similar group health plan of the Company in
which such Continuing Employee was participating immediately prior to the Effective Time. Nothing
in this Section 7.9 or elsewhere in this Agreement shall be construed to create a right in any
employee to employment with Parent, the Surviving Corporation or any other Subsidiary of the
Surviving Corporation and the employment of each Continuing Employee shall be “at will” employment.
7.10 Stockholder Litigation. Until the earlier of the termination of this Agreement
in accordance with its terms or the Effective Time, the Company shall give the Parent the
opportunity to participate in the defense or settlement of any stockholder litigation against the
Company or any member of the Company Board relating to this Agreement or any of the transactions
contemplated by this Agreement, and shall not settle any such litigation without the Parent’s prior
written consent.
7.11 Parent Guaranty. The Parent hereby unconditionally guarantees the Purchaser’s
obligations under this Agreement and agrees to be liable for any breach of this Agreement by the
Purchaser.
7.12 Transfer Restrictions. The Company agrees, with respect to each stockholder of
the Company that is a party to the Stockholders’ Agreement, that if any such stockholder attempts
to Transfer (as defined in the Stockholders’ Agreement), vote or provide any other person with the
authority to vote any of the shares of Company Common Stock owned by such stockholder other than in
compliance with the Stockholders’ Agreement, the Company shall not (a) permit any such Transfer on
the Company’s books and records, (b) issue a new certificate representing any of the shares of
Company Common Stock or permit any book entries for any such Transfer with respect to any shares of
Company Common Stock that are in uncertificated form or (c) record such vote, in each case, unless
and until such stockholder shall have complied with the terms of the Stockholders’ Agreement.
ARTICLE VIII
CONDITIONS
8.1 Conditions to Obligation of Each Party to Effect the Merger. The respective
obligations of each party to this Agreement to effect the Merger shall be subject to the
fulfillment at or prior to the Effective Time of each of the following conditions:
- 67 -
(a) Offer. The Purchaser shall have purchased all shares of Company Common Stock
validly tendered and not withdrawn pursuant to the Offer.
(b) Stockholder Approval. This Agreement shall have been adopted by the requisite
vote or consent of the stockholders of the Company, to the extent required by applicable law.
(c) No Injunctions. No Governmental Entity of competent jurisdiction shall have
enacted, issued, promulgated, enforced or entered any order, executive order, stay, decree,
judgment or injunction (preliminary or permanent) or statute, rule or regulation which is in effect
and which has the effect of making the Merger illegal or otherwise prohibiting consummation of the
Merger or the other transactions contemplated by this Agreement; provided that in no event
shall this condition be satisfied if a Japanese court or other Japanese governmental authority of
competent jurisdiction shall have issued an order, stay, decree, judgment or injunction
(preliminary or permanent) to Takeda Pharmaceutical Company Limited, the representative director of
Takeda Pharmaceutical Company Limited, all or a part of the directors of Takeda Pharmaceutical
Company Limited, or the Chief Executive Officer of Takeda Pharmaceutical Company Limited, directing
any of them to not consummate, or to not allow Parent or Purchaser to consummate the Merger, or
making illegal, or restraining or preventing, any of such consummation.
ARTICLE IX
TERMINATION, AMENDMENT AND WAIVER
9.1 Termination. This Agreement may be terminated at any time prior to the Effective
Time, as follows:
(a) by mutual written consent of the Parent, the Purchaser and the Company;
(b) by either the Parent or the Company:
(i) if the Offer is not consummated on or before July 22, 2009 (the
“Outside Date”); provided, however, that the right to
terminate this Agreement pursuant to this Section 9.1(b)(i) shall not be available
to any party whose failure to fulfill any obligations under this Agreement has
been a principal cause of or resulted in the failure of the Offer to be
consummated on or before the Outside Date;
(ii) if any Governmental Entity issues a nonappealable final order, decree or
ruling or takes any other nonappealable final action, in each case having the
effect of permanently restraining, enjoining or otherwise prohibiting the
acceptance for payment of, or payment for, any shares of Company Common Stock
pursuant to the Offer or consummation of the Merger; or
- 68 -
(iii) if as the result of the failure of any of the conditions set forth in
Annex I to this Agreement, the Offer shall have terminated or expired in
accordance with its terms without the Purchaser having purchased any shares of
Company Common Stock pursuant to the Offer; provided, however,
that the right to terminate this Agreement pursuant to this Section 9.1(b)(iii)
shall not be available to any party whose failure to fulfill any obligations under
this Agreement has been a principal cause of or resulted in the failure of any
such condition.
(c) by the Parent, prior to the Specified Time:
(i) if the Company breaches or fails to perform in any material respect any
of its representations, warranties or covenants contained in this Agreement, which
breach or failure to perform (A) would give rise to the failure of a condition set
forth in Annex I or Section 8.1 and (B) cannot be or has not been cured within 20
days after the giving of written notice to the Company of such breach or failure
to perform;
(ii) if the Company Board or any committee thereof, whether or not in the
exercise of their fiduciary or other legal duties, (A) withdraws or modifies, or
publicly proposes to withdraw or modify, in a manner adverse to the Parent or the
Purchaser, its approval or recommendation of the Offer, the Merger, this Agreement
or the Stockholders’ Agreement; (B) fails to recommend to the Company’s
stockholders that they tender their shares into and accept the Offer and give the
Required Company Stockholder Vote, or following the request of the Parent after
the announcement of any Acquisition Proposal (or modification thereto) fails
within ten business days of such request to reaffirm its approval and
recommendation in favor of the Offer, the Merger, this Agreement and the
Stockholders’ Agreement and against any such Acquisition Proposal; (C) approves or
recommends or takes a position of neutrality with respect to, or proposes to
approve or recommend or take a position of neutrality with respect to, any
Acquisition Proposal; or (D) withdraws or modifies, or proposes to withdraw or
modify, the approval by the Compensation Committee of the Company Compensation
Arrangements as Approved Company Compensation Arrangements for purposes of
satisfying the requirements of the non-exclusive safe-harbor in accordance to Rule
14d-10(d)(2) under the Exchange Act (each, a “Company Adverse Recommendation
Change”); or
(iii) if the Company breaches any of its covenants contained in Section 7.1
of this Agreement.
(d) by the Company, prior to the Specified Time:
- 69 -
(i) if the Parent or the Purchaser breaches or fails to perform in any
material respect any of their respective representations, warranties or covenants
contained in this Agreement, which breach or failure to perform materially impairs
the Parent’s and the Purchaser’s ability to consummate the Offer or the Merger and
which breach or failure to perform cannot be or has not been cured within 20 days
after the giving of written notice to the Parent of such breach or failure to
perform (provided that the Company is not then in material breach of any
representation, warranty or covenant contained in this Agreement); or
(ii) if: (A) the Company has not breached Section 7.1 of this Agreement (or,
in the case of a breach by any Representative of the Company or any of its
Subsidiaries of Section 7.1, as provided in the last sentence of Section 7.1(a),
been deemed to have breached Section 7.1 of this Agreement); (B) the Company Board
has received a Superior Proposal; (C) in light of such Superior Proposal, the
Company Board shall have determined in good faith, after consultation with outside
counsel, that a failure to withdraw or modify its approval or recommendation of
this Agreement, the Offer and the Merger and enter into a definitive agreement to
consummate such Superior Proposal would be inconsistent with the fiduciary duties
of the Company Board to the Company’s stockholders under applicable law; (D) the
Company has notified the Parent in writing of the determinations described in
clause (C) above, attaching the most current version of such definitive agreement
to such notice; (E) during the four business day period following the Parent’s
receipt of the notice referred to in clause (D) (1) the Company shall have offered
to negotiate with (and, if accepted, negotiated in good faith with), and shall
have caused its respective financial and legal advisors to offer to negotiate with
(and, if accepted, negotiate in good faith with), the Parent in modifying the
terms and conditions of this Agreement and (2) the Company Board shall have
determined in good faith (after consultation with the Financial Advisor or a
nationally recognized independent financial advisor), after the end of such four
business day period, and after considering the results of such negotiations and
the revised proposals made by the Parent, if any, that the Superior Proposal
giving rise to the notice described in clause (D) continues to be a Superior
Proposal; provided that any amendment, supplement or modification to the
financial terms or other material terms of any Acquisition Proposal shall be
deemed a new Acquisition Proposal and the Company may not terminate this Agreement
pursuant to this Section 9.1(d)(ii) unless the Company has satisfied the
conditions set forth in clauses (D) and (E) with respect to such new Acquisition
Proposal; (F) the Company concurrently pays to the Parent the fee due under
Section 9.3; and (G) the Company Board concurrently approves, and the Company
concurrently enters into, a definitive agreement providing for the implementation
of such Superior Proposal.
- 70 -
9.2 Effect of Termination. In the event of the termination of this Agreement as
provided in Section 9.1, all obligations and agreements of the parties set forth in this Agreement
shall forthwith terminate and be of no further force or effect, and there shall be no liability on
the part of the Parent, the Purchaser or the Company hereunder, except as set forth in Section
4.22, this Section 9.2, Section 9.3 and Article X, which provisions shall survive such termination;
provided that the foregoing shall not relieve any party for liability for damages actually incurred
as a result of any intentional breach of this Agreement.
9.3 Fees and Expenses.
(a) Except as otherwise provided in this Section 9.3, each party shall bear all of the fees
and expenses incurred by it in connection with the negotiation and performance of this Agreement,
and no party may recover any such fees and expenses from the other parties upon any termination of
this Agreement.
(b) The Company shall pay to the Parent $2,250,000 in cash if:
(i) this Agreement is terminated by the Parent pursuant to
Section 9.1(c)(ii);
(ii) this Agreement is terminated by the Company pursuant to
Section 9.1(d)(ii);
(iii) this Agreement is terminated by the Parent pursuant to Section
9.1(c)(iii) following an intentional breach by the Company of Section 7.1; or
(iv) after the date of this Agreement: (A) prior to the termination of this
Agreement, any person makes an Acquisition Proposal (with, in each place where the
term “Acquisition Proposal” is used in this Section 9.3(b)(iv), all references to
“15%” in the definition of “Acquisition Proposal” deemed to be references to
“50%”) or amends an Acquisition Proposal made prior to the date of this Agreement;
(B) this Agreement is terminated pursuant to Section 9.1(b)(i), 9.1(b)(iii) or
9.1(c)(i); and (C) within one year of such termination the Company enters into a
definitive agreement to consummate, or consummates, any Acquisition Proposal
(regardless of whether made before or after the termination of this Agreement);
provided that any termination fee payable pursuant to this Section 9.3(b) following a
termination of this Agreement shall be reduced by the amount actually paid to the Parent in expense
reimbursements pursuant to Section 9.3(c) below.
Any fee due under Section 9.3(b)(i) or (iii) shall be paid by wire transfer of same-day funds
on the date of termination of this Agreement. Any fee due under Section 9.3(b)(ii) shall be paid
by wire transfer of same-day funds concurrently with the termination of this Agreement.
- 71 -
Any fee due under Section 9.3(b)(iv) shall be paid by wire transfer of same-day funds on or prior
to the date on which the condition set forth in clause (C) of Section 9.3(b)(iv) is satisfied.
(c) The Company shall reimburse the Parent for actual expenses incurred by the Parent of up to
$750,000 in the aggregate in connection with the negotiation, preparation and performance of this
Agreement if (i) this Agreement is terminated by the Parent or the Company pursuant to Section
9.1(b)(iii) as a result of the Minimum Condition having not been satisfied or (ii) if the Support
Period (as defined in the Stockholders’ Agreement) terminates with respect to the Stockholders
identified on Attachment A to the Stockholders’ Agreement with an “*” by virtue of clause
(y)(d) of Section 1.1 of the Stockholders’ Agreement. Any amounts due under this Section 9.3(c)
shall be paid by wire transfer of same-day funds within two business days after the date of
termination of this Agreement or termination of such Support Period, as applicable;
provided that the reimbursement of any amounts due under this Section 9.3(c) may, at the
Company’s election, be deferred until the earlier to occur of the date (1) the Company enters into
a definitive agreement to consummate, or consummates, any Acquisition Proposal and (2) the Company
closes any debt or equity financing with gross proceeds to the Company or any of its Subsidiaries
equal to no less than $10,000,000.
9.4 Amendment. At any time prior to the Effective Time, the parties may amend, modify
and supplement this Agreement in any and all respects, whether before or after any vote of the
stockholders of the Company or the Purchaser contemplated hereby; provided,
however, that after any such stockholder approvals shall have been obtained, no amendment
shall be made which, under applicable law, requires the further approval of such stockholders
without such approval. Any such amendment, modification or supplement shall be valid only if set
forth in a written instrument executed and delivered by a duly authorized officer on behalf of each
of the parties.
9.5 Extension; Waiver. At any time prior to the Effective Time, the parties may (a)
extend the time for the performance of any of the obligations or other acts of the other parties,
(b) waive any inaccuracies in the representations and warranties of the other parties contained in
this Agreement or in any document delivered pursuant to this Agreement, or (c) subject to the
proviso in Section 9.4, waive compliance with any of the agreements or conditions of the other
parties contained in this Agreement. Any agreement on the part of a party to any such extension or
waiver shall be valid only if set forth in a written instrument executed and delivered by a duly
authorized officer on behalf of such party. The failure of any party to this Agreement to assert
any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights.
9.6 Procedure for Termination, Amendment, Extension or Waiver. A termination of this
Agreement pursuant to Section 9.1, an amendment, modification or supplement of this Agreement
pursuant to Section 9.4 or an extension or waiver of this Agreement pursuant to Section 9.5 shall,
in order to be effective, require, in the case of the Purchaser or the Company, action by its Board
of Directors or the duly authorized designee of its Board of Directors (which,
- 72 -
in the case of the Company, shall include the approval contemplated by Section 1.3(c), to the
extent then applicable).
ARTICLE X
MISCELLANEOUS
10.1 Nonsurvival of Representations and Warranties. The respective representations
and warranties of the Company, the Parent and the Purchaser contained in this Agreement shall
expire with, and be terminated and extinguished upon, the Effective Time.
10.2 Notices. All notices and other communications hereunder shall be in writing and
shall be deemed duly delivered (i) four business days after being sent by registered or certified
mail, return receipt requested, postage prepaid, or (ii) one business day after being sent for next
business day delivery, fees prepaid, via a reputable nationwide overnight courier service, in each
case to the intended recipient as set forth below:
(a) If to the Parent or the Purchaser:
|
|
|
|
|
|
|
00 Xxxxxxxxxx Xxxxxx |
|
|
Xxxxxxxxx, XX 00000 |
|
|
Attention: Xxxxxx X. Xxxxxxx |
|
|
|
|
Senior Vice President and General Counsel |
|
|
Telecopy No.: (000) 000-0000 |
|
|
|
|
|
with a copy to: |
|
|
|
|
|
Xxxxxx Xxxxxx Xxxxxxxxx Xxxx and Xxxx LLP |
|
|
00 Xxxxx Xxxxxx |
|
|
Xxxxxx, XX 00000 |
|
|
Attention: Xxxxx X. Xxxxxxx |
|
|
|
|
Xxxxxx Xxxxxxxx |
|
|
Telecopy No.: (000) 000-0000 |
(b) If to the Company:
|
|
|
|
|
|
|
0 Xxxxxx, Xxxxx 000 |
|
|
Xxxxxx, XX 00000 |
|
|
Attention: Xxxxxxx X. Xxxxxxx |
|
|
|
|
President and Chief Executive Officer |
|
|
Telecopy No.: (000) 000-0000 |
|
|
|
|
|
with a copy to: |
- 73 -
|
|
|
|
|
|
|
Xxxxxx Godward Kronish LLP |
|
|
0000 Xxxxxxxx Xxxx |
|
|
Xxx Xxxxx, XX 00000 |
|
|
Attention: Xxxxxxx X. Xxxxxx, Esq. |
|
|
Telecopy No.: (000) 000-0000 |
Any party to this Agreement may give any notice or other communication hereunder using any
other means (including personal delivery, messenger service, telecopy, telex, ordinary mail or
electronic mail), but no such notice or other communication shall be deemed to have been duly given
unless and until it actually is received by the party for whom it is intended. Any party to this
Agreement may change the address to which notices and other communications hereunder are to be
delivered by giving the other parties to this Agreement notice in the manner herein set forth.
10.3 Entire Agreement. This Agreement (including the Schedules and Exhibits hereto)
constitutes the entire agreement among the parties hereto and supersedes any prior understandings,
agreements or representations by or among the parties hereto, or any of them, written or oral, with
respect to the subject matter hereof; provided that the Confidentiality Agreement shall remain in
effect in accordance with its terms.
10.4 No Third Party Beneficiaries. Other than the provisions of Section 7.7, this
Agreement is not intended, and shall not be deemed, to confer any rights or remedies upon any other
person other than the parties hereto and their respective successors and permitted assigns, to
create any agreement of employment with any person or to otherwise create any third-party
beneficiary hereto.
10.5 Assignment. Neither this Agreement nor any of the rights, interests or
obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of
law or otherwise by any of the parties hereto without the prior written consent of the other
parties, and any such assignment without such prior written consent shall be null and void, except
that the Parent and/or the Purchaser may assign this Agreement to any direct or indirect wholly
owned Subsidiary of the Parent without the consent of the Company, provided that the Parent and/or
the Purchaser, as the case may be, shall remain liable for all of its obligations under this
Agreement. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the
benefit of, and be enforceable by, the parties hereto and their respective successors and permitted
assigns.
10.6 Severability. Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability
of the remaining terms and provisions hereof or the validity or enforceability of the offending
term or provision in any other situation or in any other jurisdiction. If the final judgment of a
court of competent jurisdiction declares that any term or provision hereof is invalid or
unenforceable, the
- 74 -
parties hereto agree that the court making such determination shall have the power to limit
the term or provision, to delete specific words or phrases, or to replace any invalid or
unenforceable term or provision with a term or provision that is valid and enforceable and that
comes closest to expressing the intention of the invalid or unenforceable term or provision, and
this Agreement shall be enforceable as so modified. In the event such court does not exercise the
power granted to it in the prior sentence, the parties hereto agree to replace such invalid or
unenforceable term or provision with a valid and enforceable term or provision that will achieve,
to the extent possible, the economic, business and other purposes of such invalid or unenforceable
term.
10.7 Counterparts and Signature. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original but all of which together shall be
considered one and the same agreement and shall become effective when counterparts have been signed
by each of the parties hereto and delivered to the other parties, it being understood that all
parties need not sign the same counterpart. This Agreement may be executed and delivered by
facsimile or “PDF” transmission.
10.8 Interpretation. When reference is made in this Agreement to an Article or a
Section, such reference shall be to an Article or a Section of this Agreement unless otherwise
indicated. The table of contents, table of defined terms and headings contained in this Agreement
are for convenience of reference only and shall not affect in any way the meaning or interpretation
of this Agreement. The language used in this Agreement shall be deemed to be the language chosen
by the parties to express their mutual intent, and no rule of strict construction shall be applied
against any party. Whenever the context may require, any pronouns used in this Agreement shall
include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and
pronouns shall include the plural, and vice versa. Any reference to any federal, state, local or
foreign statute or law shall be deemed also to refer to all rules and regulations promulgated
thereunder, unless the context requires otherwise. Whenever the words “include”, “includes” or
“including” are used in this Agreement, including Annex I, they shall be deemed to be
followed by the words “without limitation.” Where this Agreement refers to information that was
“made available”, that means that such information was either (a) provided directly to the Parent
or Parent’s outside counsel or outside auditing firm in its capacity as the Parent’s agent or tax
advisor, (b) included in the Intralinks online workspace entitled “IDM Pharma ERoom” on or before
11:59 pm (EST) on the second business day preceding the date hereof or (c) filed by the Company
with the SEC on the SEC’s Electronic Data Gathering, Analysis, and Retrieval system at least two
business days prior to the date of this Agreement. As used in this Agreement, the term “person”
means any individual, corporation, partnership, joint venture, association, trust, limited
liability company, unincorporated organization or other entity. For purposes of this Agreement,
the Company shall not be deemed to be an Affiliate or subsidiary of the Purchaser or the Parent.
As used in this Agreement, references to any “agreement” to which a person is bound means any
contract, agreement, instrument, obligation, undertaking, lease, license, arrangement, commitment
or understanding, whether written or oral, in each case that is legally binding on such person and
as it may be amended or otherwise modified from time to time. As used in this Agreement,
references to the “Company’s
- 75 -
knowledge” or “knowledge of the Company”, or any other phases of similar meaning, means the
actual knowledge (after reasonable investigation) of the individuals identified in Section 10.8 of
the Company Disclosure Schedule. As used in this Agreement, a “business day” means any day that is
not a Saturday, Sunday or other day on which banking institutions are required or authorized by law
to be closed in New York, New York, except in Section 1.1(b), where such term shall have the
meaning assigned to it in Rule 14d-1 promulgated under the Exchange Act. No summary of this
Agreement prepared by any party shall affect the meaning or interpretation of this Agreement.
10.9 Governing Law. This Agreement shall be governed by and construed in accordance
with the internal laws of the State of Delaware without giving effect to any choice or conflict of
law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause
the application of laws of any jurisdictions other than those of the State of Delaware.
10.10 Remedies. Except as otherwise provided herein, any and all remedies herein
expressly conferred upon a party will be deemed cumulative with and not exclusive of any other
remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any
one remedy will not preclude the exercise of any other remedy. The parties hereto agree that
irreparable damage would occur in the event that any of the provisions of this Agreement were not
performed in accordance with their specific terms or were otherwise breached. Accordingly, the
parties hereto shall be entitled to an injunction or injunctions to prevent breaches of this
Agreement and to enforce specifically the terms and provisions of this Agreement, this being in
addition to any other remedy to which they are entitled at law or in equity.
10.11 Submission to Jurisdiction. Each of the parties hereto (a) consents to submit
itself to the exclusive personal jurisdiction of the Delaware Court of Chancery, New Castle County,
or if that court does not have jurisdiction, a federal court sitting in the State of Delaware in
any action or proceeding arising out of or relating to this Agreement or any of the transactions
contemplated by this Agreement, (b) agrees that all claims in respect of such action or proceeding
may be heard and determined in any such court, (c) agrees that it will not attempt to deny or
defeat such personal jurisdiction by motion or other request for leave from any such court, and (d)
agrees not to bring any action or proceeding arising out of or relating to this Agreement or any of
the transaction contemplated by this Agreement in any other court. Each of the parties hereto
waives any defense or inconvenient forum to the maintenance of any action or proceeding so brought
and waives any bond, surety or other security that might be required of any other party with
respect thereto. To the extent permitted by applicable law, any party hereto may make service on
another party by sending or delivering a copy of the process to the party to be served at the
address and in the manner provided for the giving of notices in Section 10.2. Nothing in this
Section 10.11, however, shall affect the right of any party to serve legal process in any other
manner permitted by law.
- 76 -
10.12 WAIVER OF JURY TRIAL. EACH OF THE PARENT, THE PURCHASER AND THE COMPANY HEREBY
IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER
BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF THE PARENT, THE PURCHASER OR THE COMPANY IN THE
NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF.
[Remainder of page intentionally left blank.]
- 77 -
IN WITNESS WHEREOF, the Parent, the Purchaser and the Company have caused this Agreement to be
executed as of the date first written above by their respective officers thereunto duly authorized.
|
|
|
|
|
|
|
|
|
TAKEDA AMERICA HOLDINGS, INC. |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Iwaaki Taniguchi |
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
Iwaaki Taniguchi |
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
President |
|
|
|
|
|
|
|
|
|
|
|
|
JADE SUBSIDIARY CORPORATION |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Xxxxxx X. Xxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
Xxxxxx X. Xxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
SVP, General Counsel |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IDM PHARMA, INC. |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Xxxxxxx X. Xxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
Name: |
|
Xxxxxxx X. Xxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
Title: |
|
President and CEO |
|
|
|
|
|
|
|
|
|
- 78 -
ANNEX I
CONDITIONS OF THE OFFER
Capitalized terms used in this Annex I but not defined herein have the meanings assigned to
such terms in the Agreement and Plan of Merger (the “Agreement”) of which this Annex I is a part.
Notwithstanding any other provisions of the Offer or the Agreement, the Purchaser shall not be
required to accept for payment or, subject to any applicable rules and regulations of the
Commission, including Rule 14e-1(c) under the Exchange Act, to pay for any shares of Company Common
Stock tendered pursuant to the Offer, and (so long as permitted by the terms of the Agreement) may
terminate or amend the Offer, and may postpone the acceptance of, or payment for, any shares of
Company Common Stock, if:
(i) immediately prior to the expiration of the Offer (as extended in accordance with the
Agreement), the number of shares of Company Common Stock validly tendered and not properly
withdrawn does not equal at least a majority of such shares of Company Common Stock outstanding on
a fully diluted basis on the date of purchase (where “on a fully diluted basis” means the number of
shares of Company Common Stock outstanding, together with the shares of Company Common Stock which
the Company may be required to issue pursuant to warrants, options or other obligations outstanding
at that date under employee stock or similar benefit plans or otherwise, whether or not vested or
then exercisable) (the “Minimum Condition”);
(ii) immediately prior to the expiration of the Offer (as extended in accordance with the
Agreement), any requisite waiting period (and any extension thereof) under the HSR Act shall not
have expired or been terminated; or
(iii) at any time on or after the date of the Agreement and before the Specified Time, any of
the following shall occur and shall continue to exist:
(a) there shall be instituted, pending or threatened in writing any suit, action or proceeding
by any Governmental Entity (1) challenging, making illegal or otherwise restraining or prohibiting,
or seeking to challenge, make illegal or otherwise restrain or prohibit, the transactions
contemplated by the Agreement, including the Offer and the Merger, or seeking to obtain from the
Company or (to the extent such suit, action or proceeding relates to the transactions contemplated
by the Agreement or the Stockholders’ Agreement, including the Offer and the Merger) the Parent or
any of its Affiliates, any damages in excess of $400,000, (2) seeking to prohibit or limit the
ownership or operation by the Company, the Parent or the Purchaser of all or any portion of the
business or assets of the Company and its Subsidiaries, other than the Company’s IDM-2101 product
candidate or the Company’s UVIDEM product candidate or in any other de minimis respect, (3) to the
extent such suit, action or proceeding relates to the transactions contemplated by the Agreement or
the Stockholders’ Agreement, including the Offer and the Merger, seeking to prohibit or limit in
any respect the ownership or
A - 1
operation by the Parent and its Affiliates of all or any portion of the business or assets of
the Parent and its Affiliates, (4) seeking to compel the Company, the Parent or the Purchaser to
dispose of or to hold separate all or any portion of the business or assets of the Company or any
of its Subsidiaries, other than the Company’s IDM-2101 product candidate or the Company’s UVIDEM
product candidate or any other de minimis assets, (5) to the extent such suit, action or proceeding
relates to the transactions contemplated by the Agreement or the Stockholders’ Agreement, including
the Offer and the Merger, seeking to compel the Parent or any of its Affiliates to dispose of or to
hold separate in any respect all or any portion of the business or assets of the Parent or any of
its Affiliates, (6) seeking to impose any limitation on the ability of the Company, the Parent or
the Purchaser to conduct the business or own the assets of the Company or any of its Subsidiaries,
other than the Company’s IDM-2101 product candidate or the Company’s UVIDEM product candidate or
any other de minimis assets, (7) to the extent such suit, action or proceeding relates to the
transactions contemplated by the Agreement or the Stockholders’ Agreement, including the Offer and
the Merger, seeking to impose any limitation in any respect on the ability of the Parent or any of
its Affiliates to conduct the business or own the assets of the Parent or any of its Affiliates,
(8) seeking to impose limitations on the ability of the Parent or the Purchaser to acquire or hold,
or to exercise full rights of ownership of any shares of Company Common Stock, including the right
to vote such Shares on all matters properly presented to the Company’s stockholders, or (9) seeking
to require divestiture by the Parent or the Purchaser of all or any of the shares of Company Common
Stock; provided that in no event shall this condition be satisfied if a Japanese court or
other Japanese governmental authority of competent jurisdiction shall have issued an order, stay,
decree, judgment or injunction (preliminary or permanent) to Takeda Pharmaceutical Company Limited,
the representative director of Takeda Pharmaceutical Company Limited, all or a part of the
directors of Takeda Pharmaceutical Company Limited, or the Chief Executive Officer of Takeda
Pharmaceutical Company Limited, directing any of them to not consummate, or to not allow Parent or
Purchaser to consummate the Offer or the Merger, or making illegal, or restraining or preventing,
any of such consummation;
(b) there shall be any action taken, proposed or threatened, or any statute, rule, regulation,
legislation, interpretation, judgment, order or injunction proposed, enacted, promulgated, entered,
enforced, amended or issued, by any Governmental Entity, which is applicable to or deemed
applicable to (x) the Parent, the Purchaser, the Company or any Subsidiary or (y) the Offer, the
Merger, the Agreement or the Stockholders’ Agreement, other than the routine application to the
Offer, the Merger or the transactions contemplated by the Stockholders Agreement of the waiting
period provisions under the Xxxx-Xxxxx-Xxxxxx Act, that result in, or would reasonably be expected
to result in, directly or indirectly, any of the consequences referred to in paragraph (a) above;
(c) since the date of the Agreement, there shall have occurred any Change which has had, or
would reasonably be expected to result in, a Company Material Adverse Effect;
A - 2
(d) the representations and warranties of the Company set forth in Sections 4.1, 4.4(a) or
clause (i) of Section 4.7 of the Agreement shall not be true and correct as of the date on which
the accuracy of such representations and warranties is determined as though made on such date,
except to the extent such representations and warranties are specifically made as of a particular
date, in which case such representations and warranties shall not be true and correct as of such
date;
(e) the representations and warranties of the Company set forth in Sections 4.2(a) or 4.2(f)
of the Agreement shall not be true and correct as of the date on which the accuracy of such
representations and warranties is determined as though made on such date, except for any de minimis
inaccuracy therein, and except to the extent such representations and warranties are specifically
made as of a particular date, in which case such representations and warranties shall not be true
and correct as of such date;
(f) any representations and warranties of the Company set forth in the Agreement (other than
in Sections 4.1, 4.2(a), 4.2(f), 4.4(a), and clause (i) of Section 4.7) shall not be true and
correct as of the date on which the accuracy of such representations and warranties is determined
as though made on such date, except (A) to the extent such representations and warranties are
specifically made as of a particular date, in which case such representations and warranties shall
not be true and correct as of such date, and (B) where the failure to be true and correct (without
regard to any materiality or Company Material Adverse Effect qualifications contained therein), has
not had, and would not reasonably be expected to result in, a Company Material Adverse Effect;
(g) the Company shall have failed to perform in any material respect any obligation or to
comply in any material respect with any agreement or covenant of the Company to be performed or
complied with by it under the Agreement;
(h) the consents and approvals marked with “*” on Section 4.4(b) of the Company Disclosure
Schedule shall not have been obtained;
(i) there shall have occurred any Company Adverse Recommendation Change; or
(j) the Agreement shall have been terminated in accordance with its terms;
which in the reasonable judgment of the Parent and the Purchaser, in any such case and regardless
of the circumstances giving rise to any such condition, makes it inadvisable to proceed with the
Offer or with acceptance for payment or payment for Shares.
The foregoing conditions are for the sole benefit of the Parent and the Purchaser and may be
asserted by the Parent and the Purchaser regardless of the circumstances giving rise to any such
condition and may be waived by the Parent or the Purchaser (except for the Minimum Condition), in
whole or in part, at any time and from time to time, in their respective sole
A - 3
discretion. The failure by the Parent or the Purchaser at any time to exercise any of the
foregoing rights will not be deemed a waiver of any such right, the waiver of any such right with
respect to any particular facts and circumstances shall not be deemed a waiver with respect to any
other facts and circumstances and each such right will be deemed an ongoing right that may be
asserted at any time and from time to time. Any determination by the Parent or the Purchaser
concerning the events described in this Annex I shall be final and binding upon all
parties.
A - 4